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In the UK, prostate cancer is the most prevalent male cancer and approximately 40% of men 
will have metastatic disease at diagnosis. The treatment pathway in metastatic prostate 
cancer is offered often without any histological or genetic knowledge of the tumour and 
there is currently no reliable biomarker to monitor response to treatment. 
Over the past decade, there has been increasing interest in circulating tumour cells (CTCs). 
These cells, which have broken away from the tumour of origin and can be captured via a 
simple blood test, can be quantified, sequenced or examined for antigen expression. Stem 
cell marker expression, specifically Oct4, SOX2 and Nanog, has been found to correlate with 
aggressive disease when looking at solid prostate tissue. Consequently, exploring the 
expression of these markers in circulating tumour cells could enable the development of a 
new biomarker in prostate cancer. 
This study had three aims. The first was to optimise an assay using flow cytometry to enable 
detection of the stem cell markers Oct4, SOX2 and Nanog, alongside epithelial and 
mesenchymal markers in CTCs from patients with metastatic prostate cancer. The second 
aim was to explore the prognostic role of these markers and the final aim was to culture 
CTCs from patients to enable downstream utilisation. 
Blood was obtained from seventy-eight patients with different stages of prostate cancer and 
processed using two flow-cytometry based methods; one on the Imagestream, a combined 
flow cytometer and high-resolution microscope, and the second using conventional multi-
channel FACS. Enumeration of total number of CTCs in addition to the individual marker 
positive cells was correlated with existing clinical data (PSA and Alkaline Phosphatase level, 
in addition to survival). Cells from six patients were successfully maintained in culture for up 
to a year. Attempts to prove the genotype of these cells included real time qPCR, SNP Array 
and whole exome sequencing experiments. Cells from one patient were implanted into five 
NSG mice and experiments to look at both chemokine expression and the Young’s modulus 
of the cells were also performed. 
No correlation was found between either CTC count or antigen expression and the clinical 
outcome of the patients. Unfortunately, due to a lack of good quality DNA the sequencing 
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experiments didn’t yield any data and despite one of the mice developing a hind leg 
paralysis, there was no histological evidence of an engrafted tumour. The chemokine 
receptor and Young’s modulus experiments showed promising early results and form part of 
some ongoing collaborative projects. 
The first aim of developing an assay to detect prostate cancer CTCs was achieved, and 
survival data at a later time point is going to be collected to ascertain whether the markers 
explored in this study have a prognostic role. Whilst cells were successfully cultured, the 
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LUTS – Lower urinary tract symptoms 
MAB – Maximum androgen blockade 
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MMP – Matrix Metalloproteinase 
mpMRI – Multiparametric MRI 
MRI – Magnetic resonance imaging 
mRNA – Messenger RNA 
MSC – Mesenchymal stem cell 
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mTOR – Mechanistic target of rapamycin 
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NDM – New diagnosis metastatic 
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Oct4 - octamer-binding transcription factor 4 
PBS- Phosphate buffered saline 
PCR – Polymerase chain reaction 
PDX – Patient derived xenograft 
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PerCP – Peridinin chlorophyll protein  
PI3K- Phosphoinositide 3-kinase 
PIN – Prostate intraepithelial neoplasia 
PSA – Prostate specific antigen 
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PSMA – prostate specific membrane antigen 
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RT-PCR – Reverse transcriptase polymerase chain reaction 
RT-qPCR – Real time quantitative polymerase chain reaction 
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TBST – Tris-buffered saline and polysorbate 20 
TGF-ß – Transforming growth factor beta   
TMPRSS2 – Transmembrane protease serine 2  
TNM – Tumour, node and metastasis (staging system) 
TP53 – Tumour protein 53 
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TURP – Trans-urethral resection of the prostate 
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UV – Ultra Violet 
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Chapter 1.  Introduction 
1.1 The prostate gland 
The prostate is an exocrine gland of the male reproductive system.  It produces 
protein-rich secretions, which make up approximately 30% of seminal fluid (Lilja, 
1993). The most abundantly expressed protein by prostatic cells is the kallikrein, 
prostate specific antigen (PSA) (Lilja, 1993). This serine protease, also known as KLK3, 
allows proteolysis of the coagulated ejaculate, which subsequently enables release 
and motility of the spermatozoa contained within this gel (Lilja, 1988). 
The prostate is a walnut-shaped gland located in the male pelvis, anterior to the 
rectum, immediately inferior to the urinary bladder and surrounding the urethra 
(McNeal, 1968). Anatomically it can be divided into three zones: the outer peripheral 
zone, the medial transitional zone and the central zone (McNeal, 1988). These are 
bordered by an anterior stromal area containing fibroblasts and smooth muscle cells. 
Prostate cancers are most frequently found in the peripheral zone, which assists in 
diagnosis as they can be clinically palpated via the rectum. 
The prostate is a highly branched gland formed of epithelial tissue (Wang et al., 
2001). The ducts within the gland are lined by secretory luminal cells, above a basal 
layer which is understood to contain stem cells (Choi et al., 2012, Ousset et al., 2012, 
McNeal, 1988). Rare neuroendocrine cells can also be found within the epithelium 
(Wang et al., 2001). It is the androgen-dependent columnar cells of the luminal layer 
that secrete PSA and the androgen receptor (Lang et al., 2009). 
As men age, their prostate size increases and this can lead to clinical lower urinary 
tract symptoms (LUTS) (Lim, 2017). The incidence of benign enlargement of the 
prostate, or benign prostatic hyperplasia (BPH), will vary according to the criteria 
used to diagnose it but increases with age and symptomatic BPH can affect as many 
as 80% of men in their eighties (Berry et al., 1984). Although BPH is a diagnosis that 
can only be made histologically, there is no difference between the clinical symptoms 
of BPH and prostate cancer, and any male exhibiting symptoms such as difficulty 
voiding, nocturnal voiding or a reduced urinary flow should be clinically assessed to 
rule out prostate cancer (Verhamme et al., 2002). 
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1.2 Prostate cancer 
1.2.1 Background and Epidemiology 
Prostate cancer is the most common male cancer in the UK (Cancer Research UK, 
2018), accounting for 26.1% of cancers in men (Statistics, 2016), and the second most 
common male cancer worldwide (Siegel et al., 2012, Scosyrev et al., 2012b).  Over 
one million men are diagnosed in the world each year and in Great Britain it accounts 
for the second highest cause of cancer related mortality (Cancer Research UK, 2018).  
In the UK in 2016 over forty thousand men were diagnosed with the disease, and the 
lifetime risk of developing it was 1 in 8 (Cancer Research UK, 2018, Statistics, 2016).  
There has been a global increase in prevalence since the 1960s, which has been 
attributed both to improved diagnostics and the ageing population.  Prostate cancer 
is a disease that predominantly affects older men (Siegel et al., 2012, Brewster et al., 
2000); only 0.1% of cases occur in men under 50, compared to 85% in men over 65 
(Patel and Klein, 2009).  Increased access to PSA screening in America, and the 
increase in popularity of the Trans-urethral resection of the prostate (TURP) surgical 
procedure to treat bladder outflow obstruction caused by prostatic enlargement, led 
to a 44% increase in diagnosis of the disease in the 1990s (Brewster et al., 2000, 
Evans and Moller, 2003).  But whilst prevalence increases with age, and post mortem 
studies have demonstrated evidence of prostate cancer in up to 71% of men over 79 
(Bell et al., 2015), it is important to note that not all prostate cancers are classified as 
high risk.  Given the age at which many men are diagnosed, the 84% ten year survival 
in the UK (Cancer Research UK, 2018) means that despite being the most prevalent 
male cancer, it only accounts for 7% of male cancer deaths (Statistics, 2016).  The 
increase in detection rates has led to a rise in the number of both high and low risk 
prostate cancers (Potosky et al., 1995) and treatment will vary depending on this 
information and the age of the patient. 
Whilst there are no clearly identifiable preventative risk factors, there are several 
features which may increase the likelihood of developing the disease.  In addition to 
age, ethnic origin and a family history are the predominant risks.  There is a threefold 
higher prevalence of prostate cancer amongst black men compared to Caucasians, 
and they are also at risk of developing it at a younger age (Kheirandish and 
Chinegwundoh, 2011, Ben-Shlomo et al., 2008).  Asian men have the lowest 
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incidence and despite this possibly being attributed to lower screening rates or 
access to healthcare, studies looking at cohorts who have migrated have found that 
the Asian migrant populations still have lower rates than the indigenous people (Ito, 
2014, Metcalfe et al., 2008).  
Environmental factors such as diet, cholesterol levels, incidence of diabetes and 
obesity have all been proposed to affect an individual’s risk of developing prostate 
cancer.  But without randomised studies, the evidence to enable any conclusions to 
be drawn about these relationships is too poor (Gomez-Acebo et al., 2017, Leitzmann 
and Rohrmann, 2012, Vidal et al., 2014). 
Having a father or brother with the disease increases the risk by up to 3.4 times 
(Crawford, 2003, Johns and Houlston, 2003) and those with a family history are more 
likely to be diagnosed at a younger age, possibly due to increased awareness (Bratt, 
2002).  Mendelian inheritance is responsible for 5-10% of cases of prostate cancer 
and up to 40% of patients diagnosed under the age of 55 have an inherited 
component (Shen and Abate-Shen, 2010, Carter et al., 1992, Elo and Visakorpi, 2001). 
Mutations in this age group such as those affecting BRCA2 and HOXB13 genes are 
most common (Salinas et al., 2014, Lin et al., 2009). 
1.2.2 Diagnosis of prostate cancer 
Due to the age at which prostate cancer most commonly presents, detection and 
treatment is only beneficial to the patient if intervention will reduce mortality and 
afford an acceptable quality of life.  A lack of reliable biomarkers means that there is 
currently no screening programme available in the UK, as PSA testing can diagnose 
indolent cancers, the management of which can cause more significant harm than 
leaving the patient untreated.  PSA levels can also be elevated for reasons other than 
cancer, which could lead to unnecessary interventions, some with high morbidity.  A 
Cochrane review in 2014 demonstrated that screening did increase the detection 
rate of prostate cancer, but that the majority of these were localised tumours, and 
there was no cancer-specific or overall survival benefit derived from treating such 
cancers (Hayes and Barry, 2014). 
A study published by the American Urological Association proposed that men aged 
between 55 and 69 would benefit from a PSA screening programme in order to 
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detect a small number of high risk tumours within this group, but that more harm 
would occur as a result of screening men younger and older than this range (Carter et 
al., 2013).  As a result, in 2017 the United States Representative Task Force produced 
a recommendation that men aged between 55 and 69 discussed the risk/benefit ratio 
of individual screening with their doctor so that these men could make an informed 
choice (Quality, 2018).  In the UK, PSA testing but not screening is available on the 
NHS but is not offered routinely. As per European Association of Urology (EAU) 
guidelines it is usually only requested in men under 50 if they are of African origin, 
have urological symptoms or a family history (Urology, 2018). 
Suspicion of prostate cancer from either a digital rectal examination or an elevated 
PSA will result in a prostate biopsy and/or cross-sectional or radio-isotope imaging.  
Because of the anatomical location of the prostate, access for biopsies is either trans-
perineal or trans-rectal, which carries a moderate risk of infection.  Rectal 
disinfection with iodine, or prophylactic antibiotics are often used as preventative 
measures (Aron et al., 2000) (Roberts et al., 2017). Until recently, 10-12 trans-rectal 
ultrasound biopsies taken under ultrasound guidance was the standard, with 
progression to saturation biopsies (20 or more) if suspicion was still high after a 
negative result.  More recently, trans-perineal sampling often following MRI imaging 
of the prostate, has become more popular, but a meta-analysis comparing the two 
techniques has shown no increase in detection rate between the two methods (Xue 
et al., 2017).  The recent PRECISION study comparing MRI-guided with ultrasound 
guided biopsies demonstrates a 12% higher detection rate in the former group 
(Kasivisvanathan et al., 2018) but access to this resource is not yet widespread. 
If the disease is presumed to be organ confined at diagnosis, multiparametric MRI 
(mpMRI) is the imaging modality of choice (Ahmed et al., 2017a). Unlike standard 
MRI this technique includes functional imaging such as magnetic resonance 
spectroscopy, dynamic contrast enhanced imaging or diffusion-weighted imaging in 
addition (Ghai and Haider, 2015).  This has an 80-100% success rate of detecting 
clinically significant tumours, depending on their volume (Bratan et al., 2013).  If high 
risk disease is suspected, abdomino-pelvic CT and bone-scans are often used in 
addition to mpMRI, to detect whether metastases are present (Urology, 2018).  If a 
patient is presumed to have metastatic disease at presentation, either based on 
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digital rectal examination or PSA, a bone scan is performed in preference to MRI or 
CT, in order to detect presence of bone metastases (Abuzallouf et al., 2004).  If this is 
positive, the information that could be provided by cross-sectional imaging would not 
add anything to change the management of the patient.  
1.2.3 Classification and staging of prostate cancer 
For all patients, staging is performed using the Tumour, Node and Metastasis staging 
system (Brierley J, 2017). Assessment of the tumour for staging purposes is only 
possible for those patients who have undergone radical surgery and is not based on 
biopsy results. Histological analysis of the tissue will reveal the extent of invasion of 
the tumour, potentially into adjacent structures, and this information in combination 
with imaging to detect further spread of the disease will result in a stage which is 
summarised in Table 1.1.  Stratifying patients according to this information helps 
predict outcome, and therefore treatment or suitability for clinical trials.  Tissue 
architecture within a prostate tumour is described using the Gleason scoring system. 
The tissue is graded on a scale of 1-5, based on the histological pattern, and the two 
most common areas within the tumour are used to calculate the final score, up to a 
maximum of 10.  
A study looking at biochemical recurrence after radical treatment (prostatectomy or 
external beam radiotherapy) classified prostate tumours in patients according to risk 
(Cooperberg et al., 2005). Tumours are classified into high, intermediate or low risk 
groups depending on PSA level, extent of the tumour within the pelvis, Gleason 
grade, and the presence or absence of metastatic disease as summarised in Table 




  T –Primary Tumour 
TX  Tumour cannot be assessed 
T0  No evidence of primary tumour 
T1  Clinically unapparent tumour that is not palpable 
 T1a Incidental finding in <5% of resected tissue 
 T1b Incidental finding in >5% of resected tissue 
 T1c Tumour identified by needle biopsy 
T2  Tumour that is palpable and confined within the prostate 
 T2a Tumour involves one half or less of one lobe 
 T2b Tumour involves more than half of one lobe but not both lobes 
 T2c Tumour involves both lobes 
T3  Tumour invades through the prostatic capsule 
 T3a Extracapsular extension including to bladder neck 
 T3b Invasion of seminal vesicles 
T4  Tumour is fixed or invades adjacent structures other than seminal vesicles 
external sphincter, rectum, levator muscles, and/or pelvic wall   N –Regional Lymph Nodes 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Regional lymph node metastases present 
  M – Distant Metastases 
M0  No distant metastases 
M1  Distant metastases 
 M1a Non-regional lymph nodes 
 M1b Bone 
 M1c Other site (e.g. lung) 
Table 1.1 The Tumour Node and Metastasis Staging system for Prostate Cancer (adapted 
from Brierley et al, TNM Classification of malignant tumours (Brierley J, 2017)) 
 
 
 Low Risk Intermediate 
Risk 
High Risk  
PSA PSA <10ng/mL PSA 10-20ng/mL PSA >20ng/mL Any PSA 
Gleason Grade Gleason <7 Gleason 7  Gleason >7 Any Gleason 
Pathological 
Stage 
cT1-2a cT2b cT2c cT3-4 or cN+ 
 Local   Advanced 





1.2.4 Treatment options and prognosis 
Treatment of prostate cancer can broadly be categorised into surveillance (with a 
view to treating or managing symptoms should the tumour progress), treatment with 
a curative intent, or life-prolonging management of the disease. Those men who 
present with localised disease at an advanced age or with significant co-morbidities 
may benefit from surveillance rather than intervention, as treatment of localised 
disease has been shown to only offer benefit if life expectancy is over ten years 
(Bruinsma et al., 2017).  This surveillance management is further sub-divided into 
active surveillance (monitoring normally low-volume, low-risk disease with the aim of 
starting treatment at the first sign of disease progression) or watchful waiting 
(palliative management that involves only starting treatment once the patient 
becomes symptomatic).  Both options are chosen with the aim of reducing the 
toxicity and side effects of treatment but would not be suitable if the patient has high 
risk disease. 
In a younger, fit patient, or an older man with a reasonable life expectancy, and 
intermediate or high-risk disease, radical treatment is offered with the aim of curing 
the patient from the disease.  This is predominantly in the form of either radical 
surgery, or localised or radical radiotherapy (which depending on the stage may 
include additional hormonal therapy) (Zelefsky et al., 2011). 
Whilst radical treatment can offer curative treatment for men presenting with 
localised disease, approximately 20% of men in the UK present with metastases 
(Oakley-Girvan et al., 2003, England), 2016) and those aged over 75 account for 
almost half of the cases of metastatic disease at presentation (Scosyrev et al., 2012a, 
Scosyrev et al., 2012b). Between 16.5% and 25.6% of men who have had curative 
treatment will develop what is known as a biochemical recurrence (a sustained and 
increasing rise in PSA from an undetectable level to over 0.2ng/mL) (Boorjian et al., 
2011, Antonarakis et al., 2012, Peters et al., 2018) and up to 29.8% of these men will 
develop metastatic disease (Antonarakis et al., 2012). 
EAU guidelines recommend castration for those with metastatic disease, either by 
bilateral sub-capsular orchidectomy, or by starting androgen deprivation therapy 
(ADT) (Heidenreich A., 2013, Urology, 2018). This will help palliate symptoms and 
slow progression to symptomatic disease and sequelae such as spinal cord 
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compression (Pagliarulo et al., 2012).  This leads to remission in 80-90% of patients 
(Hellerstedt and Pienta, 2002) until the cancer becomes androgen independent; so 
called castrate-resistant prostate cancer (CRPC) which occurs at a median time of 12-
33 months (Denis and Murphy, 1993). Median overall survival from the time of 
diagnosis is 42 months and from castration resistance is approximately 18 months 
(James et al., 2015, Tangen et al., 2012). 
Treatment of CRPC is offered according to Eastern Co-operative Oncology Group 
(ECOG) performance status, patient preference, co-morbidities and age and is 
summarised in Figure 1.1.  Management of metastatic prostate cancer has changed 
dramatically in recent years, due to the availability of second line agents, and 
information gathered from large randomised trials such as STAMPEDE and LATITUDE 
(James et al., 2015, Fizazi et al., 2017) which has helped demonstrate survival 
benefits both from these new interventions as single agents and from different 
combinations of these therapies. 
 
 
Figure 1.1 A Flowchart to demonstrate treatment of metastatic castrate resistance 
prostate cancer (adapted from EAU guidelines (Urology, 2018)). Treatment is based 




1.3 The molecular properties of cancer cells 
1.3.1 Genetic alterations – background 
Hanahan and Weinberg’s seminal paper on the hallmarks of cancer in 2000 identified 
six traits that cancer cells exhibit which separates them from normal healthy cells 
(Hanahan and Weinberg, 2000).   Following the expansion of understanding of 
cellular interactions and regulatory pathways, they revisited these concepts in 2011. 
In this update they described the importance of classifying tumour cells as a complex 
tissue rather than an individual collection of cells, and that the interaction between 
the different cell types within a tumour plus the host microenvironment all play a 
role in tumorigenesis (Hanahan and Weinberg, 2011).  
Understanding these hallmark traits and characteristics of tumour cells, and the 
signalling pathways involved in proliferation and metastasis is key when considering 
the genomic alterations known to be prevalent in prostate cancer. 
 
 
Figure 1.2 The eight hallmarks (1. sustaining proliferative signalling, 2. evading growth 
suppressors, 3. resisting cell death, 4. enabling cellular immortality, 5. inducing angiogenesis, 
6. activating invasion and metastasis, 7. avoiding immune destruction and 8. reprogramming 
cellular energy)  and two characteristics (1. tumour promoting inflammation and 2. genome 
instability and mutation) of cancer cells as described by Hanahan and Weinberg. (printed 





1.3.2 The hallmarks of cancer 
The first hallmark is the ability to sustain proliferative signalling. Healthy tissue 
architecture is maintained by the homeostatic control of the number of cells within 
the tissue. Regulation of the production and release of signals that allow progression 
through the cell cycle is therefore necessary to limit the growth and division of cells 
within the tissue.  Cancer cells override these regulatory pathways, resulting in a 
permanent ‘switched on’ state, and ensuing excessive cell proliferation.  
The second trait is a cancer cell’s ability to evade the regulatory processes that 
supress cell proliferation, which would be a natural method of controlling the 
uninhibited proliferation outlined above.  Tumour suppressor genes such as RB or 
TP53 act as gatekeepers to determine either progress through the cell cycle, or 
senescence and apoptosis.  Mutations affecting these regulatory pathways can result 
in inactivation or inhibition of these suppressors. 
The third hallmark is a cell’s ability to avoid apoptosis.  This mechanism of cell death 
is a natural sequela of physiological stresses, such as DNA damage following hyper-
proliferation, or signalling imbalances from elevated levels of oncogenes.   
The ability to become immortal, despite multiple replications is the fourth hallmark 
of a cancer cell.  Normal healthy cells have a limited number of replication cycles 
before either reaching a crisis point and undergoing apoptosis or entering the non-
proliferative state of senescence.  Tumour cells can replicate an unlimited number of 
times, and do not appear to reach such a crisis.     
Angiogenesis is an embryological phenomenon, or a temporary physiological process 
activated in the developed human, for example during wound healing or the female 
menstrual cycle.  However, the need for tumours to develop their own vasculature in 
order to sustain growth and remove metabolic waste is enabled by an abnormal 
signalling process, predominantly affecting vascular endothelial cells. This ‘angiogenic 
switch’ results in ongoing vascularisation and is the fifth hallmark of cancer (Hanahan 
and Weinberg, 2011). 
The sixth trait, which was the final feature of Hanahan and Weinberg’s original 
description, is the ability of a cell to invade or metastasise. For a cell to leave a 
tumour and form a metastatic deposit in a different tissue, a series of discrete 
simultaneous steps are required, including shedding into the circulation, survival 
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within the vasculature and arrest and extravasation into a new organ (Chambers et 
al., 2002).  This concept was first discussed by Paget when he described his ‘seed and 
soil hypothesis’ in the late nineteenth century (Fidler, 2003).  This theory described 
the propensity for certain cancers to metastasise to pre-defined tissues, which was 
attributed to the relationship between the tumour cell (the seed) and the host 
environment (the soil). This was subsequently challenged by Ewing in the early 
twentieth century (Ewing, 1928) who proposed that the anatomy of the vasculature 
was instead responsible (e.g. in prostate cancer, Batson’s venous plexus is a network 
of valve-less veins, connecting the deep pelvic veins with the internal vertebral veins, 
and thus allowing a potential direct anatomical spread of tumour cells from the 
prostate to the spine) (Nathoo et al., 2011).  A combination of these theories in 
addition to other concepts such as epithelial to mesenchymal transition (EMT), the 
relationship between the tumour cells and the surrounding tissue, and the role that 
non-cancerous cells play in invasion, e.g. by secreting enzymes that degrade the 
extracellular matrix, has meant that metastasis is now understood to have two 
distinct phases.  Phase one is the journey of the tumour cells from the tissue of origin 
to a distant site, and phase two is the adaptation of the cells to the adopted 
environment at this site in order to form a successful colony. 
In the revised paper, Hanahan and Weinberg described two new hallmarks and two 
characteristics that enable the expansion of tumour cells (Hanahan and Weinberg, 
2011). These characteristics are the inflammatory response that aids tumour growth, 
and the genetic instability of tumour cells.  Inflammation can be a normal 
physiological response to cellular injury, but it can have the unwanted effect of 
providing a flood of molecules such as growth factors and enzymes. These are then 
utilised by the tumour cells to promote growth or encourage alterations to the 
tumour micro-environment e.g. extracellular matrix breakdown, turning the 
inflammatory response from a physiological to a pathological process.  The second of 
these characteristics describes how tumour cells outgrow and dominate the healthy 
cells within a tissue.  For tumour cells to display the hallmark characteristics outlined 
above, there must be a series of genetic alterations within these cells. These can 
either come about through spontaneous mutation, or impaired gene expression, e.g. 
inactivation of tumour suppressor genes due to the tumour cells secreting altered 
signals.  Ultimately, DNA defects are usually identified, and the cell terminated 
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before expansion is enabled. For such defects to result in clonal expansion 
demonstrates the instability of these cells caused by an inability to respond to DNA 
damage. 
The two new hallmarks of cancer cells are the reprogramming of energy metabolism 
and the evasion of immune destruction (Hanahan and Weinberg, 2011).  The fact 
that solid tumours are more prevalent in both immuno-compromised individuals and 
animal models, suggests that there is an important role played by the immune 
system in tumour regulation.  Whilst the relationship is complex - cancers in immuno-
compromised individuals are often virally mediated - there is evidence of a more 
favourable prognosis in tumours displaying a higher proportion of cytotoxic T 
lymphocytes and natural killer cells, compared to those with lower numbers (Larsen 
et al., 2014). 
The second of these new hallmarks describes the alteration of cellular energy 
metabolism in order to sustain the increased metabolic demands brought about by 
cellular expansion.  The switch to glycolysis as the preferred pathway for glucose 
metabolism, even in aerobic conditions is found in tumour cells.  Despite this 
resulting in lower energy yields when compared to oxidative phosphorylation, this is 
counteracted by upregulation of glucose transporters into the cytoplasm.  Activation 
of oncogenes such as RAS and Myc, in addition to hypoxic conditions can upregulate 
glycolysis, and there are often two subpopulations found within the tumour cells – 
those which are glucose dependent and those which use the lactate waste product of 
these cells as their fuel. 
 
 
1.4 The molecular characteristics of prostate cancer 
1.4.1 Background 
Prostate cancer genomic alterations are complex, but understanding not only where 
the mutations arise but also when they occur during the evolution of the prostate 
tumour, from localised to metastatic castrate-resistant, can help us have a better 
appreciation of risk, and assist drug and target discovery (Schoenborn et al., 2013, 
Berger et al., 2011). Combined with the knowledge of the hallmark characteristics of 
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tumour cells it enables an appreciation of how the common mutations found in 
prostate cancer cause abnormal cell growth and tumour formation. Whilst a small 
number of mutations are familial, the majority are somatic (Kral et al., 2011), and 
those most commonly seen in prostate cancer affect cell proliferation and regulation, 
or cause genetic instability due to prevention of DNA damage repair or impaired 
transcription.  
Mutations can broadly be categorised into somatic copy number alterations (SCNAs) 
(either deletions or amplifications), structural rearrangements or point mutations 
(Schoenborn et al., 2013). SCNAs are very common in prostate cancer, and the 
increased incidence in metastatic compared to primary tumours is indicative of the 
increased genomic instability in advanced disease.  Structural rearrangements ensue 
when repair of DNA breaks, occurring as a normal consequence of replication, is 
defective, resulting in fusion or rearrangement of chromosomes (Tomlins et al., 
2005). Point mutations, where a single nucleotide base is either inserted or deleted, 
are often found in tumour suppressor genes, oncogenes or DNA mismatch repair 
enzymes in prostate cancer (Taylor et al., 2010, Kumar et al., 2011). 
The most frequent genomic alterations seen in advanced prostate cancer are those 
affecting the androgen receptor signalling pathway, the PI3K/mTOR/AKT pathway, 
transcription factors, and oncogenes/tumour suppressor genes (Schoenborn et al., 
2013, Shtivelman et al., 2014, Alvarez-Cubero et al., 2017, Perdomo et al., 2018). A 





Name of gene Percentage found in 
Primary Tumour % 
Percentage found in 
Metastatic Tumour % 
Type of 
alteration 
AR 0 65 Amplification, 
Mutation 
ZBTB16 4 11 Mutation, 
Homozygous 
deletion 
NCOR1 3 6 Mutation, 
Homozygous 
deletion 
NCOR2 2 8 Mutation, 
Homozygous 
deletion 
FOXA1 4 11 Mutation 
SPOP 11 8 Mutation 
 
a) The most common genomic alterations affecting primary and metastatic prostate 
cancer samples related to the Androgen Receptor signalling pathway 
 
Name of gene Percentage found in 
Primary Tumour % 
Percentage found in 
Metastatic Tumour % 
Type of 
alteration 
PTEN 17 40 Mutation, 
Homozygous 
deletion 
PIK3CA 2 5 Mutation 
PIK3CB 1 7 Mutation, 
amplification 
PIK3R1 0 5 Mutation 
 
b) The most common genomic alterations affecting primary and metastatic prostate 





Name of gene Percentage found in 
Primary Tumour % 
Percentage found in 
Metastatic Tumour % 
Type of 
alteration 
ATM 6 5 Mutation 
BRCA2 3 7 Mutation, 
Homozygous 
deletion 
CDK12 2 5 Mutation 




c) The most common genomic alterations in primary and metastatic prostate cancer 
affecting DNA repair 
 
Name of gene Percentage found in 
Primary Tumour % 
Percentage found in 
Metastatic Tumour % 
Type of 
alteration 
TP53 8 50 Mutation, 
homozygous delt. 
RB1 1 9 Mutation, 
homozygous delt. 
KMT2C 4 15 Mutation 
KMT2D 3 12 Mutation 
ERG 46 42 Fusion 
MYC 7 13 Amplification 
d) The most common genomic alterations in primary and metastatic prostate cancer 
affecting other genes. 
Table 1.3 The most common genomic alterations in primary and metastatic prostate cancer 
affecting a) the androgen receptor signalling pathway, b) the PI-3-Kinase pathway, c) DNA 






1.4.2 The androgen receptor signaling pathway 
The androgen receptor (AR) is a nuclear protein, coded for by the AR gene on the X 
chromosome (Gao et al., 2005). It is regulated by the binding of the two ligands 
testosterone or 5-α-dihydrotestosterone in the cytoplasm, and primarily acts as an 
intracellular transcription factor.  It is predominantly expressed in tissues such as the 
prostate or epididymis (Keller et al., 1996), and as prostate cancer is androgen 
sensitive, blocking production of the ligands, or binding of these at the receptor site 
form the basis of several treatments. 
In localised prostate cancer the AR has not been found to be altered, but instead 
there can be mutations affecting regulators or co-factors of the AR in up to 50% of 
these tumours (Taylor et al., 2010). In contrast in castrate-resistant disease, 
alterations in the AR have been found in up to 60% of tumours and activation of the 
AR still occurs despite castrate levels of circulating androgens (Taylor et al., 2010, 
Grasso et al., 2012). For the tumour to survive and continue to proliferate despite 
low levels of androgens mean that alternative mechanisms of AR activation have 
occurred in the castrate model. Gene amplification (Visakorpi et al., 1995), activation 
of AR mutations (Sun et al., 2006), formation of splice variants (Dehm et al., 2008, Hu 
et al., 2009) an increase in the expression or activation of AR regulators or co-factors 
e.g. FOXA1 (Grasso et al., 2012) and increased synthesis of androgens from within the 
tumour (Stanbrough et al., 2006) are all potential mechanisms by which the AR can 
be reactivated in advanced disease.  
The ligand-binding domain is the most frequent site of AR mutations and can result in 
truncated forms of the receptor (Alvarez-Cubero et al., 2017). ARv7 is a splice variant 
of the receptor that lacks a ligand binding domain and is resistant to the actions of 
tumour-suppressor SPOP (An et al., 2014). It has been the focus of attention in recent 
years because of the associated resistance to drugs Enzalutamide and Abiraterone 
(Antonarakis et al., 2014). 
 
1.4.3 The PI3K/AkT/mTOR pathway 
The PI3K/AkT/mTOR pathway is important in regulation of the cell cycle and is 
activated in several cancers in response to different growth factor receptors or cell 
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adhesion molecules (LoPiccolo et al., 2008, Yap et al., 2008). In prostate cancer, 
activation of this pathway is often caused by mutations in the tumour suppressor 
PTEN (Taylor et al., 2010, Berger et al., 2011) and leads to unregulated cellular 
proliferation. It is associated with more aggressive disease and poorer disease 
specific outcomes (Majumder and Sellers, 2005, Yoshimoto et al., 2007). 
Activation of PI3K causes phosphorylation of the cellular phospholipid 
phosphoinositides, which has a key role in intracellular signalling. This causes 
activation of AKT, a sereine/threonine kinase which also plays an important role in 
cell fate, affecting apoptosis, transcription and progression through the cell cycle 
(LoPiccolo et al., 2008). MTOR, another sereine/threonine kinase, is produced as 
either a direct or indirect product of AKT and is important for protein translation 
(Schoenborn et al., 2013). 
Mutations in the individual PI3KCA, AKT1 and MTOR genes can lead to upregulation 
of this pathway, in addition to tumour suppressor genes as previously mentioned 
(Robbins et al., 2011, LoPiccolo et al., 2008). Because of the relative frequency in 
which mutations affecting this pathway present (up to 50% of primary tumours and 
100% of metastases (Schoenborn et al., 2013, Robbins et al., 2011)), and the 
correlation with aggressive disease, therapeutic targets have been explored, some of 
which are in early clinical trials (Chang et al., 2015, Yap et al., 2008). 
 
1.4.4 Transcription Factors 
Because of their role in the regulation of gene expression, mutations affecting 
transcription factors will have a significant impact on the expression of key genes. In 
prostate cancer, mutations in the forkhead box proteins FOXA and FOXO, which are 
DNA binding transcription factors, affect the AR signalling pathway. Amplifications 
and point mutations in FOXA1 have been demonstrated in the disease (Robbins et al., 
2011, Grasso et al., 2012), and the ensuing suppression of AR signalling causes a 
more aggressive, de-differentiated tumour to develop (Imamura et al., 2012). 
Mutations in FOXA1 are one of the most commonly observed alterations see in 
prostate cancer, and can be found in between 7 and 10% of patients (Institute, 2018, 
Taylor et al., 2010, Grasso et al., 2012). Conversely FOXO proteins have a tumour 
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suppressor role, and regulate transcription related to epithelial-mesenchymal 
transition. Therefore mutations causing decreased expression in FOXO will impede 
DNA damage repair, inhibit regulation of cell cycle progression and facilitate 
unregulated EMT (Katoh et al., 2013, Ma et al., 2018). Post-translational 
phosphorylation of FOXO proteins can occur in prostate cancer due to upregulation 
of AKT, which inhibits their function as transcription factors (Katoh et al., 2013). 
To date there are no clinically available agents directed at these forkhead box 
proteins, but they remain of interest as potential therapeutic targets. 
 
1.4.5 Oncogenes and tumour suppressor genes 
Alterations to proto-oncogenes, either by point mutations, chromosomal 
rearrangement or gene amplification result in these genes becoming activated 
oncogenes, and the subsequent activation of unregulated cell proliferation.  
Amplifications of the MYC oncogene are found in a third of patients with castrate-
resistant prostate cancer (Shtivelman et al., 2014), and this can cause sustained 
signalling and immortality (Gil et al., 2005).  This gene also opposes the action of 
NKX3.1, an important prostatic tumour suppressor gene, (Shtivelman et al., 2014) 
and when MYC amplification is found in conjunction with NKX3.1 loss in primary 
tumours it is associated with a high risk of recurrence (Locke et al., 2012). 
Oncogenic fusion products can occur as a result of chromosomal rearrangement. The 
most commonly seen example of this in prostate cancer is the fusion of the androgen 
regulated TMPRSS2 gene with members of the ETS family (most commonly the ERG 
oncogene) resulting in the TMPRSS2-ERG fusion gene. This binds to and inhibits 
existing androgen receptors, causing DNA damage and preventing further AR 
expression, resulting in the development of poorly differentiated tissue. Presence of 
this specific mutation is therefore associated with advanced and aggressive disease 
and is found in at least 50% of prostate tumours (Tomlins et al., 2005, Mehra et al., 
2008). Increased and impaired expression of ERG can also occur as a result of the 
TMPRSS2-ERG fusion gene; an example of which is a shortened ERG protein, resistant 
to the effects of the tumour suppressor SPOP (Shtivelman et al., 2014). 
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Mutations in the speckle-type POZ tumour suppressor SPOP are found in 6-10% 
(Institute, 2018) of prostate cancers and are associated with a poor prognosis 
(Barbieri et al., 2012). They occur independently of other mutations, specifically 
those affecting PTEN, PI3K, TP53 and TMPRSS2-ERG fusion (Barbieri et al., 2012, 
Zhang et al., 2014). Mutations in SPOP are not only associated with impaired ERG 
degradation but also with inactivation of AR degradation (Adamo and Ladomery, 
2016, Gan et al., 2015). 
Other common tumour suppressor gene mutations include those in TP53 and PTEN. 
TP53 mutations can be found in 18% of prostate cancers (Institute, 2018) and 
prevent the normal cell cycle arrest when DNA damage is detected, thus allowing 
progression of cells containing altered DNA. Loss of phosphatase PTEN, a tumour 
suppressor which is a regulator of both the PI3K/AkT/mTOR pathway and the G2/S 
checkpoint in the cell cycle, is seen in approximately 20% of patients with organ 
confined disease and 50% of those with metastatic cancer (Jamaspishvili et al., 2018).  
The loss of one allele of PTEN is seen in high grade prostate intraepithelial neoplasia 
(PIN), a precursor of prostate cancer, but loss of both alleles is predictive of 
progression and a more aggressive phenotype. Increased production of glucose 
mediator GLUT-1 is seen as a consequence of impaired PTEN regulation of 
thePI3K/AkT/mTOR pathway. This encourages increased cellular glucose uptake to 
fuel aerobic glycolysis which as previously discussed is one of the new hallmarks of 
cancer cells. 
 
1.5 Tumour heterogeneity and the metastatic process 
1.5.1 Background 
Identifying mutations in these genes and pathways is important both in the discovery 
of a new predictive biomarker in prostate cancer but also potentially as targets for 
therapeutic intervention. Sequencing of tumours has provided expansion of the 
understanding of commonly occurring mutations, and recent studies have started 
teasing out the order in which these mutations occur (Wedge et al., 2018). 
Personalised medicine may be able to provide an individualised prognosis and 
identify therapeutic options, but it can be expensive. Unless the presence or absence 
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of a specific gene can be linked to a defined clinical outcome, e.g. resistance to a 
treatment such as in breast cancer or gastrointestinal stromal tumours (Day et al., 
2017, Mei et al., 2018), then it is less clinically useful. It therefore does not currently 
contribute to the treatment pathway outside of clinical trials in the majority of 
tumours (Robinson et al., 2015).  
As demonstrated, mutations can develop during the progression of the disease, 
therefore for sequencing to be of help in guiding treatment, it must be performed on 
tissue that can reflect not only the previous treatment, but the most genomically 
altered part of the tumour (Robinson et al., 2015). As previously discussed, taking 
biopsies from prostate, bone or lymph nodes in the predominantly elderly population 
is a significantly morbid procedure, and the treatment decision based on the results 
would have to be considered validated enough to make the risk worthwhile. 
Tissue sampling must also take into consideration the heterogeneity of the tumour, 
and in the case of a metastatic patient, whether the biopsy sample from a solid lesion 
is representative of disseminated disease. Sampling bias from solid tumours may 
prevent the detection of the most aggressive sub-clone.(Burrell et al., 2013)  One 
study describes an upgrading of 54.4% of tumours following radical prostatectomy, 
that were thought to be Gleason 3+3 tumours at biopsy, demonstrating that even at 
whole cell level the inaccurate detection of the most aggressive cancer cells may 
occur (D'Elia et al., 2014). When subcellular expression is of interest it is vital to 
identify the most aggressive population to begin with. 
 
1.5.2 Heterogeneity in cancer in general 
It is well documented that inter-tumour heterogeneity exists amongst tumours of the 
same tissue type.(Lawrence et al., 2013, Vogelstein et al., 2013, Burrell et al., 2013). 
This can occur due to specific mutations affecting the signalling pathways and may 
affect the rate of disease progression or the response to a certain treatment e.g. 
hormone sensitivity in breast cancer (Burrell et al., 2013, Weigelt and Reis-Filho, 
2009). Indeed the treatment that is offered, especially in cancers such as breast 
cancer, is often based on different biomarkers being identified between different 
individuals (Bedard et al., 2013). 
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Further to this there is evidence that within an individual tumour there are areas of 
heterogeneity and different sub-clone populations, and that this intra-tumour 
heterogeneity is clinically significant (Burrell et al., 2013, Meacham and Morrison, 
2013, Greaves and Maley, 2012, Lawrence et al., 2013, Robertson-Tessi et al., 2015). 
There are two main theories as to how tumours develop in this way; the theory of 
clonal evolution and the cancer stem cell theory. 
1.5.3 The theory of clonal evolution 
The theory of clonal evolution proposed by Nowell in 1976 is based on Darwinian 
concepts and describes how any of the cells within a tumour could be responsible for 
the development of a genotypically different sub clone (Nowell, 1976). During cell 
division, mutations are inherited by daughter cells and with the increasing number of 
cell divisions, cells acquire more and more mutations. As described earlier, if these 
mutations affect the identification of abnormal cells or the ability to halt abnormal 
cell division, these cells will continue to increase in number and will result in genetic 
instability.  Within a tumour either a clonal sweep, linear evolution or branched 
evolution will occur (Burrell et al., 2013). In the case of a clonal sweep, a mutated cell 
divides and the daughter cells outnumber and take over the entire tumour, 
ultimately not causing a heterogeneous pattern. However intra-tumour 
heterogeneity occurs as a result of linear or branched evolution due to a new clone 
failing to oust the existing cell population, or multiple sub clones developing 
simultaneously. Some of these sub clones may be eliminated by treatment but the 
most aggressive survive and go on to cause metastases and further sub clone 
formation (Nowell, 1976, Bedard et al., 2013, Klein, 2013).  
Evidence to support the theory of clonal evolution is demonstrated by the 
progression of a benign adenoma to an adenocarcinoma which can then form 
metastases. 
1.5.4 The cancer stem cell theory 
In contrast to the theory of clonal evolution, the cancer stem cell theory proposes 
that there are only specific cells within a tumour that are responsible for tumour 
development (Fabian et al., 2009). These cancer stem cells behave in a similar way to 
normal healthy stem cells in that they are capable of self-renewal, are resistant to 
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apoptosis and can differentiate into numerous cell types (Gil et al., 2008). This 
concept was first proposed by Bonnet and Dick in the late 1990s, when they explored 
the expression of surface markers of cells to be transplanted for a leukaemic 
xenograft model (Bonnet and Dick, 1997). They discovered that much lower numbers 
of cells expressing a specific combination of markers caused tumour development in 
immuno-compromised mice, in comparison to a larger number of heterogeneous 
cancer cells. 
Cancer stem cells give rise either to daughter stem cells or to progenitor cells, the 
latter of which have a limited capacity to self-renew but are fast-cycling and can 
differentiate following interaction with the local tissue microenvironment. It is 
proposed that it is these progenitor cells that are the casualties of chemotherapy, but 
that the slow-cycling stem cells are the reason for a period of dormancy after 
treatment, followed by recurrent metastases (Fabian et al., 2009, Gil et al., 2008). 
Normal healthy stem cells can become cancer stem cells following a series of genetic 
or epigenetic mutations.  
Bonnet and Dick’s work was pivotal in the support of this theory over Nowell’s, 
however there are questions to consider. One of the challenges in terms of 
identifying these cells is that the markers on the cell surface are either no different to 
the other cells or stem cells within the tissue, or there is considerable variation 
between different stem cells and the proteins they express (Scatena et al., 2013). 
This makes identifying the specific population of interest very difficult. It is also 
possible, albeit with a much higher number of cells, to induce in vivo tumour 
formation with an un-sorted cell population. However, given the inability to identify 
specific cancer stem cell markers, this could be explained by a heterogeneous cancer 
stem cell population. 
1.5.5 The role of the microenvironment 
Whilst it is not clear which of these theories is correct, what is known for certain is 
that tumour development and heterogeneity occur as a result of both intrinsic 
epigenetic and genetic changes, and the extrinsic interactions of the tumour with its 
microenvironment (Scatena et al., 2013, Gupta and Massague, 2006, Junttila and de 
Sauvage, 2013, Burrell et al., 2013). As we know from Hanahan and Weinberg’s work, 
a cell’s ability to overcome apoptosis is one of the hallmarks of cancer. But the ability 
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of a cancer cell to interact with its host environment will not only increase its 
survival, but its ability to metastasise (Gupta and Massague, 2006).  
Tumours undergo Gompertzian growth, displaying a prolific early phase followed by 
slowing of growth as the tumour increases in size (Hanin and Bunimovich-
Mendrazitsky, 2014). During this, the tumour cells and the native healthy cells will 
compete with each other for nutrients, vascular supply and space to expand (Greaves 
and Maley, 2012). The surrounding tissues in a healthy subject will normally impede 
tumour development, but damage to these tissues, e.g. via UV light, radiotherapy or 
dietary variations such as an increase in adipose tissue, can promote changes. This 
can result in local responses such as an increase in inflammatory infiltrates or 
vascularisation, which could assist with tumour growth or act as a protective 
measure against targeted therapies (Greaves and Maley, 2012, Junttila and de 
Sauvage, 2013).  
The plasticity of the tumour cells, as supported by the cancer stem cell theory, means 
that they may exhibit different phenotypes if they embed in different anatomical 
locations, due to the interaction with the host environment (Klein, 2013, Bedard et 
al., 2013). Different sub-clones may favour a specific micro-environment either in the 
treatment naïve patient or following pharmacological intervention (Burrell et al., 
2013, Junttila and de Sauvage, 2013, Gatenby et al., 2011).  Protein expression can 
differ between cells of different sub-populations, and this has made it possible to 
identify the origin of metastatic deposits from within the primary tumour or other 
metastases (Lawrence et al., 2013, Gundem et al., 2015).  
1.5.6 Metastasis and the spread of cells from the primary tumour 
Metastasis is considered to be the primary cause of disease-related death in patients 
with cancer (Fidler, 2003, Gupta and Massague, 2006, Pantel and Brakenhoff, 2004, 
Klein, 2008), accounting for up to 90% of cancer mortality (Gupta and Massague, 
2006). The cells within a tumour that evolve with certain attributes such as increased 
motility, invasiveness and an ability to survive targeted treatments are more likely to 
escape from the tumour of origin (Bednarz-Knoll et al., 2012). These cells escape into 
the vasculature either from the primary tumour, or from existing metastatic deposits 
(Gundem et al., 2015) via a number of proposed mechanisms, and a proportion of 
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these will form distant colonies in target organs (Gupta and Massague, 2006, Kim et 
al., 2009, Chiang and Massague, 2008). In order for this to happen, a series of steps 
must occur, and failure to progress along this cascade may prevent the development 
of metastases (Fidler and Kripke, 2015, Fidler, 2003). These steps are outlined in 
Figure 1.2.  
 
Figure 1.3 A diagram to demonstrate the steps involved in the development of 
metastasis. Taken from The pathogenesis of cancer metastasis: the seed and soil 
hypothesis revisited (Fidler, 2003) 
 
It was originally thought that the formation of metastases was seen in the advanced 
stages of tumour progression. However it is now understood that cells can escape 
from the tumour at an early stage and lie dormant at distant sites until the relevant 
oncogenes are activated, or the host environment supports propagation (Klein, 
2008). These disseminated cancer cells (DCCs) are present in the lymph nodes and 
bone marrow of patients with known tumours or with a previous cancer diagnosis 
but considered to be in remission with no clinical or radiological signs of metastases 
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(Klein, 2013, Bednarz-Knoll et al., 2012). Sampling of these cells has demonstrated 
considerable heterogeneity. Some of the patients with these DCCs will never develop 
metastases and therefore these cells may either die or lack the stem cell 
characteristics that would enable them to progress. But some of these DCCs will 
embed, and the combination of their genetic code and their interaction with the host 
environment will enable them to proliferate and develop secondary tumours 
sometimes many years from the initial diagnosis of the primary. 
1.5.7 Epithelial to Mesenchymal Transition 
In order for cells to detach from the primary tumour and escape into the adjacent 
vessels, they need to undergo either active or passive detachment. Passive transfer 
into the vasculature could occur due to physical tumour invasion, and would not 
require the cells to change physically (Bednarz-Knoll et al., 2012). However, it has 
been proposed that some undergo a phenotypic change called epithelial-
mesenchymal transition (EMT) (van Denderen and Thompson, 2013, Christiansen and 
Rajasekaran, 2006).  This process is similar to the epithelial-mesenchymal transition 
and subsequent mesenchymal-epithelial transition (MET) that occurs in embryos to 
allow movement of cells and colonisation in different anatomical 
locations(Christiansen and Rajasekaran, 2006) or in wound healing (Stone et al., 
2016).  It is unclear whether the process is a full requirement for all cells as biopsies 
of solid metastases have shown epithelial characteristics (Tarin et al., 2005, 
Christiansen and Rajasekaran, 2006).  The fact that epithelial cells have been 
detected from blood samples in patients with metastatic disease would support the 
argument that not all cells need to undergo this process in order to escape from the 
primary tumour, or that EMT is incomplete and cells may still display epithelial 
characteristics (Thiery and Sleeman, 2006, Christiansen and Rajasekaran, 2006, 
Armstrong et al., 2011).   
EMT is an evanescent and reversible process that is associated with aggressive 
disease, formation of metastases and resistance to chemotherapy and other drug 
treatments (Mani et al., 2008, May et al., 2011, Yang et al., 2004, Christiansen and 
Rajasekaran, 2006). Cancer stem cells often express mesenchymal markers and 
induction of EMT can also induce progenitor cells to develop stem cell like 
characteristics (Mani et al., 2008, Kong et al., 2011). Epithelial cells classically interact 
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with each other via close cell membrane contact along the length of the cell. They 
display apical-basal polarisation and have a structured cytoskeleton. Adoption of the 
mesenchymal phenotype results in a change in polarity and cytoskeleton and a 
reduction of the cell contact so that interaction with adjacent cells is much more 
focal. These changes result in the cells being held much more loosely together, 
encourage increased motility, and degradation of the extra-cellular matrix (Thiery 
and Sleeman, 2006, Christiansen and Rajasekaran, 2006, Bednarz-Knoll et al., 2012). 
E-cadherin, a transmembrane protein expressed by epithelial cells, is down-regulated 
during EMT in exchange for an upregulation of the mesenchymal marker N-cadherin 
(Bednarz-Knoll et al., 2012).  
It is thought that cells undergo EMT as a result of the interaction with their local 
environment, and that stresses such as hypoxia or pH changes can induce the 
relevant signals. One of the characteristics of EMT is a resistance to apoptosis, so it is 
thought that a cell that undergoes this phenomenon is more likely to survive as it 
escapes into the bloodstream and travels through this potentially hostile 
environment to a distant site (Valdes et al., 2002, Barrallo-Gimeno and Nieto, 2005, 
Peinado et al., 2007). The induction of migratory potential in adjacent cells can also 
occur as a result of cytokine expression by cells undergoing EMT (Voss et al., 2011, 
Fernando et al., 2011). This may assist with invasion and the potential of a cell to 
metastasise. Protein synthesis can also be down-regulated as a result of the unfolded 
protein response, a feature of EMT that decreases the rigidity of the cell (Wouters 
and Koritzinsky, 2008). 
A combination of growth factors, transcription factors and micro-RNAs are 
responsible for the activation of EMT (Bednarz-Knoll et al., 2012, Mani et al., 2008, 
Tam and Weinberg, 2013). Signals from the microenvironment induce signalling 
between cells, which in turn causes activation of various transcription factors 
including TWIST, SLUG, SNAIL and ZEB-1 (Zheng and Kang, 2014). The TGF-β and WNT 
signalling pathways are both responsible for the induction of EMT and result in the 
phosphorylation of cytoplasmic proteins which have a key role in the regulation of 
genes affecting cell mortality (De Craene and Berx, 2013). Higher levels of these 
proteins have been found in tumour cells in advanced, aggressive disease (Mani et 
al., 2008, May et al., 2011, Li et al., 2013).  
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In prostate cancer, despite being a tumour of epithelial origin, expression of 
EMTrelated genes or mesenchymal proteins has also been associated with advanced 
disease. Increased N-cadherin expression and loss of E-cadherin correlates with 
higher Gleason score and poorer clinical outcome (Contreras et al., 2010, Gravdal et 
al., 2007). And in castrate resistant disease, a prevalence of genes associated with 
EMT has been found when compared to tumours that are still androgen sensitive 
(Gorges et al., 2012, Armstrong et al., 2011, Chen et al., 2013). 
Proteins such as CD44, MT1-MMP, Vimentin, Twist, SNAIL, SLUG, and ZEB1 and 2 are 
all increased in EMT and could act as potential biomarkers for the detection of cells 
undergoing this process (Hernandez et al., 2015, Li et al., 2013, Raimondi et al., 
2011). 
1.5.8 Heterogeneity in the patient with metastatic prostate cancer 
In recent years there has been a move away from the reliance on solid tissue biopsies 
in advanced prostate cancer.  In those patients who develop metastatic disease 
following radical treatment, biopsies or whole prostate specimens may be many 
years old and basing targeted treatments on genetic information from this tissue 
would be suboptimal. 
Prostate biopsy is a morbid procedure that is usually reserved for the aid of diagnosis 
in younger patients, or those with lower PSA values who are likely to receive radical 
treatment. Diagnosis in patients who have a clinically suspicious prostate (T3/T4) is 
made by a combination of PSA, digital rectal examination and bone scan or CT 
(Heidenreich A., 2013).  With the current treatment cascade, prostate, lymph node or 
bone biopsy serve no additional purpose once metastatic disease has been diagnosed 
and carry a high morbidity. The standard treatment of androgen deprivation therapy 
would be initiated for all men falling into this category, and despite our knowledge of 
tumour heterogeneity, there is currently no way to predict which of these men would 
respond well, and which are likely to develop early castrate resistance. 
Whilst some of the current clinical trials include serial biopsies in order to gain 
further understanding of the molecular changes that occur in conjunction with 
disease resistance, we do not have routine access to IHC specimen libraries in 
metastatic patients compared to those who have undergone radical surgery.  This, 
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along with the sampling bias associated with any solid tissue biopsy because of 
tumour heterogeneity, has meant that response to treatment is still based on serum 
PSA levels, and to date, no new biomarker has been developed for use in the clinic. 
A large number of the studies looking at sequencing of metastatic tumours have 
been performed on post-mortem samples, or as part of a clinical trial (Robinson et 
al., 2015). Putting the cost aside, without any solid tissue to sequence in the majority 
of metastatic prostate cancer patients, and no reliable biomarker, we are effectively 
treating these men blindly. Once castrate-resistance occurs, progression along the 
treatment cascade is largely reliant on PSA levels and clinical symptoms. 
 
1.6 Biomarkers in prostate cancer and potential options for new markers 
1.6.1 Background 
In patients diagnosed with metastatic disease, and also those who present with it 
following treatment with curative intent, especially in the ageing patient, it would be 
prudent to predict at this diagnosis who is likely to respond well to ADT.  This would 
allow earlier commencement of second-line agents before there is a significant 
decline in cardiovascular status. Monitoring of response both to ADT and other 
treatments such as docetaxel, enzalutamide and abiraterone is also currently 
suboptimal because of the lack of a reliable biomarker. In the era where personalised 
medicine is becoming an increasingly popular concept there is a distinct need for a 
new prostate cancer biomarker. 
1.6.2 PSA 
As discussed, PSA is the only FDA approved biomarker available for use in clinical 
practice in the UK, but can be elevated for reasons other than prostate cancer, and 
also downregulated in advanced or poorly differentiated disease (Leibovici et al., 
2007).  PSA values are inconsistent with tumour burden and levels at diagnosis of 
metastatic cancer do not correlate with the subsequent success of ADT. This makes it 





1.6.3 Prostate-specific Membrane Antigen 
Prostate-specific membrane antigen (PSMA) is a type II membrane protein that acts 
as a glutamate-releasing carboxypeptidase (Carter et al., 1996). Although expressed 
in all types of prostate tissue, it has also been found in other tumours including renal, 
bladder, testicular and breast (Chang, 2004). Despite it being upregulated in prostate 
cancer when compared to benign prostate disease (Israeli et al., 1994), until recently 
its role a biomarker in prostate cancer has not been utilised. Early studies showed 
that its expression was not significantly different in the serum of patients with benign 
versus malignant disease (Murphy et al., 2000).  
The expression of PSMA is now known to be inversely related to the androgen levels 
of a tumour (Meller et al., 2015), and recent interest has increased due to the 
understanding that PSMA-induced glutamate release has been shown to activate the 
PI3K-AKT-mTOR pathway (Kaittanis et al., 2018). PSMA ligands such as 68Ga-PSMA-11 
have been used an adjunct to Choline-PET scans to look for early recurrence in 
prostate cancer patients treated with curative intent (Afshar-Oromieh et al., 2017, 
Afshar-Oromieh et al., 2015). It has increased the sensitivity of these scans but it 
currently only available for use as part of clinical trials. 
1.6.4 Epithelial vs Mesenchymal markers 
Although over 90% of solid tumours have an epithelial phenotype (Christiansen and 
Rajasekaran, 2006), some are mesenchymal in origin, e.g. sarcoma and melanoma. 
Because of the potential for cells to undergo EMT, ideally even cells from an 
epithelial tumour should be analysed for their expression of both epithelial and 
mesenchymal proteins. If this occurred in addition to a tumour specific marker they 
could be resolutely identified as circulating tumour cells from a specific tumour of 
origin. Unfortunately, this assumes an existent reliable tumour-specific biomarker, 
which is not available in prostate cancer.   
Typical epithelial markers such as EpCAM and Cytokeratin have a higher expression in 
epithelial tumours when compared to normal epithelial tissue (Litvinov et al., 1994). 
They are the most commonly used epithelial markers when looking at epithelial 
cancers (Barriere et al., 2014), but other proteins involved with tissue architecture 
such as E-cadherin or Zona Occludens (ZO) have also been used (Gall and Frampton, 
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2013, Lindley and Briegel, 2010). In tissue undergoing EMT, epithelial marker 
expression is often downregulated and therefore not detectable. 
Mesenchymal markers such as fibronectin and vimentin have been co-expressed 
alongside cytokeratin in patients with metastatic breast and prostate cancer 
(Armstrong et al., 2011). However, as prostate cancer is an epithelial and not a 
mesenchymal tumour, looking for markers associated with EMT rather than pure 
mesenchymal markers may be more useful. Proteins such as Twist1, Zeb1, Akt and 
PI3K (Odero-Marah et al., 2018, Barriere et al., 2012, Lo et al., 2017) have all been 
explored. 
1.6.5 Androgen Receptor 
Because of the dependence of prostate tumour growth on AR signalling, the AR has 
been used as a biomarker in the detection of prostate cancer for many years (Chen et 
al., 2004). With the discovery of up to twenty-two splice variants of the AR (Chen et 
al., 2004), detection of these and other genomic alterations discussed previously 
have been used when looking at prostate cancer (Beltran et al., 2016). 
1.6.6 Matrix-Metalloproteinases 
Matrix metalloproteinases (MMPs) have been studied extensively with respect to 
tumour biology because of their ability to degrade the extracellular matrix; a key step 
in the metastatic process (Seiki, 2003, Escaff et al., 2010, Fingleton, 2008).  There are 
28 of these zinc-dependent endopeptidases, usually expressed in cells of 
mesenchymal origin. Studies looking at the link between MMP expression and 
prostate cancer have found higher serum levels of MMP-2 and MMP-9 in patients 
with prostate cancer compared to healthy controls, but no difference between those 
with bony metastases compared to locally confined disease (Incorvaia et al., 2007, 
Salminen et al., 2006). Similarly levels of MMP-7 were found to be higher in patients 
with metastatic prostate cancer compared to healthy controls and those with focal 
disease (Szarvas et al., 2011). Some of the MMPs have been expressed in epithelial 
tumour cells and membrane type-1 matrix metalloproteinase known as MT1-MMP or 
MMP-14 as per the classification system has been shown to induce morphological 
change from the epithelial to mesenchymal phenotype in prostate cancer cells (Cao 
et al., 2008). Whilst it is not a prostate specific marker, due to the propensity of 
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prostate cancer to metastasise to bone, it could be used as a surrogate in the 
absence of a reliable prostate specific biomarker. 
1.6.7 Stem cell markers 
Many studies have looked at the cancer stem cell in prostate cancer, and the role of 
stem cell marker expression has been explored in relation to tumour progression 
(Ruscetti et al., 2015, Bae et al., 2011), metastasis (Matsika et al., 2015, Mochizuki et 
al., 2004, Conley-LaComb et al., 2012), and resistance to treatment (Qin et al., 2012, 
Hoogland et al., 2014, Kerr et al., 2015). It is unlikely that cancer stem cells are true 
stem cells, as their ability to divide and differentiate are different from, albeit similar 
to stem cells, (Valent et al., 2012), but they will express a variety of stem cell 
markers. This variation in expression has been one of the challenges in identifying 
them, as due to tumour heterogeneity there will be differences in marker expression 
(Deng and Tang, 2015) between tumours, which in turn need to be correlated with 
clinical significance. In prostate cancer, cancer stem cell markers such as CD117 (Kerr 
et al., 2015, Wiesner et al., 2008), CD133 (Miyazawa et al., 2014, Oktem et al., 2014), 
CD44 (Klarmann et al., 2009, Oktem et al., 2014), and CXCR4 (Dubrovska et al., 2012) 
have been explored.  
Following Yamanka’s seminal work looking at using embryonic stem cell makers 
Oct3/4, SOX2, Klf4 and c-myc to restore pluripotency in mouse (Takahashi and 
Yamanaka, 2006) and human fibroblasts (Takahashi et al., 2007), the expression of 
these four transcription factors has frequently been used to prove the stem-ness of 
cancer stem cells. Expression of embryonic stem cell gene signatures in breast cancer 
was shown to be  associated with an adverse prognosis(Ben-Porath et al., 2008) and 
since those data in 2008, this has been replicated in other cancers such as bladder, 
prostate, renal and rectal (Amini et al., 2014, Hepburn et al., 2019, Rasti et al., 2018, 
You et al., 2018).   
Work generated from prostate tissue by my group, prior to the start of this project, 
demonstrated that specific key regulators of the embryonic stem cell gene expression 
network, transcription factors Oct4, Sox2 and Nanog (OSN), are significantly up-
regulated in patients that develop castrate resistant disease more rapidly, and 93% of 




Figure 1.4 The survival curve for patients expressing Oct4/SOX2/Nanog in prostate tumours. 
Patients were categorised as having either high (n = 69) or low (n = 67) expression, as 
determined by visual assessment of immuno-histochemical staining of prostate tumours. 
Taken from The induction of core pluripotency master regulators in cancers defines poor 
clinical outcomes and treatment resistance (Hepburn et al., 2019). 
1.6.8 Circulating biomarkers 
As discussed already, the disseminated cancer cells that have broken away from the 
tumour to cause metastatic deposits will at some point be found in the circulation. 
Many researchers believe these, or a subset of these cells, to be the cancer stem cells 
from the original tumour (Harris and Kerr, 2017, Reya et al., 2001, Schilling et al., 
2012). Over the past decade there has been increasing interest in these so-called 
circulating tumour cells (CTCs) and also circulating tumour DNA (ctDNA); the DNA 
fragments from disrupted tumour cells . Exploring the protein expression, or 
sequencing these cells or ctDNA to look for known mutations can provide useful 
clinical and prognostic information without the need for a solid tumour biopsy 
(Boysen et al., 2018, Chaux et al., 2012, Reid et al., 2010, Thoma, 2014, Torquato et 
al., 2019). Translational studies, such as the TRACERX study (Tracking cancer 
evolution through therapy) have looked at sequencing ctDNA from patients with non-
small cell lung cancer (Abbosh et al., 2017). By detecting single-nucleotide variants 
(SNVs) from the ctDNA in patients pre and post-operatively, it has been possible to 
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predict disease relapse. Whilst individual patient sequencing is expensive, it may help 
to guide who receives post-surgical chemotherapy in lung cancer patients. Currently 
only 5% of patients receive benefit from this treatment and 20% experience 
significant toxic side effects (Abbosh et al., 2017). A higher volume of ctDNA, as 
determined by a higher allele fraction, has also been found to be associated with 
more aggressive disease in both lung (Abbosh et al., 2017) and breast cancer (Garcia-
Murillas et al., 2015).  
Other circulating biomarkers such as messenger RNAs (mRNA) (Souza et al., 2017, 
Ross et al., 2012, Olmos et al., 2012) and micro RNAs (miRNA) (Matin et al., 2018, 
Richardsen et al., 2019) also contain genetic information about the tumour and have 
been investigated in patients with prostate cancer.   
Whichever circulating biomarker is chosen, a simple blood sample, which carries a 
much lower risk to the patient than a prostate biopsy, and can be easily repeated at 
serial intervals, is an appealing platform for biomarker discovery.  
 
1.7 Circulating tumour cells 
1.7.1 CTCs and their role as a liquid biopsy 
Although tumour cells were first identified in the circulation in the nineteenth 
century (Ashworth, 1869), it was not until the early 2000s that interest in them took 
off. Because they can be accessed via a blood sample, they offer a way of potentially 
accessing genetic information about the tumour to aid in diagnosis and prognosis, or 
provide information for therapeutic targets (Danila et al., 2011c, Bedard et al., 2013, 
Hu et al., 2013). Blood samples are easily obtainable, can be repeated at several 
time-points throughout the course of the disease and carry minimal risk to the 
patient. In addition, the problem arising from the changing expression of different 
sub-clones as a result of adaptations in the local environment from therapeutic 
interventions can in theory be overcome by serial blood sampling (Gatenby et al., 
2011). In the patient with metastatic prostate cancer, they offer an insight into the 
extent of the disease which cannot reliably be ascertained by conventional 





The FDA defines a circulating tumour cell as one with the following characteristics: 
positive for the epithelial membrane glycoprotein EpCAM, and the cytoskeleton 
protein Cytokeratin (CK) 8,9 or 19, an intracellular nucleus, negative CD45 expression 
(a common protein expressed by all types of leucocyte) and a cell area of more than 
4x4µm2 (Attard and de Bono, 2011).  A study looking at the presence of CTCs in 
healthy volunteers concluded that cells reaching the classification were occasionally 
present in the blood of patients with no known cancers.  But these events were so 
rare and the numbers so small that a CTC count of 2 or more was classified as 
abnormal (Allard et al., 2004). To date the only FDA approved platform for detection 
of CTCs is the Veridex CellSearch, which uses the principles of positive immuno-
magnetic selection for EpCAM, before further analysis based on additional protein 
expression (Kagan et al., 2002). 
1.7.3 Morphology 
Studies of the physical structure of CTCs have found them to be highly pleomorphic 
and for there to be considerable heterogeneity in their shape (Park et al., 2014). This 
is perhaps unsurprising given that they represent a highly disparate population. The 
increased level of cytomorphological variation has been demonstrated to correlate 
with poor prognosis in prostate cancer (Ligthart et al., 2013). CTCs are usually larger 
than leucocytes, and whilst in other cancers this increase in size is discernible, 
prostate CTCs are smaller than those found in patients with breast or colorectal 
cancer (Coumans et al., 2013) in addition to being smaller to prostate cancer cell lines 
(Park et al., 2014, Coumans et al., 2013). They have a higher nuclear: cytoplasmic 
ratio due to the relative size of the nucleus in a small cell, which makes them more 
rigid and less deformable, an important feature when considering filtration devices 
for capture. The nucleus is often hyperchromatic or lobulated; also a characteristic 
which can assist detection (Dhar et al., 2016). 
1.7.4 Enumeration 
One of the main issues affecting the detection of CTCs is the ability to pick out the 
tumour cells from the background of millions of leucocytes and erythrocytes. Even in 
patients with a heavy metastatic burden, these CTCs are comparably rare events, and 
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on average it is thought that the ratio may be as few as one CTC per billion blood 
cells (Maheswaran and Haber, 2010, Ross et al., 1993). This poses a challenge for 
identification but recent advances in cell sorting technology have enabled low 
numbers of tumour cells to be identified from this background noise (Alix-Panabières 
and Pantel, 2014, Danila et al., 2011c).  
The original studies looking at the presence of CTCs in patients with metastatic 
cancer reported prognostic information based on CTC count. A higher number of 
CTCs at diagnosis or an increase during treatment is associated with poorer overall 
survival, and more of these cells are seen in patients with bony metastases compared 
to those with M1a disease (metastases to non-regional lymph nodes) (Danila et al., 
2007, Lorente et al., 2018).   
Johann de Bono’s seminal work looking at the number of CTCs in patients with 
metastatic prostate cancer and treatment with chemotherapy demonstrated an 
increase in overall survival of 21.7 months vs 11.5 months for those patients who had 
a CTC count of 5 or less per 7.5ml of blood before treatment, detected via the 
CellSearch platform (p = <0.0001) (de Bono et al., 2008). Patients whose count 
decreased to 5 or less following chemotherapy had a favourable prognosis compared 
to those who had more than 5 and it was shown that CTC count was more sensitive 
than PSA values in predicting survival and recurrence. This was a key factor leading to 
the approval of CTC count as an FDA verified research method in the assessment of 
metastatic prostate cancer. In both breast and colorectal cancer, the number of CTCs 
used as a threshold for poor prognosis is 5 and 3 respectively (Cristofanilli et al., 
2004, de Bono et al., 2008, Cohen et al., 2008). 
More recently, in patients treated with abiraterone acetate, a post-treatment CTC 
count of less than 5 per 7.5ml of blood has also been shown to correlate with a more 
favourable prognosis, although the study had low numbers of patients (Danila et al., 
2011a). In patients with androgen sensitive disease a count of 3 or more CTCs can 
predict time to progression of castrate resistance (Goodman et al., 2011). 
However, with the number of CTCs detected in an individual patient often being very 
low, even with a high capture efficiency there is a risk of classifying patients into the 
wrong prognostic group.  Further analysis of CTC count has shown that the actual CTC 
number is indicative of prognosis, with higher CTC counts associated with poorer 
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survival (Scher et al., 2009) and a significant increase or decrease in number being 
more relevant than crossing the threshold of 5 cells per blood sample.  CTC count 
now forms part of the TNM staging system for breast cancer (Lv et al., 2016) but its 
value with respect to changing treatment decisions is undefined.   
There have also been studies demonstrating that over a third of patients with 
metastatic disease falling into the poor prognosis category have no CTCs in their 
blood (Mego et al., 2011, Riethdorf et al., 2007). This could be due to the rigid 
classification of what a CTC is, and because of the heterogeneity of advanced 
tumours; phenotypic changes such as EMT are not accounted for and cells are not 
detected. 
As a result CTC count is not yet a constituent of clinical guidelines and does not have 
any bearing on treatment choice outside of clinical trials (Alix-Panabières and Pantel, 
2014).     
1.7.5 Characterisation 
Whilst enumeration of CTCs has been shown to provide prognostic clinical 
information, studies are now looking at sub-cellular characterisation to enable 
further understanding of the biology of these cells and to provide additional 
prognostic information or for the development of therapeutic agents (Alix-
Panabières and Pantel, 2014).   
In addition to conventional flow cytometry, platforms such as the CellSearch and 
Imagestream not only sort the cells but allow investigation of sub-cellular 
characteristics by enabling the detection of additional proteins of interest using 
immunofluorescence microscopy.  Fluorescence in situ hybridisation (FiSH) has been 
used to look for genetic mutations and in metastatic prostate cancer studies using 
this technique have identified mutations in PTEN, the androgen receptor and the 
TMPRSS2-ERG fusion (Attard et al., 2009, Shaffer et al., 2007, Leversha et al., 2009).  
Reverse transcription polymerase chain reaction (RT-PCR) and reverse transcription 
quantitative PCR (RT-qPCR) amplify specific transcripts to allow characterisation but 
there is a high false positive rate and it is not possible to determine whether the 
read-out is sourced from a true CTC or another cell within the blood (Lowes and 
Allan, 2014).  Micro-arrays with specific probes can be utilised to provide detailed 
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genetic information at an RNA or DNA level.  Whilst this is a useful technique and can 
be used as an absolute comparison between different samples, or samples from the 
same patient at different stages of treatment, it provides huge amount of data and 
can be costly to analyse (Magbanua et al., 2012, Lowes and Allan, 2014).  Sequencing 
techniques such as Sanger sequencing, pyrosequencing and next-generation 
sequencing can also be used to determine the genotype of CTCs.  Using next-
generation sequencing, several mutations found in CTCs from patients with colorectal 
cancer were identified that had originally been overlooked in the primary tissue but 
were found on subsequent analysis (Heitzer et al., 2013). 
Functional assays such as the EPISPOT are also available but rely on cell culture so 
fixed or apoptotic cells would not be assessed using this method.  The EPISPOT 
technique involves the culture of CTCs on plates containing fluorescently-conjugated 
antibodies against proteins of interest followed by visualisation using a fluorescence 
microscope (Danila et al., 2011b, Ramirez et al., 2014). 
Characterisation is potentially impeded by the technique used to select the CTCs. 
Background noise from samples contaminated with excess white blood cells is an 
issue – less so if looking for the presence or absence of a gene, but potentially 
problematic if looking for quantitative levels of expression (Hu et al., 2013). The 
choice of detection platform to use will depend on the phenotype of the tumour 
(whether it is largely epithelial or mesenchymal), the morphology of the cells, the 
question needing to be answered (e.g. enumeration versus the need for downstream 
analysis) and the local availability and cost of processing. 
1.7.6 Isolation methods – background 
Several different methods such as immuno-selection, filtration techniques and 
translational assays have been utilised to detect CTCs. As discussed, the CellSearch 
platform is the only FDA validated method for detection of CTCs. This was initially 
validated in 2004 for the use in breast cancer (Allard et al., 2004, Cristofanilli et al., 
2004, Riethdorf et al., 2007) and subsequently prostate in 2007 (Danila et al., 2007, 
de Bono et al., 2008) and colo-rectal cancer in 2008 (Cohen et al., 2008).  An 85% 
capture rate is reported using this method (Allard et al., 2004).   
38 
 
The detection of CTCs is possible via a variety of techniques based on the principles 
of either positive or negative selection. Positive selection relies upon the sensitivity 
of the machine or procedure to identify the small number of CTCs amongst the 
billions of other cells. Negative selection involves the removal of red and white blood 
cells in order to allow the CTCs to be detected more easily. However, by depleting 
the other cells first to negatively select for the CTCs there is the risk of damaging the 
cells of interest during the sorting process.   
There are two important issues to address when evaluating CTC detection platforms. 
The first is the reproducibility of any technique.  For a biomarker to be of clinical use 
it needs to be robust enough to withstand inter-laboratory use and despite many 
methods quoting high recovery rates of CTCs in an experimental setting, they have 
not been reproduced by other laboratories.  The second is that the definition of a CTC 
appears to vary and those platforms that do not use the FDA criteria may not be 
measuring the same cell population.  It is possible that the FDA definition needs to be 
revised and that by being too restrictive it is not identifying the true number of CTCs.  
But those that use tumour specific markers in place of the standard epithelial 
markers cannot be directly compared to the CellSearch.   
1.7.7 Isolation – protein-based selection 
Cells can be sorted based on their expression of specific proteins using conventional 
flow cytometry or a combination of flow, immunofluorescence or magnetic selection.  
The majority of clinical studies use protein-based selection due to the high retrieval 
rates and reproducibility.  Fluorescently-conjugated antibodies can be used to detect 
target antigens on the cells of interest and depending on the type of platform used 
for analysis, information on the location and level of a specific protein either on the 
cell surface or within a cell can be collected.  If the platform contains multiple filters, 
it enables several proteins to be analysed simultaneously. Obtaining a visual image of 
the cell also helps rule out false positive results. A major disadvantage of using 
fluorescence is the bleed that transpires from using fluorochromes of similar 
wavelengths.  If two fluorochromes attached to different antibodies emit similar 
wavelengths they could be excited by light of one wavelength and give overlapping 
results. There are ways of minimising this effect but care must be taken to avoid 
eliminating cells (Lowes and Allan, 2014). Ideally fluorochromes of very different 
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wavelengths would be used but most flow cytometers or light-microscopes are 
limited by the numbers of filters they have and when investigating multiple proteins 
this is not always practical. Downstream analysis is possible if a platform with a cell 
sorting capacity is used (Watanabe et al., 2014, Vishnoi et al., 2015, Magbanua et al., 
2012, Gorner et al., 2015, Carpenter et al., 2014). 
The CellSearch uses immuno-magnetic beads conjugated to the EpCAM antibody. 
Cells positive for EpCAM are magnetically selected and visually analysed by a trained 
technician to ensure they meet the FDA morphological criteria (Danila et al., 2011c). 
These cells are then analysed further for expression of CK, CD45 and DAPI. It is 
possible to use one additional tumour specific marker when using the CellSearch 
which allows further characterisation. This could be one of the three that have been 
made commercially available, HER2, EGFR and IGF-1R, or users have the option to 
develop their own using the remaining fluorescent channel (Lowes and Allan, 2014). 
Microfluidic chips have been developed using silicon micro-pillars, embedded with 
EpCAM antibodies, arranged in a herringbone pattern (Nagrath et al., 2007, Gleghorn 
et al., 2010, Stott et al., 2010, Ozkumur et al., 2013). The herringbone structure aids 
micro-fluidic mixing which allows the best opportunity for antibody contact as the 
larger cells, most likely to be CTCs, are more likely to come into contact with the 
pillars. 
Other methods such as nanostructured substrates and microtubes have also utilised 
anti-EpCAM antibodies but are not in widespread use (Wang et al., 2009, Wang et al., 
2011).  In vivo sampling has been used to detect CTCs on a real time basis in patients 
with lung and breast cancer (Saucedo-Zeni et al., 2012). A wire impregnated with 
EpCAM antibodies was inserted via a venous cannula into patients for 30 minutes 
and CTCs were detected in 92% of patients.  Further validation studies are ongoing 
with respect to this technique. 
Protein-based selection can not only be used for positive enrichment, but it is can be 
also used for the negative depletion of leucocytes.  Immuno-magnetic beads 
conjugated to the CD45 antibody can be used to deplete whole blood of white blood 
cells.  Although this process has been shown to cause minimal effect on the retrieval 
rate of CTCs, it does not accomplish high purities due to residual white cells 
(Harouaka et al., 2014, He et al., 2008).   
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The Imagestream platform is a combined flow-cytometer and high resolution 
microscope (Zuba-Surma et al., 2007). This enables cell sorting based on size and/or 
protein expression which can be done either via the analysis software or visually.  
The majority of white cells are depleted using immuno-magnetic separation prior to 
processing, thus it uses principles of negative selection, with the aim of achieving a 
high CTC output.  Five lasers are used to detect fluorescence from cells expressing 
proteins attached to conjugated antibodies.  Recovery of CTCs is approximately 50-
60% (Dent et al., 2015) so its use in clinical trials with respect to enumeration may be 
limited.  However, it provides very detailed cellular images so its strength is in sub-
cellular analysis. 
1.7.8 Isolation – physical properties 
There are many ways of isolating CTCs based on their physical properties. Separating 
CTCs from erythrocytes is possible using centrifugation, using the assumption that 
CTCs have a higher density than other cells within the blood.  The cells can be 
subsequently identified using methods such as RT-PCR but most studies report a low 
yield, usually well below 50% (Rosenberg et al., 2002, Muller et al., 2005, Weitz et al., 
1998). This method has been successfully utilised to obtain CTCs from patients with 
small cell lung cancer which have then been implanted into mice to create an in vivo 
model (Hodgkinson et al., 2014). 
Di-electrophoresis is an alternative method that involves the application of an 
electric field to whole blood samples.  If the field is non-uniform the cells become 
polarised and different populations with the same polarisation move towards one of 
the electrodes.  So far this method is in the early stages of clinical use but retrieval 
rates of 70-95% have been documented in spiked cell line samples (Yang et al., 1999, 
Gupta et al., 2012).    
Microfilters work on the principle that CTCs are larger than the majority of the cell 
population in blood and allow the passage of cells smaller than 8µm through specially 
designed pores.  In theory this would allow rapid processing of whole blood samples.  
Several different filter systems exist, made from different materials with different 
shaped pores and they have been used in clinical studies of lung, liver and prostate 
cancer (Hofman et al., 2011, Vona et al., 2004, Chen et al., 2013).  Capture rates of 
89% have been reported (Zheng et al., 2007). 
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The Parsortix system is a platform using micro-filters that capture CTCs in cassettes 
assuming that they are larger and more resistant to compression (Miller et al., 2018). 
Cells can be processed from any bodily fluid, not just blood, which could be useful 
when looking at specific cancers that present with ascites or in bone marrow. When 
compared to the CellSearch Platform, recovery rates were no worse (Hvichia et al., 
2016) and one study found that CTCs were detected in more patients when using the 
Parsortix as EpCAM-negative cells were identified, that subsequently stained positive 
for Cytokeratin (Chudziak et al., 2016). 
There is a risk of missing CTCs if size criteria alone is used.  Compared to erythrocytes 
and leucocytes, CTCs were originally assumed to be larger and less fragile (Alix-
Panabières and Pantel, 2014). Erythrocytes are a-nuclear and predominantly less 
than 4µm in diameter.  Leucocytes differ in size depending on their sub-classification 
but can be up to 20µm in diameter (Bergman, 1995)  As the FDA definition includes 
nucleate cells with a diameter over 4µm, CTCs cannot be distinguished from white 
cells based on size alone.  Filter technology could be improved by reducing pore size, 
but the purity would then be low and subsequent enrichment steps would need to be 
enhanced which may reduce the retrieval rate of the cells on interest.   
1.7.9 Isolation – direct analysis 
It is possible to avoid the risk of cell loss, or the error in detection that occurs with 
techniques using either positive or negative selection, by analysing the whole 
nucleated cell population within a blood sample.  Following the lysis of erythrocytes, 
cells are seeded onto slides, frozen, and high throughput scanning devices can 
examine up to 25 million cells per minute (Harouaka et al., 2014).  It has been utilised 
in some clinical studies (Werner et al., 2015, Marrinucci et al., 2012) but its use is 
currently not widespread. 
1.7.10 Downstream analysis of CTCs for personalised medicine 
Because of the ability to not only enumerate but characterise CTCs, they can now be 
utilised for disease screening or monitoring in response to treatment. Enumeration 
following specific treatments has been explored in pancreatic (Ankeny et al., 2016), 
breast (Smerage et al., 2014, Cristofanilli et al., 2019) and prostate cancer (Lu et al., 
2013, Danila et al., 2011a). In men with prostate cancer treated with androgen 
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deprivation therapy, CTCs have been detected despite un-recordable PSA levels, 
suggesting seeding of the disease when it is apparently dormant (Thalgott et al., 
2013).  Trials looking at the viability of using CTC count as a cancer-related endpoint 
following treatment have discovered that it is a more sensitive prognostic tool than 
PSA decline or an increase in bone or visceral metastases (de Bono et al., 2008, 
Danila et al., 2007).  
Prediction of response to chemotherapy has been shown to be almost 84% accurate 
in patients with small cell lung cancer when looking at chromosomal copy number 
aberrations (CNA) in CTCs (Carter et al., 2017). Similarly, mutations that develop 
during the course of treatment can be identified by serial sampling of CTCs, and in 
non-small cell lung cancer, EGFR mutations linked to drug resistance have been found 
after sequencing CTCs (Forde and Ettinger, 2015).  
In prostate cancer, predicting failure of treatment with enzalutamide and abiraterone 
in metastatic disease has been shown by detecting the AR-V7 variant of the androgen 
receptor in CTCs (Antonarakis et al., 2014). AR mutations have also be found in other 
studies looking at patients with castrate resistant disease on these two treatments 
(Attard et al., 2009, Crespo et al., 2015, Jiang et al., 2010). AR signalling, specifically 
with respect to the relationship with PSA and PSMA has also been explored in CTCs 
(Miyamoto et al., 2012). Attempts were made to look at TMPRSS2-ERG fusion status 
in CTCs to see if this could predict success of abiraterone treatment (Danila et al., 
2011a), but whilst CTC expression was found to correlate to the expression in solid 
tissue, no predictive value was determined. PTEN gene loss in solid tissue has also 
been shown to correlate with PTEN loss in CTCs (Punnoose et al., 2015). 
Whilst these exciting advances form the basis for clinical trials, the adoption of CTC 
enumeration or characterisation does not yet form part of routine clinical practice. 
This is due to the difficulty in reproducing cell counts from the same patient (Leon-
Mateos et al., 2016), the widespread variability of platforms with different recovery 
rates, and the difference in cancer phenotypes, rendering methods such as the 
CellSearch invalid for non-epithelial tumours. 
The utilisation of CTCs for target discovery is an emerging field, and successful 
organoid creation (Drost et al., 2016) and xenograft models (Hodgkinson et al., 2014) 
have been developed. Propagation in culture has been achieved (Cayrefourcq et al., 
43 
 
2015, Kolostova et al., 2015, Kulasinghe et al., 2016) which has enabled this 
heterogenous population to be explored in more detail. Although developing such 
models on an individual patient basis is not currently financially viable outside of the 
research arena, it has advanced the understanding of tumour genetics, and will 
hopefully continue to do so.  
 
1.8 Rationale for the project 
With a wealth of treatments available for metastatic prostate cancer, the lack of a 
predictive biomarker to determine the rate of disease progression is a real issue in 
the management of men with advanced prostate cancer. Although sequencing is now 
much more common following initiatives such as the 100 000 genomes project 
(Consortium, 2019) it is still in its early stages, and the identification of a biomarker 
from a simple blood sample could really benefit patients. In the predominantly 
elderly population that has the disease, declining cardiovascular status is inevitable, 
and earlier introduction of the current second line treatments may increase disease 
specific and overall survival. 
When considering how to approach this project, the local resources and expertise 
were taken into account. Because colleagues within the institute had developed an 
assay using the Imagestream (Dent et al., 2015) to detect CTCs, it was felt that this 
would be a good opportunity to adapt this for use in prostate cancer. The advantage 
of the Imagestream is that multiple markers could be explored concurrently, which 
would potentially allow novel additional information to be obtained, compared to the 
data obtained from CellSearch experiments. Due to the number of studies looking at 
the frequently detected genomic alterations in prostate cancer and the size of the 
cohort that could be included in this study, looking purely at these alterations in CTCs 
was unlikely to yield anything novel. The work that colleagues in the group had 
undertaken looking at the embryonic stem cell signature work in solid prostate tissue 
provided an opportunity to explore this in CTCs (Hepburn et al., 2019). If transcription 
factors Oct4, SOX2 and Nanog could be detected in CTCs from patients with prostate 
cancer, it could be hypothesised that these patients would progress more rapidly to 




In addition, exploring the role of matrix-metalloproteinases, specifically MMP-14 due 
to its ability to induce EMT in prostate cancer (Cao et al., 2008), would give a 
potentially novel way of identifying prostate cancer CTCs undergoing EMT, a 
phenomenon that is currently not possible to explore with the CellSearch platform. 
Plans to culture CTCs would mean that downstream experiments could be 
performed, and this could be utilised by the drug discovery groups within the NICR. 
On a personal level, my rationale for undertaking this work is to enable me to have a 
better understanding of the molecular mechanisms behind prostate cancer. As a 
practising Urologist, I see patients with advanced prostate cancer on a daily basis and 
understand the need for a more sensitive biomarker. My ambitions to be involved, 
and potentially design and lead clinical trials in this area would be supported by a 
more substantial knowledge of the processes involved in molecular biology research, 




Aims and Hypothesis 
 
Aims 
1) To optimise an assay using flow cytometry to enable detection of the stem cell 
markers Oct4, SOX2 and Nanog, alongside epithelial and mesenchymal markers, in 
circulating tumour cells from patients with metastatic prostate cancer. 
 
2) To prospectively evaluate the prognostic value of Oct4, Sox2, Nanog and MT1-MMP 
in circulating tumour cells in metastatic prostate cancers. 
 




The expression of the stem cell markers Oct4, SOX2 and Nanog in circulating tumour cells 
(CTCs) from patients with prostate cancer is associated with more aggressive disease, and 






Chapter 2. Materials and Methods 
2.1 General Laboratory Practice 
All experiments were performed adhering to Newcastle University safety standards for 
working with chemical and biological substances.  Attendance at Control of Substance 
Hazardous to Health (COSHH) and BioCOSHH training was mandatory during the first year of 
the project.  Risk assessments were carried out for each type of experiment and stored in 
the laboratory safety file.  Appropriate protective clothing, gloves or glasses were worn, and 
experiments were carried out in the most suitable location e.g. under fume hoods. 
 
2.2 Primary cell culture 
2.2.1 Routine cell culture using cell lines 
Plates, flasks and other tissue-culture plastic-ware were sourced from Corning. Cell culture 
was performed using an aseptic technique in a class II BioMat-2 microbiological safety 
cabinet (Medical Air Technology Ltd.).  Cell lines were sustained as adherent cultures in 
Roswell Park Memorial Institute (RPMI) media (Hepes modification) (Sigma Aldrich) with 
10% foetal bovine serum (FBS) and 20mM L-glutamine (Sigma Aldrich) to make Full Media.  
Incubation of cells was performed at 37˚C in a humidified environment in incubators with 5% 
CO2 (Heraeus Equipment Ltd.).  Cells were tested for mycoplasma every other month in 
accordance with Institute policy (MycoAlert). 
The following six cell lines were used during experiments (Table 2.1). The first three (LNCaP, 
PC3 and CWR-22Rv1) are prostatic, the fourth (MCF7) from a breast tumour and the final 
two (U2OS and SJSA-1) from an osteosarcoma. In addition, mesenchymal stem cells 
harvested from a patient, and induced pluripotent stem (iPS) cells derived from benign 







Cell Line Tumour origin Anatomical site Reference 
LNCaP Prostate Lymph node metastasis (Seim et al., 2017) 
PC3 Prostate Bone metastasis (Seim et al., 2017) 
CWR-22Rv1 Prostate Mouse xenograft 
(prostate tumour CWR22) 
(Sramkoski et al., 1999) 
MCF7 Breast Pleural effusion (Comsa et al., 2015) 
U2OS Osteosarcoma Bone primary (Niforou et al., 2008) 
SJSA-1 Osteosarcoma Bone primary (Research, 2019) 
Table 2.1 A table listing the cell lines used in this project, their tumour of origin and their 
anatomical site. 
 
Cells under passage 30 were used at all times. Thawing occurred at room temperature and 
the thawed cells were then mixed with 10ml of RPMI Full Media before transfer to a 25cm3 
flask containing 20ml of media. Culture was performed until they had reached 75% 
confluency and they were then split into a 75cm3 or 175cm3 flask, depending on 
requirements for subsequent experiments.  
Phosphate Buffered Saline (PBS) (137 nM NaCl, 83 mM KCl, 10 nM Na2HPO4) was prepared 
for mass laboratory use using PBS tablets in sterilised de-ionised water.  Trypsin was 
prepared using stocks of Trypsin (Sigma Aldrich) diluted to 10% with PBS. 
Cells were passaged by aspirating the media from the flask and washing the adherent layer 
with PBS. 10% Trypsin was added to lift the cells off the flask, and the flask was incubated for 
five minutes at 37˚C. Media was then added (volume dependent on flask size) and the 
cell/media/trypsin suspension was transferred to a universal container. This was then spun 
at 400g for five minutes in a bench-top centrifuge. The supernatant was aspirated, and 
media was added to re-suspend the cell pellet. The required volume of cell suspension was 
then transferred to a fresh flask containing full media and the cells were incubated until 
required. If passage was not required after three days then cells were washed with PBS and 




2.2.2 Cell culture of mesenchymal stem cells 
Cells were obtained from the bone marrow of a paediatric patient and selected using FACS 
(with thanks to Kenny Rankin and Daniel Hipps). Ethical approval for this was granted by the  
NRES Committee North East – Newcastle and North Tyneside 1 Ethics Committee, (July 2018, 
REC Number 17-NE-0361, IRAS Reference Number 233551, ethics form in Appendix). The 
Mesenchymal Stem Cell Phenotyping kit (Miltenyi Biotec) was used to identify Mesenchymal 
Stem Cells by labelling the bone marrow cells with a cocktail of the following fluorescently 
conjugated antibodies: CD14(PerCP), CD20(PerCP), CD34(PerCP), CD45(PerCP), CD73(APC), 
CD90(FITC) and CD105(PE). The Mesenchymal Stem Cells expressing CD73, CD90 and CD105 
were sorted from the remaining cells and expanded in culture. Incubation was performed at 
37°C in humidified conditions with 5% CO2. Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma Aldrich) was used as the basal media, to which 2.5mls/l of Penicillin/Streptomycin, 
0.5mls/l of Gentamicin, 4.5g/l of glucose, 5ml/L of FBS and 2mM of Glutamine were added 
to make full media.  
Media was changed every 48 hours and cells were passaged using Trypsin (as above) when 
they reached 75% confluency. 
2.2.3 Cell culture of iPS cells 
Cells were obtained from benign prostate tissue from patients at the Freeman Hospital, to 
generate iPS cells (with thanks to Emma Curry). Ethical approval for this was granted by the  
NRES Committee North East – Newcastle and North Tyneside 1 Ethics Committee, (July 2018, 
REC Number 17-NE-0361, IRAS Reference Number 233551, ethics form in Appendix).  The iPS 
cells were cultured at 37°C in the incubators described above using mTESR1 medium (Stem 
Cell Technologies) on hESC-qualified Matrigel coated plates (Corning). Full mTESR1 medium 
was made by adding 100ml of the 5x mTESR1 supplement (Stem Cell Technologies) to 400ml 
of mTESR1 basal medium (Stem Cell Technologies). Aliquots of 50ml were kept at –20°C and 
when thawed were used within two weeks. Matrigel plates were prepared by mixing thawed 
hESC-qualified Matrigel (Corning) and DMEM/F12 (Sigma Aldrich) which had been kept at 
4°C (quantities were dependent on plate size). Sufficient Matrigel/DMEM/F12 mixture to 
cover the base of the plate was added and left at room temperature for one hour to set. The 
plates could be used straight away or could be covered with parafilm and kept in sterile 
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conditions at 4°C for up to one week. Prior to passage, plates were prepared by removing 
the Matrigel and adding mTESR1 full media. 
Cells were closely observed for colony formation, and media was replaced at a maximum of 
every 48 hours. To passage iPS cells, fresh plates were prepared as above, media was 
aspirated, and the adherent layer of cells washed with Dulbecco’s PBS (Gibco). (This contains 
no calcium or magnesium). 1mg/ml of Dispase (Stem Cell Technologies) was added to each 
well / plate and the plate then incubated for five minutes at 37°C. The Dispase was aspirated 
and cells washed with DPBS. Cells required manual dissection and colony selection, which 
was performed using sterile pipettes in a fume hood containing a dissection microscope 
(Nikon SMZ1000). Each colony was transferred to a new plate or well that had been 
prepared prior to passage, and incubated at 37°C. 
To create a suspension of iPS cells from adherent colonies, media was aspirated and cells 
were washed as above with DPBS. A volume of Gentle Cell Dissociation Reagent (Stem Cell 
Technologies) (volume dependent on plate size but enough to cover the adherent cells) was 
added to each plate. Following a ten-minute incubation at 37°C, manual disturbance of the 
cell colonies was achieved by pipetting the solution, and the cells/reagent pipetted into a 
universal container. DMEM/F12 media (Sigma Aldrich) was used to wash the plate and 
obtain any residual cells. A matched volume of DMEM/F12 was added to the universal 
before centrifugation on a bench-top centrifuge at 300g for five minutes. The supernatant 
was then aspirated, and cells re-suspended in DMEM/F12 for downstream use. 
2.2.4 Cell culture of circulating tumour cells 
Twelve-well plates (Corning) were prepared with 2ml of Mesenchymal Stem Cell Growth 
Medium (Lonza) in each well. This full media was made from the constituents of the 
Mesenchymal Stem Cell Growth Medium Bullet-kit (Lonza), which contains the basal media, 
set volumes of L-glutamine and antibiotics, and a pre-determined cocktail of growth 
supplements. All the constituent parts were combined, kept at 4°C and used within six 
months. After infections in initial experiments, additional Nystatin (ThermoFisher Scientific) 
was added to the Full Media at a dilution of 1:100. 
4mls of patient blood (ethics form in Appendix) was processed using the Easy Sep CTC 
Human enrichment kit (Stem Cell Technologies) described in section 2.6.2. The resulting cell 
suspension (in a 15ml Falcon tube, (Corning)) was very gelatinous so centrifugation at 400g 
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for ten minutes on a bench-top centrifuge was performed. The supernatant was discarded, 
apart from a very small volume at the bottom of the Falcon tube (no pellet was visible due to 
low cell numbers). 2.4mls of Full Mesenchymal Stem Cell Growth Media was used to 
resuspend the cells and this was divided equally between the twelve wells. Media was 
changed every 48 hours. 
To passage these cells, media was aspirated and each well of the cells washed with 2mls of 
DPBS. 2mls of Gentle Cell Dissociation Reagent (Stem Cell Technologies) was added to each 
well prior to incubation at 37°C for ten minutes. Manual disturbance of the remaining 
adherent cells was performed using a sterile pipette, and the cell/reagent suspension was 
transferred to a Falcon tube containing 1ml of media. Bench-top centrifugation was 
performed at 400g for ten minutes and the supernatant aspirated. Fresh media was added 
to the pellet to resuspend, and the cell suspension was then divided into plates or flasks 
containing fresh Full Mesenchymal Stem Cell Media. 
 
 
2.3 Collection, storage and preparation of whole blood samples to use on 
Imagestream and FACS 
2.3.1 Patients 
Blood was collected from patients at the Freeman Hospital, Newcastle-upon-Tyne, using 
consent forms accepted by the NRES Committee North East – Newcastle and North Tyneside 
1 Ethics Committee, who approved the use of patient blood for this study (October 2012, 
REC Number 12-NE-0256, ethics form in Appendix). All patients attended Urology or Uro-
oncology clinics and were either diagnosed, or were new patients, with suspected prostate 
cancer. Patients with different stages of the disease were targeted to try and obtain 
representative samples. Samples taken from new patients whose investigations 
subsequently showed no evidence of prostate cancer were used as the benign cohort. 
2.3.2 Collection and storage of blood 
Vacutainers (BD Biosciences) were used to obtain the samples to ensure sterility, and blood 
was collected in tubes containing potassium ethylene-diaminetetraacetic acid (K2EDTA) (BD 
Biosciences). Samples were put into plastic bags and transported back to the NICR at room 
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temperature in a second bag clearly marked with the UN 3373 label (used for diagnostic 
human specimens). All specimens were processed within four hours of sampling. Samples 
were logged using the Achiever Medical sampling tracking system, which was updated once 
processing had occurred. 
Any whole cells remaining after processing were kept at –80°C in a locked freezer designated 
for specimens that were covered by the HTA. HTA training was undertaken within the first 
year of the project and renewed after three years.  
2.3.3 Red cell lysis 
For each 2ml of blood to be processed, a 50ml Falcon tube was prepared. 5mls of 10% MACS 
BSA solution (Miltenyi Biotec) was added to each Falcon tube and put on to a bench-top 
tube roller for twenty minutes to ensure coating of the entire tube. The MACS was then 
aspirated to leave an empty, coated tube. A 1:5 dilution of PhosFlow Fix/Lyse buffer (BD 
Biosciences) and distilled water was made, and 40ml of this solution was added to each 
Falcon tube. Tubes were warmed in a water bath for one hour at 37°C prior to the addition 
of whole blood. 
200µl of FcR blocking agent (Miltenyi Biotec) was added to each original 4ml blood tube and 
mixed by gently pipetting. 2mls of blood was then pipetted into the prepared Falcon tube 
containing 40mls of the diluted Fix/Lyse buffer. Tubes were inverted six times to ensure full 
mixing and then replaced in the water bath for a further 20 minutes. The tubes were then 
transferred to a bench-top centrifuge and spun at 500g for eight minutes. The supernatant 
was aspirated and the remaining pellet (containing white cells and potential CTCs) was 
resuspended in 500µl of Robosep buffer (Stem Cell Technologies) and transferred to a 15ml 
Falcon tube. Each 50ml Falcon tube was washed with 1ml of Robosep to capture any 
remaining cells, and this was added to the 15ml Falcon tube from the same sample.  
2.3.4 White cell depletion 
Each 15ml Falcon tube was spun on a bench-top centrifuge at 500g for eight minutes at 
room temperature. The supernatant was aspirated, and the cell pellet was resuspended in a 
further 500µl of Robosep buffer. 50µl/ml of the EasySep Human CD45 Depletion cocktail 
(Stem Cell Technologies) was added and mixed via gentle pipetting. The tube was then left at 
room temperature for 15 minutes. 100µl/ml of EasySep Dextran RapidSpheres (Stem Cell 
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Technologies) was added to the tube, gently mixed via pipetting and left at room 
temperature for ten minutes. 4.5mls of Robosep buffer was added to the Falcon tube and 
gently pipetted. 10µl was then aspirated onto a haemocytometer to count the cells. 
The tube was inserted (with cap off) into the EasySep magnet, The Big Easy, (Stem Cell 
Technologies) for ten minutes at room temperature. Following this, the tube with magnet 
still attached was inverted into a clean 15ml Falcon tube. A further 10µl was aspirated onto 
the haemocytometer and cells counted, to enable the depletion to be calculated. The 
contents of the tube were then spun at 500g for eight minutes on a bench-top centrifuge, 
and the supernatant discarded. 
2.3.5 Permeabilisation and addition of antibodies 
A permeabilisation agent was made using the 10x PermWash (containing Saponin and FBS) 
(BD Biosciences) diluted into distilled water at a 1:10 ratio. 1ml of the 1:10 solution was 
added to each 15ml Falcon tube and the re-suspended cells were transferred to an 
Eppendorf. Cells were Incubated in the permeabilisation agent for one hour at room 
temperature or overnight at 4°C. Eppendorfs were spun in a bench-top Eppendorf centrifuge 
at 400g for five minutes and the supernatant discarded. Cells were re-suspended in 100µl of 
1:10 PermWash prior to the addition of antibodies. 
2.3.6 Antibodies used for samples processed on the Imagestream and FACS 
Antibodies used for the Imagestream and FACS assays described in Chapters 3 and 4 
respectively are listed in Tables 2.2 and 2.3. Optimisation is discussed in these chapters. 
Antibody Fluorochrome Isotype control Concentration Manufacturer 
EpCAM PE-Vio615 REA(S) 1:200 Miltenyi Biotec 
Oct4 AF488 IgG1 1:50 BD Biosciences 
SOX2 AF555 IgG2a 1:50 BD Biosciences 
Nanog Per-CP Cy5.5 IgG1 1:50 BD Biosciences 
CD45 PECy7 IgG1 1:50 BioLegend 
DAPI - - 1:500 BioLegend 
Table 2.2 A table listing the antibodies, isotype controls, concentrations and manufacturers 




Antibody Fluorochrome Isotype 
control 
Concentration Manufacturer 
EpCAM BV650 IgG1 1:200 BD Biosciences 
Cytokeratin PE Cy7 IgG1 1:200 2BScientific 
Vimentin AF647 IgG1 1:100 Santa Cruz 
MT1-MMP PE IgG1 (3µl:10
4 cells) Merck 
Millipore 
Oct4 BV421 IgG1 1:50 BD Biosciences 
SOX2 FITC REA 320 1:50 Miltenyi 
Nanog PerCP Cy5.5 IgG1 1:50 BD Biosciences 








Table 2.3 A table listing the antibodies, isotype controls, concentrations used and 
manufacturers for the antibodies used in the FACS assay described in Chapter 4. 
 
All antibodies were added to the Eppendorfs containing the cells suspended in the 100µl of 
1:10 PermWash at the concentrations listed above. For the MT1-MMP, CD45 and CD16 in 
the FACS assay, 10µl of the suspension was aspirated onto a haemocytometer so that the 
volume of antibody could be applied per volume of cells. This is because these three 
antibodies are expressed by white cells and the number of white cells would vary between 
patients. 
Following incubation for one hour at room temperature, Eppendorfs were spun at 400g for 
five minutes on a bench-top centrifuge and the supernatant discarded. Cells were then 
resuspended in 200µl of Robosep (remaining in the Eppendorf) if for processing on the 





2.4 Processing and Analysing samples on the Imagestreamx 
2.4.1 The Imagestreamx 
The Imagestreamx Mark II (Merck) is a combined high-resolution microscope and flow 
cytometer which allows the user to view the image of any event displayed on the dot plot. It 
is described in detail in Chapter 3. 
2.4.2 Laser set-up to enable comparable data 
In order to compare results between clinical samples, laser settings must be kept the same. 
The laser settings are initially determined by running a sample containing cells expressing 
each antigen of interest and adjusting the strength of each laser so that the lowest power is 
used whilst still being able to visualise the cell. In this case a combination of cell types is 
required as no one cell will display all antigens. If the lasers are all run on high power there 
will be significant fluorescence bleed into adjacent channels which will result in false 
positives. The antithesis of this is the risk of not detecting cells that only weakly express the 
antigen. As with antibody optimisation, the laser set-up needs to be performed using cell 
lines or synthetic beads rather than the clinical samples, so there is always a risk that the 
laser settings may be too low for detecting expression in the clinical samples. A compromise 
needs to be reached and acceptance of under-detection was chosen over the risk of 
collecting data with large numbers of false positives (Table 2.4). 
Laser (nm) Power used (mW) Maximum Power 
Available (mW) 
405 50 150 
488 30 200 
561 40 200 
642 85 150 





2.4.3 Single colour controls 
Cell lines or Ultracomp ebeads (ThermoFisher Scientific) were used as single colour controls 
for the Imagestream experiments. 100 000 cells or 1 drop of ebeads were stained with each 
individual antibody that was used in the experiment and suspended in 100µl of Robosep. 
The Brightfield camera was turned off and the laser strength was set initially on maximum 
and then decreased to the lowest level possible that still enabled good visualisation of the 
cell/bead. This was repeated for cells/beads expressing each antibody in turn until settings 
for all lasers had been determined. A suspension of cells containing cells/beads expressing 
all antibodies was run to ascertain whether the final laser settings permitted adequate 
visualisation and the laser settings were fixed and recorded. 500-1000 cells/beads for each 
individual antibody were then captured and this data was used to prepare a compensation 
matrix. This matrix calculated the spectral overlap of each fluorophore. 




Figure 2.1 Images of the synthetic speed beads displaying fluorescence of three antibodies 
Oct4, SOX2 and Nanog at 1:50 concentration. 
2.4.4 Compensation matrix 
The fluorescence in the channel of each sample from the single colour control is plotted 
against the fluorescence in the adjacent channel in order to determine what true 
fluorescence is and what is bleed. The best fit linear regression for each fluorochrome is 
determined and this data then contributes to a compensation matrix. This shows the 
proportion of overlap of each fluorochrome into adjacent channels. Overlap of <0.1 (10%) is 
considered acceptable by the manufacturer but the smaller the overlap the more accurate 
the data. If a value of more than 10% is observed, a graph of the fluorescence in the channel 
plotted against the channel into which it bleeds can be plotted. This can help identify 
outliers (e.g. doublets or debris that is very bright). Gating this out will help identify true 
positives and the matrix can be recalculated. 
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Once the clinical sample has been run, the completed matrix is then applied to the raw 
image data file to create a data analysis file. Cell populations can then be analysed according 
to a number of variables, including size (area), shape and intensity of the attached 
fluorochrome. 
2.4.5 Thresholds and reduction of false positives 
Due to the presence of mesenchymal stem cells in healthy blood, performing the assay on 
patients without prostate cancer would identify any circulating, non-cancer Oct4, SOX2 and 
Nanog positive cells. It is therefore necessary to perform the assay on healthy volunteers 
and compare the results with those cells detected in patients with known metastatic 
prostate cancer in order to determine thresholds of significance. 
Bloods samples were obtained from twelve healthy male volunteers and processed using the 
NICR assay. They were divided into three; one third were processed as cells only, one third 
were labelled with the isotype controls of Oct4, SOX2, Nanog and CD45, and also with DAPI, 
and the final third with the antibodies themselves in addition to DAPI. Blood from six 
patients with advanced disease was also prepared using the same assay and stained with the 








Figure 2.2 Graphs to show the Intensity of Fluorescence of Oct4 in Healthy Volunteer Blood Samples with no staining, stained with isotype control, 
stained with antibodies and compared to blood from patient samples. The results from all cells taken from twelve different healthy volunteers were 
combined to provide the three control graphs on the left, and then compared to cells from six patients with metastatic prostate cancer. The dotted 







Figure 2.3 Graphs to show the Intensity of Fluorescence of SOX2 in Healthy Volunteer Blood Samples with no staining, stained with isotype control, 
stained with antibodies and compared to blood from patient samples. . The results from all cells taken from twelve different healthy volunteers were 
combined to provide the three control graphs on the left, and then compared to cells from six patients with metastatic prostate cancer. The dotted 








Figure 2.4 Graphs to show the Intensity of Fluorescence of Nanog in Healthy Volunteer Blood Samples with no staining, stained with isotype control, 
stained with antibodies and compared to blood from patient samples. . The results from all cells taken from twelve different healthy volunteers were 
combined to provide the three control graphs on the left, and then compared to cells from six patients with metastatic prostate cancer. The dotted 
line demonstrates the threshold above which cells would be considered to be putative CTCs. 
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Despite graphical evidence of expression of Oct4, SOX2 and Nanog in healthy white blood 
cells, there was a log shift increase in expression of Oct4 and SOX2 in the cells from clinical 
samples.  This would suggest that cells gated below the 1.4e4 level of intensity should be 
excluded as non-significant. When looking at Nanog, some of the cells in the clinical sample 
did  overlap from the intensityof 1e4. Only small numbers of Nanog positive cells were found 
at an intensity lower than 1.6e4 so this was considered the threshold and it was accepted 
that there would be a possibility that Nanog positive cells below this would be missed. It was 
felt this would be more accurate than including possible false positives. 
The Imagestream enables direct observation of the cells, and the majority of whole cells 
from the healthy volunteer samples that expressed the stem-cell markers, also expressed 
CD45, which would additionally enable exclusion of these cells. Mesenchymal stem cells have 
been shown to display haematopoetic markers (Maleki et al., 2014), therefore this 
experiment not only demonstrates the increased  fluorescence in the patient samples, but 
also highlights the relevance of using the Imagestream, to visually exclude false positives 
(Figures 2.5, 2.6 and 2.7). 
 
a) Oct4 / CD45 positive cell 
 
b) Oct4 positive CTC 
Figure 2.5 Imagestream images showing Oct4 expression in a possible stem cell from a 
healthy volunteer sample and a CTC from a patient sample. 
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a) SOX2 / CD45 positive cell 
 
b) SOX2 positive CTC 
Figure 2.6 Imagestream images showing SOX2 expression in a possible stem cell from a 




a) Nanog / CD45 positive cell 
 
b) Nanog positive CTC 
Figure 2.7 Imagestream images showing Nanog expression in a possible stem cell from a 
healthy volunteer sample and a CTC from a patient sample 
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2.4.6 Preparation of a template and sample processing 
Unlike conventional FACS, not all data could be collected as file size would be too big to 
open. Therefore, various gating strategies based on fluorescence, size or nuclear content 
were used to collect data. For clinical samples, cells were gated based on DAPI signal (cells 
with no signal were assumed to be fragments) and then negative expression for CD45 (to 
exclude white cells). Further selection was felt to be too restrictive at this data collection 
stage. All Eppendorfs were covered with foil to prevent degradation of fluorescence and the 
whole sample was processed until the Eppendorf was empty. 
2.4.7 Post-processing analysis 
Each raw image file (rif) was combined with the appropriate compensation matrix (cif) to 
create a data analysis file (daf). Cells could be analysed based on various factors including 
size, fluorescence and nuclear content using the associated Imagestream analysis software, 
IDEAS. Fluorescence thresholds for positive identification of CTCs using stem cell markers are 
described in Chapter 3. Cell counts for each clinical sample were recorded and statistical 
analysis was performed using Prism GraphPad (version 8) and MedCalc.net (for odds ratios). 
 
 
2.5 Processing and Analysing samples on the FACS Machine 
2.5.1 Choice of FACS machine 
The BD FACS Fusion (BD Biosciences) was used for this study. It has cell sorting capabilities 
and is described in more detail in Chapter 4. 
2.5.2 Single colour controls 
Cell lines or Ultracomp ebeads (ThermoFisher Scientific) were also used as single colour 
controls for the FACS experiments. 100 000 cells or 1 drop of ebeads were stained with each 
individual antibody that was used in the experiment and suspended in 500µl of Robosep in a 
FACS tube. Cells/beads with individual fluorescently-conjugated antibodies were run in the 
same way, initially on maximum laser setting and then decreased to the lowest level possible 
that still enabled excitation to a level above the paired isotype control. Cells with no staining 
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and cells with the isotype of each antibody were used to determine the positive expression 
of the beads or cells with antibody. Again, this was repeated for cells/beads expressing each 
antibody in turn until settings for all lasers had been determined.  
A suspension of cells containing cells/beads expressing all antibodies was run to check the 
final laser settings, which were then fixed and recorded. Single colour controls were 
repeated every four weeks or if a new vial of antibody was purchased. 
2.5.3 Processing of samples and gating strategies 
FACS tubes were covered in foil to prevent degradation of fluorescence. When each tube 
was nearly empty, additional Robosep buffer was added so that as many cells as possible 
were processed. All data was captured but cells were sorted based on cell size (to exclude 
debris) and negative expression of both CD45 and CD16. The gates were set using spiked 
whole blood and the same template applied to all clinical samples. 
2.5.4 Post processing analysis 
All data was analysed using the gate templates for the fluorescence of each individual 
antibody described during optimization in Chapter 4. Analysis was conducted initially using 
the FACS programme FlowJo (Version 10.6.1), and subsequently with FCS Express (Version 
6). Statistical analysis was again performed using Prism GraphPad (version 8) and 
MedCalc.net (for odds ratios). 
 
 
2.6 Extracting CTCs from whole blood 
2.6.1 Preparing cell lines spiked into blood 
All of the experiments in this section were initially performed using cell lines (PC3 or U2OS) 
and healthy volunteer blood. Blood was collected using a vacutainer (BD Biosciences) in an 
EDTA tube (4mls) (BD Biosciences) from colleagues in the NICR under the ethical conditions 
outlined by the institution. Cells were harvested using trypsin as described in section 2.2.1 
and when resuspended in media following the centrifugation, 10µl was transferred to a 
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haemocytometer to enable cells to be counted. The required number was calculated per 
volume of the cell suspension and pipetted into the vial of blood. 
After each method was tested recovered cells were then stained with either DAPI and 
Vimentin (PC3 cells) or DAPI and CD44 (U2OS cells) prior to processing on the Imagestream. 
Single colour controls were run and laser settings were established prior to processing, and 
the same template used for all arms of this experiment. All experiments were conducted in a 
hood under sterile conditions. 
2.6.2 RosetteSep Density Centrifugation 
The RosetteSep CTC Enrichment cocktail containing Anti-CD36 (Stem Cell Technologies) was 
used. 50µl of the cocktail /ml of blood was mixed in a Falcon tube by gently pipetting and 
left to incubate at room temperature for 20 minutes. An equal volume (2mls) of Dulbecco’s 
PBS (DPBS) with 2% FBS (Stem Cell Technologies) was then added to the blood and mixed 
gently. 2ml of Lymphoprep Density Gradient Medium (Stem Cell Technologies) was added to 
a fresh Falcon tube and the blood/PBS mixture from the first tube was carefully pipetted 
onto the density medium in the second tube, with care taken to avoid mixing. Centrifugation 
in a bench-top centrifuge was then performed at 1200g for 20 minutes, at room 
temperature with the brake off. The top third of the top layer (plasma) was discarded and 
the layer beneath at the plasma/density medium interchange was carefully pipetted into a 
fresh Falcon tube. A matched volume of DPBS was added to this tube and centrifuged at 
300g for ten minutes with the brake on low. The supernatant was discarded, and the 
previous step repeated. The second supernatant was discarded, and the recovered cells 
transferred to an Eppendorf in Robosep for the addition of antibodies. 
2.6.3 Magnetic Separation 
Single marker selection 
The Straight from Whole Blood CD45 Microbeads (human) kit was used for this experiment 
(Miltenyi Biotec). This contains MACS Whole Blood Columns and the Microbead cocktail. 
Separation buffer is made using a 1:20 dilution of MACS BSA solution with autoMACS Rinsing 
solution (both Miltenyi Biotec). This is kept at 4°C throughout the experiment. A 30µm nylon 
mesh filter can be purchased additionally to filter blood into a single cell suspension and 
remove clots. A MACS magnet and stand is also required for the experiment (Miltenyi). 
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Blood was passed through the filter into a Falcon tube and 50µl of the microbeads from the 
kit per ml of blood were added and mixed via gentle pipetting before incubation at 4°C for 
15 minutes. Whole Blood Columns were placed in the magnetic stand and attached to the 
MACS magnet (Miltenyi Biotec). (Each column had capacity for 7.5ml of blood). 3ml of 
separation buffer from the kit was inserted into the column to wash the column through. 
Once drained, a fresh Falcon tube was inserted underneath the column and the 2ml of blood 
with microbeads was then carefully pipetted into the column. 500µl of separation buffer was 
used to wash out the blood tube and was then pipetted into the column. A further 2 x 2ml of 
separation buffer was inserted into the column to wash through any remaining cells.  
Red blood cell lysis of the erythrocytes in the recovered cell population was performed by 
preparing a 1:10 dilution of the Red Blood Cell Lysis Solution 10x (Miltenyi Biotec) with 
distilled water. An equal volume of the lysis solution was added to the cell solution, vortexed 
for five seconds and incubated for ten minutes at room temperature. The tube was then 
centrifuged at 300g for five minutes and the supernatant discarded. The residual cells were 
resuspended in 100µl of Robosep and transferred to an Eppendorf for addition of antibodies. 
Multiple marker selection 
The EasySep Direct Human CTC Enrichment kit (Stem Cell Technologies) was used for this 
experiment. This contains the Direct Human CTC Enrichment Cocktail and EasySep Direct 
RapidSpheres. Medium is PBS free from calcium and magnesium (DPBS), containing 2% FBS 
and 2mM EDTA (either purchased as the EasySep buffer (Stem Cell Technologies) or made 
from the constituent parts. The Big Easy magnet used in section 2.3.3 is also required for this 
experiment. 
The blood was transferred from its collection tube to a 15ml Falcon tube and 50µl of the 
enrichment cocktail per ml of blood was mixed via gentle pipetting and incubated at room 
temperature for five minutes. The RapidSpheres were vortexed for ten seconds and 50µl of 
these per ml of blood was added. An equal volume of the medium was added and gently 
mixed, before the Falcon tube was placed in the magnet for ten minutes (with lid off). The 
tube with magnet still attached was inverted into a fresh 15ml Falcon tube and a further 
50µl of RapidSpheres per ml of original blood sample was added to the fresh sample. This 
was then placed immediately into the magnet again for ten minutes and the tube and 
magnet inverted into a fresh Falcon. The remaining cells were then centrifuged at 400g for 
five minutes and the supernatant discarded. 100µl of Robosep was added and cells 
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transferred to an Eppendorf for antibody labelling, or for the clinical samples, 2.4ml of 
Mesenchymal Stem Cell Media (Lonza) was added prior to plating out in twelve-well plates. 
2.6.4 Physical Separation (Parsortix) 
The Parsortix PR1 Cell Separation System (Angle) comprises the machine, a buffer, and 
disposable cassettes that are used to capture the cells. Standard PBS (as described in section 
2.2.1) is used as the buffer for priming and processing. In the NICR the machine is on a 
laboratory bench and therefore not in a sterile environment. Each stage of the process is 
listed as a specific programme on the instrument and the user follows the protocol and start 
each programme in turn. 
The machine was put through a wash protocol prior to starting (about ninety minutes) using 
a cleaning cassette (replaced once a month) and a new cassette was loaded into the cassette 
holder. Priming was then performed when selecting programme PX2_P. Blood processing 
was then started by priming the line that drew blood into the machine, using programme 
PX2_S99F. The blood tube containing blood at room temperature was then attached to the 
machine with the line inside, and the blood was drawn up into the machine. The tube was 
inverted when it was almost empty, to ensure as much blood was drawn up as possible. 
To harvest the cells, which were now inside the cassette, programme PX2_H was selected 
and a clean 15ml Falcon tube inserted under the harvest line. The harvest valve was turned 
anti-clockwise to position HAR and the cells in 200µl of buffer were eluted into the Falcon 
tube. The option of flushing the lines and cassette with a further 1ml was utilised and this 
was added to the Falcon tube, which was then spun at 400g for five minutes, the 
supernatant discarded and 100µl of Robosep used to suspend the pellet prior to transfer to 
an Eppendorf for antibody staining. 
Programme PTX2_CT was then selected to allow cleaning of the instrument prior to the next 
sample. 
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2.7 DNA extraction and downstream utilisation 
2.7.1 DNA extraction and amplification 
The Repli-g Mini kit (Qiagen) was used for these experiments. This contained nuclease free 
water, REPLI-g Mini DNA Polymerase, REPLI-g Mini reaction buffer, DLB buffer and stop 
solution. Microcentrifuge tubes were purchased separately (Qiagen). Cells were passaged 
from culture, washed carefully with DPBS (Stem Cell Technologies) and resuspended in 5µl of 
nuclease-free water. 
A buffer (D1) was created by mixing 9µl of DLB buffer with 32µl of nuclease-free water. A 
second buffer (N1) was created by mixing 12µl of stop solution with 68µl of nuclease-free 
water. Both were vortexed and kept on ice prior to use. A master mix was created by mixing 
10µl of nuclease-free water, 29µl of the Mini-reaction buffer and 1µl of the DNA Polymerase.  
5µl of cell suspension was pipetted into a microcentrifuge tube and 5µl of buffer D1 was 
added and vortexed for five seconds and centrifuged briefly. This was followed by incubation 
at room temperature for five minutes. 10µl of buffer N1 was added to the tube, vortexed 
and centrifuged briefly. 30µl of the master mix was then added to the tube and incubated at 
30°C for 16 hours. The sample was then heated for three minutes at 65°C to inactivate the 
DNA Polymerase. 
The amplified DNA quantity was then measured using the Qubit as described in section 
2.7.2. For the sequencing experiments (SNP Array and Whole Exome Sequencing) the 
amplified DNA was kept at –20°C and for the PCR experiments it was diluted 1:20 with 
nuclease-free water and 3µl of the diluted sample was used for each PCR experiment. 
2.7.2 Measuring DNA quantity 
The quantity of DNA recovered following the extraction and amplification in the previous 
step was measured using the Qubit (ThermoFisher Scientific). This platform consists of the 
machine (a benchtop fluorometer), a Qubit assay kit and 500µl polypropylene PCR tubes. 
The assay kit contained Qubit Reagent, Qubit Buffer and two separate standard solutions for 
calibration (standard 1 and standard 2).   
Each sample from section 2.7.1 was run in a separate tube and labelled prior to the start. A 
master mix of 1:200 Qubit Reagent: Qubit Buffer was created; 200µl of this was prepared 
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per sample as the master mix. 190µl of the master mix was added to the tubes used for 
standards, and 10µl of each standard was added to this and vortexed. The assay type was 
selected (dsDNA high sensitivity) and the two tubes containing the standards were inserted 
consecutively to enable a fluorescence vs concentration calibration graph to be drawn.  
190µl of the master mix was added to 10µl of each clinical sample. Each sample was then 
inserted into the machine and the DNA quantity recorded. 
2.7.3 Real time quantitative PCR 
In order to ascertain the DNA copy number of three genes (PSA, AR-V7 and TMPRSS2) real 
time qPCR was performed using the diluted DNA from samples in section 2.7.1. 384-well 
plates were used with each well containing 9µl of a master mix. This master mix comprised 
5µl of the double-stranded DNA binding dye SYBR Green, 3.2µl of sterile distilled water, and 
0.4µl of each of the forward and reverse primers listed in Table 2.4 (Sigma Aldrich). A control 
housekeeping gene (GAPDH) was run in parallel and a negative control containing DNA-free 
water was also used. 
Plates were run on the Applied Biosystems 7900HT Platform (ThermoFisher Scientific) 
initially at 50°C for two minutes, followed by two minutes at 95°C and 40 cycles of 15 
seconds at 95°C before one minute at 60°C. Dissociation curves were checked to ensure a 
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Table 2.5 A Table to show the forward and reverse primers used for the PCR experiment. 
2.7.4  SNP Array 
A Single-Nucleotide Polymorphism (SNP) Array was attempted using the amplified DNA from 
section 2.7.1. This was used as a method because detecting specific amplifications and 
deletions that were known to be present in prostate cancer would prove the cells were 
prostatic in origin, rather than white blood cells. DNA was transferred on ice to the Northern 
Genetics Service at the Centre for Life, Newcastle University, for this to be performed (with 
thanks to Dr Chris Lowe).  
2.7.5 Whole exome sequencing 
Whole exome sequencing was attempted by using the amplified DNA from section 2.7.1. 
This method was used as a way of attempting to identify any prostate cancer specific 
mutations, rather than specifically targeting certain genes. DNA was transferred on ice to the 
Centre for Life at Newcastle University for this to be performed (with thanks to Dr Chris 
Lowe). 
 
2.8 Chemokine receptor experiments 
2.8.1 Immunofluorescence 
Cells were trypsinised, spun and resuspended in media. 10µl of the cell suspension was put 
on a haemocytometer and the volume of media containing 200 000 cells was calculated. A 
master mix of cells was made, containing 200 000 cells multiplied by the number of samples 
required. Six-well plates were labelled for each antibody and corresponding isotype control. 
  70 
A microscope coverslip was dipped into methanol for sterilisation, left to air-dry and placed 
into each well of the plate required for a different concentration of the antibody. 2ml of 
RPMI media (Sigma Aldrich) was added to each well and the volume of media containing  
200 000 cells was pipetted into each well. 
Plates were cultured in the incubator overnight at 37°C. The following day, media was 
aspirated from each well and 1ml of PBS was pipetted in carefully to wash the cells. The PBS 
was aspirated and 1ml of 4% paraformaldehyde (Sigma Aldrich) was added to each well (this 
was performed in a fume hood). The plates were left at room temperature for twenty 
minutes to allow fixation. Following this, the paraformaldehyde was discarded, and the cells 
washed twice with 1ml of PBS. 1ml of 0.1% Triton (ThermoFisher Scientific) was applied to 
each well to enable permeabilisation, and they were then incubated at room temperature 
for ten minutes. 4% BSA solution was made by dissolving 4g of BSA powder (Sigma Aldrich) 
in 100ml of PBS. 1ml of 4% BSA solution was pipetted into each well as a block, and they 
were then incubated for thirty minutes at room temperature. 
Parafilm was taped to an ice-box lid and 50µl of each antibody or isotype control (Table 2.5) 
at each concentration was pipetted as a spot onto the parafilm. Each coverslip was then 
placed face down on the spot and incubated for one hour at room temperature. Three PBS 
washes were carefully applied to each coverslip to wash off excess antibody. Drops of DAPI 
mounting media (Vector Laboratories) were spotted onto microscope slides and the 
coverslips placed face down on the spots. Slides were placed into slide holders and kept in 
the cold room overnight, for analysis the following day. 
Chemokine Receptor Fluorescent 
conjugate 
Isotype control Manufacturer 
CXCR6 PE REA (S) Miltenyi Biotec 
CCR7 FITC REA (S) Miltenyi Biotec 
CXCR4 APC REA (S) Miltenyi Biotec 
Table 2.6 A table listing the antibodies used in the chemokine receptor immunofluorescence 
experiments. 
 
Slides were then analysed using fluorescent microscopy on the Leica DMR microscope. 
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2.8.2 Imagestreamx 
Gentle Cell Dissociation agent (Stem Cell Technologies) was used to lift the cells off the 
plates, and the cell/media/dissociation agent was centrifuged at 400g for five minutes. The 
supernatant was discarded, and cells were resuspended in 100µl of PermWash (BD 
Biosciences). Antibodies were added at a concentration of 1:50 and left to incubate for one 
hour at room temperature. Cells were spun in a bench-top centrifuge at 400g for five 
minutes and the supernatant discarded. Due to low cell numbers, a washing step was not 




2.9 Tumour growth in NSG mice 
2.9.1 Permissions and basic care  
Five NOD/LtSz-scid IL2R_null (NSG) mice (four male and one female) were used for this 
study. Permission was granted under Home Office License number PPL70/8769, granted to 
Dr Huw Thomas. The mice were kept in the same cage and examined and weighed at least 
once a week. They were observed on a daily basis for signs of ill health. 
2.9.2 Implantation of cells 
The cells from patient CTC-JARO-110 were harvested from culture (passage 2) and using a 
haemocytometer it was estimated that there were approximately 2000 cells. They were 
transported at room temperature to the Comparative Biology Centre (CBC) within the 
university. 
The mice were weighed and taken in the cage to a laminar flow hood where anaesthesia was 
induced using isoflurane. The depth of anaesthesia was maintained throughout the 
implantation. Once anaesthetised, the knee area was shaved, and disinfectant was rubbed 
into the skin. The knee was held flexed and the cells (divided equally between all five mice) 
were injected into the distal femur using a 29G needle and insulin syringe. The mice were 
then monitored and given a subcutaneous injection of 5mg/kg of Carprofen prior to waking, 
for analgesia. 
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2.9.3 Extermination, imaging and dissection 
All mice were anaesthetised using isoflurane and once a sufficient depth of anaesthesia 
achieved a syringe was injected into their heart to withdraw the circulating blood volume. 
Once their heart had stopped beating, an anterior midline incision was made along the 
length of the mouse and dissection was performed. Spine, femurs and liver were dissected 
out and put into formalin pots for fixation and subsequent immunohistochemistry. 
For the two mice who had X-rays of their femur, they were transferred to the X-ray room 
prior to dissection but after death. X-rays were taken by a qualified vet. For the mouse who 
underwent a CT scan, it was taken to the CT room after death and CT images were 
performed by Dr Samir Luli. Individual CT slice images were reconstructed using the micro-CT 
software (Bruker).  
2.9.4 Immunohistochemistry 
The mouse organs were embedded in paraffin blocks following fixation and 3mm slides were 
cut. They were de-waxed by immersion for five minutes in xylene and hydrated through a 
100% to 50% ethanol gradient. Following this they were rinsed with water and placed in a 
decloaking chamber with a citrate buffer (pH6) to enable antigen retrieval. To reduce the 
incidence of non-specific background staining due to endogenous peroxidase, slides were 
blocked for ten minutes at room temperature with 3% hydrogen peroxide solution.  
A wash of the slides with TBST-T was performed. TBS-T was made by adding 26g of TRIS and 
320g of sodium chloride to 1.5L of distilled water and placing on a stirrer. To prevent non-
specific binding of the antibodies, 2.5% horse serum was used to block the slides for twenty 
minutes, and then a further wash in TBST-T was performed before addition of the primary 
antibody. The antibodies used for this experiment are listed in Table 2.6 and were prepared 
using 4% BSA (made by dissolving 2g of BSA (Sigma Aldrich) in 50ml of PBS). The antibodies 
were applied to the slide, ensuring full coverage, and left to incubate at room temperature 
for one hour. Following this, a further TBS-T wash was performed and a Mouse-on-Mouse 
detection kit (Vector Laboratories) was applied for fifteen minutes to reduce the background 
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Antibody Host species Concentration Manufacturer 
Anti-human 
mitochondria 
Mouse 1:200 AbCAM 
PSA Rabbit 1:200 Roche 
MT1-MMP Rabbit 1:200 Merck 
Table 2.7 A table listing the antibodies used for the immunohistochemistry analysis. 
 
A five-minute incubation with 3,3-diaminobenzine (DAB) solution (Vector Laboratories) was 
then performed before the slides were rinsed in running water for five minutes. Slides were 
counter-stained in haematoxylin for five seconds before dehydration through an ethanol 
gradient of 50% - 100%. Following this they were immersed in xylene before mounting onto 




2.10 Measuring mechanical properties of cells using the Atomic Force 
Microscope 
2.10.1 Preparation of cells 
Cell lines (PC3 and U2OS), white cells from healthy volunteers and the cells cultured from 
four patients were cultured onto cover slips. As with the start of the immunofluorescence 
protocol, cell lines were trypsinised, spun and resuspended in media. 10µl of the cell 
suspension was put on a haemocytometer and the volume of media containing 200 000 cells 
was calculated. A master mix of cells was made, containing 200 000 cells multiplied by the 
number of samples required. Six-well plates were labelled for each antibody and 
corresponding isotype control. A microscope coverslip was dipped into methanol for 
sterilisation, left to air-dry and placed into each well of the plate required for a different 
concentration of the antibody. 2ml of RPMI media (Sigma Aldrich) was added to each well 
and the volume of media containing 200 000 cells was pipetted into each well.  
The white cells were obtained from two separate blood samples from healthy volunteers in 
the NICR. 1ml of healthy volunteer blood was mixed in a Falcon tube with PharmLyse buffer 
(BD Biosciences) which lyses the red cells without fixation. After incubating at room 
temperature for 15 minutes, the tube was spun at 400g for ten minutes and the supernatant 
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discarded. The resultant cell pellet was resuspended in 2ml of the Lonza Mesenchymal Stem 
Cell media and 50µl of the cell/media suspension was added to a six-well plate containing 
2ml of the media and sterile coverslips.  
For the patient cells, Gentle Dissociation Agent (Stem Cell Technologies) was used to lift the 
cells off the plate and the cell/media/dissociation agent was centrifuged at 400g for five 
minutes. The supernatant was discarded, and cells were resuspended in 4.8mls of 
Mesenchymal Stem Cell Media (Lonza). Half of the suspension was used for ongoing culture 
of the cells and half was transferred and divided between the wells of a six-well plate 
containing sterile coverslips. Each well contained 2ml of the media.  
Both the cell lines, white cells and the patient cells were cultured in the incubation 
conditions described earlier in the chapter. Cell lines were ready the following day but 
patient cells took approximately twelve weeks until there was enough growth to proceed 
with the experiments. Media was changed every 48 hours. 
Once confluent, plates were sealed with parafilm and transported to the School of 
Engineering, Newcastle University, to proceed with the experiment. 
2.10.2 Using the Atomic Force Microscope 
The Atomic Force Microscope was set up as shown in Figure 2.1. The tip of the probe on the 
cantilever can either be spherical or conical. Because of the experimental nature of this work 
the conical tip was used for the PC3 cells, and the spherical tip was used for the U2OS cells, 
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Figure 2.8 A diagram to show the set-up of the Atomic Force Microscope, (taken from Deng 
et al.(Deng et al., 2018)). The cell of interest would be placed on the yellow tube and 
indented with either a conical or spherical AFM probe on the end of a cantilever. The 
movement of a laser detected by a photodiode is used to create a three-dimensional image 
of the cell.  
 
A coverslip from each six-well plate was placed cell side up on the ceramic tube and the 
probe began the approach towards the cells. The repulsive or attractive force between the 
tip and the cell would change once the tip was on the surface of the cell, and the surface 
underneath the tip was then scanned. An image was generated of the immediate area 
around the probe tip, which allowed the movement of the cantilever to ensure 
centralization on a cell. Once confident of position, the tip was readjusted to the cell surface 
and the probe was inserted into the cell to cause deformation.  
The force required to indent the cell, and the distance between the cell surface and 
maximum indentation, was then used to plot force-distance curves (both approach and 
retraction). From this, the Young’s modulus of the cell wall was calculated.  
2.10.3 Post procedure analysis 
Determination of the Young’s modulus is dependent on the type of probe tip used. For the 
conical tip, the Sneddon model is used. This assumes no adhesion between the cell surface 
and the probe, no visco-elasticity and that the Young’s modulus of the material forming the 
tip is much higher than the Young’s modulus of the cell wall. Figure 2.2 demonstrates the 
conical tip inserting into a cell surface. 
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Figure 2.9 A diagram to demonstrate the conical tip of the AFM inserting into a cell surface. 
The tan of the angle between the edge and the midline, and the depth of the indentation in 
the cell are the two variables used to calculate the Young’s modulus of the cell. 
 
 
The following equation was used to determine the Young’s modulus of the cell where Esurface 
is the Young’s modulus of the cell, vsurface is the Poisson’s ratio of the cell surface, and S0-S is 









For cells indented with the spherical tip, the Hertz model is used. The same assumptions 
apply. Figure 2.3 demonstrates the spherical tip inserting into the cell surface. 
 
 
Figure 2.10 A diagram to demonstrate the spherical tip of the AFM being inserted into a cell 
surface. The radius of the tip and the depth of indentation into the cell are the two variables 
used to calculate the Young’s modulus of the cell. 
 
The following equation was used to determine the Young’s modulus of the cell. Rtip is the 
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Chapter 3. The role of the Imagestream platform in the detection 
and analysis of CTCs in metastatic prostate cancer  
Chapter Summary 
 
This chapter discusses the reason for choosing the platforms used during the main part of 
this project for the detection and analysis of CTCs. This novel assay development, using a 
combination of epithelial and stem cell markers on the Imagestream is described. This 
includes the choice of antibodies used, cell line optimisation and thresholds used for 
determining true positives, based on results obtained from healthy volunteer blood samples, 
including the spiking of prostate cancer cells into the healthy blood. Because the FDA 
definition of a CTC does not include cells that express Oct4, SOX2 and Nanog, any cells 
described in this chapter that are EpCAM positive and/or express any of these three stem 
cell antigens are deemed putative CTCs. 
 
3.1 Platform choice 
3.1.1 Background 
The decision on which platform to use in this project to detect CTCs is dependent on a 
number of factors. Cost per sample, and availability are important. The funding for this 
project is finite and whilst there are other groups within the institution working on similar 
projects in other cancers, it would not be feasible to buy an entirely new machine. The 
options are therefore restricted to what is already available at Newcastle, or within easy 
geographical reach if considering collaboration with another centre. If thinking of using a 
platform outside of the university, access to the machine must tie in with when the samples 
are obtained, and transport +/- processing costs (if using technical staff in this centre) must 
be factored in. 
Speed of use is also key. The time between obtaining the blood from the patient to the start 
of processing, and also the length of time taken to run the assay should both be kept to a 
minimum to ensure accuracy and consistency. Newcastle Hospitals has one of the largest 
Urology departments in Europe, and due to the high numbers of patients presenting with 
metastatic prostate cancer, sufficient samples could be obtained during this study from 
patients solely within the Newcastle area. This would help keep the time from sampling to 
processing to a minimum, and as constant as possible to enable comparison of results.  
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A lengthy processing assay using unfixed blood could also potentially alter results. Fixing the 
blood immediately after sampling would minimise this problem, and there are also blood 
collection tubes available that contain a preservative cocktail to allow conservation of a 
blood sample up to 96 hours at room temperature. (This will be discussed later in this 
chapter). Downstream applications such as genomic sequencing could however be limited if 
using small numbers of fixed cells, so forward planning is important. Laborious assays would 
also restrict the number of samples possible to process during this project, which would 
reduce the power of any study.  
Replication of results is also imperative, especially if considering utilisation in the clinic in the 
future. A complicated assay with multiple steps would have the potential to introduce user 
error or restrict the number of technical staff who would be available to process samples. 
Whilst this latter point is not relevant for this project as all the sample processing will be 
performed by the author of this study, it is something to consider when planning the 
potential future transfer of any successful assay into the clinical environment. If an assay 
uses a rare and expensive piece of equipment, it will limit the number of centres in which 
samples can be processed which will in itself increase the cost per sample, along with issues 
surrounding transport and time between sampling and processing. 
3.1.2 Choice of platform based on method of CTC detection 
As discussed already, options for detection of CTCs are broadly categorised into those reliant 
on protein expression, physical characteristics or those involving direct analysis. Because of 
the lack of an available high throughput scanning device, the latter method was discounted 
for this study. Cell sorting based on physical properties may overlook cells expressing the 
proteins of interest which happen to have a different morphology. Therefore, because the 
aim of this study is to explore protein expression, it would be logical to use a method of 
detection that depends on this. 
Given that the study design relies on processing whole blood, any modality used to detect 
CTCs has to possess the ability to allow processing of a large number of cells. Whilst the 
majority of the components of the blood are not of interest (e.g. leucocytes and 
erythrocytes) any assay would either need to allow quick processing of whole blood and 
accurate subsequent identification of CTCs (positive selection), or would include steps to 
deplete the superfluous cells (negative selection). Both have their limitations – positive 
selection can result in an inaccurate identification rate due to the low percentage of cells of 
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interest being recovered. To combat this, high volumes of antibody could be used to avoid 
dilution in a large volume, but this in turn could lead to inappropriate binding and false 
positives. Negative selection can cause accidental depletion of the target population.  
3.1.3 The Veridex CellSearch 
As discussed previously, the only FDA-approved technique for identifying CTCs is the Veridex 
CellSearch (Cohen et al., 2008, Cristofanilli et al., 2004, de Bono et al., 2008). This is still only 
validated for non-clinical  work, but has been used as an additional outcome measure in 
several high profile clinical trials in patients with breast cancer, prostate cancer and 
colorectal cancer (Hayes et al., 2006, de Bono et al., 2008) . This method involves a density 
centrifugation step, followed by exposure to magnetically bound EpCAM antibodies. The 
sample is then processed through a magnetic field, which is then used to positively select 
the antibody-bound CTCs. Because of the reliance on epithelial antibodies, there is the 
potential to miss detection of CTCs that are of a different phenotype, or those that do not 
attach to the magnetic particles, either due to heterogeneity or inadequate binding. Given 
the findings from some studies showing that up to a third of patients with metastatic breast 
cancer do not have any detectable CTCs (Riethdorf et al., 2007) (which could be due to 
detection error), and to address the issue of epithelial to mesenchymal transition, this 
platform does have its limitations. However, it must be acknowledged that the CellSearch is 
still the only FDA-approved platform, and it has maintained that status since 2008 despite 
the introduction and availability of numerous other CTC detection platforms.  
Newcastle University does not have a CellSearch platform, but although collaboration with 
other centres would potentially have enabled the use of one for this project, particularly for 
platform comparisons, the decision was made to use alternatives. Because the aim of this 
study is to investigate the role of mesenchymal and stem cell markers, in addition to 
epithelial markers, selecting purely based on epithelial markers could mean overlooking cells 
of interest and would therefore not be the most appropriate tool for this study. Whilst any 
other platform will not be FDA-approved, to explore and potentially advance the 
understanding of stem cell marker expression in CTCs, because of the requirement to use 
epithelial antibodies, it was felt that the CellSearch would be too restrictive. 
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3.1.4 Fluorescence Activated Flow Cytometry (FACS) 
The availability of conventional flow cytometers, and their use for processing high cell 
numbers, such as those found in whole blood, makes them an obvious choice for a 
technique that would be both accessible and theoretically cheap to run. Most universities 
with molecular or cell biology laboratories, or indeed hospital laboratories, will have their 
own flow cytometry machines and therefore processing samples using an assay developed 
for this platform would be easily reproducible.  
FACS for detecting low cell numbers is not however without its limitations. Gates used to 
include or exclude cells must be applied to all samples to ensure consistency, and when 
using fluorescence thresholds, events counted as exceeding the minimum threshold must 
also be gated according to size and cellular complexity (forward and side scatter) to ensure 
they don’t represent debris (O'Connor et al., 2001). Due to the fact that CTCs are rare 
events, and statistically many of the samples will not contain these cells, reliance on the 
absolute value of fluorescence expressed, without any imaging of the cells to substantiate 
this, lends itself to a high false positive rate. In addition, false positives due to erroneous 
antibody binding will be hard to determine, although if using the same panel of antibodies, 
this rate should be consistent throughout all samples, still allowing comparison. 
One method to overcome not knowing the exact nature of the cells that reach the positive 
threshold is to sort these cells before analysing them further using techniques such as 
conventional immunofluorescence (Miyamoto et al., 2012), Fluorescence in situ 
Hybridisation (FisH) (Punnoose et al., 2015) or by extracting DNA or RNA for PCR or 
sequencing (Steinestel et al., 2019, Miyamoto et al., 2015). Even if ultimately the basic FACS 
assay without additional sorting was accurate enough to lead to the use of this test in clinical 
practice, sorting the cells to provide information about their validity is important to do 
during the development of the assay. Meticulous scrutiny of any potential positive cell 
would enable accurate calculation of the false positive rate.   
The use of FACS with cell sorting and downstream analysis was one of the techniques used in 
this study and is discussed in Chapter 4. 
3.1.5 The ImagestreamX (Merck) 
An alternative technique that can be used to overcome the issue of whether or not an event 
is truly positive or not is to use a platform that provides the phenotypical information 
obtained through FACS with simultaneous imaging of each cellular event. The ImagestreamX 
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(Merck) is a combined high resolution microscope and flow cytometer (Zuba-Surma et al., 
2007), which allows the user to view the image of any event displayed on the dot plot. This 
platform was already in situ within the institution and an assay for CTC detection using this 
modality had recently been developed by a Newcastle group (Dent et al., 2015). For this 
reason, and because it would provide detailed data to satisfy the aims of the study, the 
ImagestreamX was chosen. 
The machine is available with up to six lasers, which excite fluorochromes, conjugated to 
antibodies, emitting light at specified wavelengths. Whilst the company cites that the use of 
up to twelve fluorochromes simultaneously is achievable, there would be a considerable 
degree of laser overlap in practice. This would either manifest as false positives, or if strict 
compensation was employed then cells which only weakly expressed an antigen would be 
missed. Due to the expected heterogeneity of the clinical samples in this study, using 
fluorochromes with the minimum overlap possible would enable detection of weakly 
positive cells whilst being confident that they were true positives. The Newcastle 
Imagestream machine has four lasers, therefore a maximum of seven antigens with separate 
fluorochromes could be reliably used for any panel.  
Similar to conventional FACS, cells must be labelled with a panel of antibodies in advance of 
processing and, when comparing samples, laser settings and antibody concentrations must 
be consistent. Cell sorting is possible based on physical characteristics and/or protein 
expression and analysis can be achieved either by using the analysis software, or, somewhat 
laboriously, through individual visual inspection of events. One major advantage of this 
platform is that it does not select the cells solely based on EpCAM, thus allowing exploration 
of the presence of non-epithelial cells of interest. Erythrocytes and the majority of white 
cells are depleted using a combination of red cell lysis and immuno-magnetic separation 
prior to processing, thus it uses principles of both positive and negative selection. Recovery 
of CTCs is approximately 50-60% (Dent et al., 2015) so its use with respect to enumeration 
may be limited. However, it provides very detailed cellular images, so its strength is in 
phenotypic analysis. 
Unlike conventional FACS where the user would keep diluting the sample as the contents of 
the FACS tube diminishes (so as to avoid ingestion of air), the Imagestream processes the 
entire contents of the sample Eppendorf. This allows a more accurate comparison of the 
true number of CTCs found between samples. However, the files collected by the 
Imagestream are very large because each event has an image associated with it. This means 
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that in order to collect usable data, it would be optimal to deplete as many of the unwanted 
cells (in this case erythrocytes and leucocytes). Despite aiming to deplete these extra cells, 
some gating still has to be employed during the running of the Imagestream samples so that 
the files are of a manageable size to use. This is unlike conventional FACS where all data is 
stored and gates can be applied afterwards during the analysis stage. Samples with higher 
concentrations of cells can be run but will need to be divided into multiple Eppendorfs. As 
each Eppendorf tube with a volume of 200µl containing a maximum concentration of 2x107 
cells/ml can take 60-80 minutes to process, running time could be impractical if samples 
contain excessive numbers of superfluous cells.  
 
3.2 The optimization of an assay to use on the ImagestreamX 
3.2.1 The choice of assay 
The protocol developed by colleagues within the NICR for CTC detection (NICR assay) was 
used as the assay to process blood in preparation to run on the Imagestream for this project 
(Dent et al., 2015). Because this protocol had been developed in detail and various reagents 
had been tested before the final protocol optimized, it was felt unnecessary to spend further 
time on optimization. Other documented assays use the same principles of erythrocyte lysis 
followed by immuno-magnetic depletion of white cells (Lopez-Riquelme et al., 2013, Zuba-
Surma et al., 2007, Zuba-Surma and Ratajczak, 2011). The remaining cells (remaining 
leucocytes and CTCs) are then permeabilised with detergent before the antibodies are 
applied. The cells are then resuspended in a buffer in an Eppendorf which can be directly 
placed into the Imagestream. 
3.2.2 Collection and storage of blood from patients and healthy volunteers 
Blood was obtained from Urology and Uro-oncology clinics at the Freeman Hospital, or from 
healthy volunteers from within the NICR. Ethical consent permitted up to 12ml of blood to 
be taken from each patient. For the purposes of this project, 4ml was used for the assay 
described in this chapter, 4ml was used for FACS analysis (Chapter 4) and in some patients a 
further 4ml was used for culturing of CTCs (Chapter 6). Although the seminal papers on CTCs 
discuss the number of CTCs per 7.5ml of blood, a smaller volume was chosen because it 
would allow a higher number of assays to be performed for each patient. 
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Blood tubes containing potassium ethylene-diaminetetraacetic acid (K2EDTA) were chosen, a 
compound which prevents clotting whilst preserving cell morphology. Tubes were filled to 
capacity as high concentrations of EDTA:blood can alter the binding of metallic ions which 
could in turn affect antibody binding sites in downstream assays (Bowen and Adcock, 2016). 
Cellular degeneration will occur if the storage temperature and time to processing is not 
optimized (Adcock et al., 2016). For this reason, blood was transported and stored at room 
temperature and processed within four hours of sampling. Preliminary experiments were 
conducted by a colleague to compare cell retrieval when using EDTA tubes compared to 
CellSave (CellSearch) tubes. The CellSave tubes are reported to stabilize the blood for up to 
96 hours by containing an undisclosed cell preservative in addition to EDTA (Qin et al., 2014, 
Kang et al., 2016). Despite this, work performed by colleagues demonstrated a decline in cell 
retrieval after 36 hours. Because these results raise concern over the efficiency of CTC 
recovery from delayed samples and also the cost of the CellSave tubes is much higher, the 
decision was made to process the blood immediately, following collection in EDTA tubes. 
3.2.3 Fixation of whole blood and lysis of erythrocytes 
The NICR assay takes a minimum of 24 hours after blood collection before the sample is 
ready to run (including incubation times). As the Imagestream does not enable cell sorting 
for further downstream processing, the decision was made to fix the cells at the earliest 
stage possible. This meant that sample collection could be performed during a morning 
clinic, the blood transported back to the lab and fixation and erythrocyte lysis could be done 
within a four-hour window. White cell depletion could then be performed before overnight 
permeabilisation, followed by antibody staining the following morning prior to running. 
Density centrifugation has traditionally been used to separate the various components of 
whole blood but lysing agents have become more popular over the past twenty years, due to 
the lower mechanical stresses placed on the cells, greater reproducibility and the ability to 
work with smaller blood volumes (Bossuyt et al., 1997, Pinto et al., 2005). Cell lysis of 
erythrocytes can be performed in combination with fixation of the remaining leucocytes to 
limit the number of steps used to deplete unwanted cells and therefore reduce the cell loss 
associated with a multi-step assay. 
Lysis relies on cells being exposed to hypotonic solutions so that water is transported into 
the cell, causing it to rupture. Additionally, chemicals can stimulate cell wall breakdown. It 
occurs in three stages in erythrocytes; firstly, spherisation of the usually bi-concave cells 
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takes place, during which time the cell surface area remains the same. This is followed by an 
increase in cellular volume before eventually the membrane tension exceeds a critical value 
and the cell ruptures (Evans et al., 2008). Organic solvents, detergents and chelating agents 
are frequently used as lysis agents.  
Cellular fixation prevents any decay or further biochemical reactions within the cell with the 
aim of preserving the cell for subsequent analysis. Cross-linking fixatives, such as aldehydes 
and precipitating fixatives such as alcohols are two of the most commonly used types in 
cellular biology and the choice of agent may depend of whether secondary or tertiary 
protein structure is the most important feature to be subsequently examined. 
The PhosFlow Lyse-Fix buffer (BD) contains both methanol and formaldehyde and allows 
fixation of the blood and lysis of the erythrocytes in one step. Although several commercial 
combined lysis and fixative agents are available, this one had been utilized and optimized by 
the NICR team.  
3.2.4 White cell depletion 
Leucocytes contain molecules within their cell surface called cluster of differentiation (CD) 
markers. These antigens can be targeted with specific antibodies, which have been 
developed following collaborative work by the Human Cell Differentiation Molecules 
Committee (HCDM). This group has identified over 350 leucocyte antigens, which will be 
expressed by different types of white cell (Molecules, 2019). Identifying leucocytes en masse 
is feasible if using a common leucocyte antigen such as CD45, which is expressed by all 
haematopoietic cells except erythrocytes (Nakano et al., 1990). The method used to deplete 
white cells in this assay used a CD45 antibody which was then bound to magnetic beads to 
enable immunomagnetic separation through a magnetic field (Dent et al., 2015). This had 
consistently yielded a depletion rate of 95% during optimization by the NICR team. Because 
there are on average 4-11 x106 leucocytes per ml of blood, and 4mls was analysed per 
patient, even a 95% depletion would result in 8-22x 105 cells remaining. When on average 
there are 1-10 CTCs per ml of blood in a patient with metastatic disease (Alvarez Cubero et 
al., 2017), even with a high depletion rate, the CTCs are incredibly rare events within the 
sample (<1 x106). 
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3.2.5 Permeabilisation 
Although the CellSearch detects cells based on epithelial (cell surface) antigens, the 
Imagestream will not allow downstream processing. Therefore, any cells of interest must be 
labelled with the appropriate fluorescently conjugated antibody prior to processing. If the 
antigens are intracellular then adequate permeabilisation must be performed. Detergents 
and organic solvents are the two most commonly used types of permeabilising agents 
(Jamur and Oliver, 2010). Solvents such as methanol or acetone can also be used as fixative 
agents due to their coagulative effect on proteins, and work by dissolving the lipids within 
cell membranes so they can be more easily penetrated by the antibodies. Detergents cause 
physical disruption (which can be reversible) to the membrane resulting in small holes 
through which antibodies can pass. In this assay, permeabilisation at the same time as fixing 
was not considered optimal as this could affect the leucocyte depletion. Using a reversible 
detergent such as Saponin would mean that cells could be permeabilised to allow staining 
for intracellular antigens, but not fragment, as only whole cells would be considered as 
positive events. The BD PermWash was therefore the chosen agent following optimisation 
by the NICR team. 
3.2.6 Processing of blood spiked with cell lines to determine retrieval rate on 
the ImagestreamX 
Retrieval rates using the ImagestreamX are reported between 55% and 65% (Dent et al., 
2015) depending on the cell type and number of cells spiked into blood. To ensure that 
comparable results could be achieved using prostate cancer cells, the NICR assay was used 
to assess retrieval rate using two different prostate cancer cell lines spiked into healthy 
volunteer blood. Cell quantities of 20 000 and 50 000 PC3 and LNCaP cell lines were spiked 
into 2mls of blood and repeated three times (Figure 3.1). Size and fluorescence were used to 
count the numbers of cells retrieved. Vimentin, DAPI and CD45 were used for the PC3 
experiment and EpCAM, DAPI and CD45 were used for the LNCaP arm. This is due to the high 
EpCAM / low Vimentin expression in LNCaP cells, but low EpCAM / high Vimentin expression 
in the PC3 cells (Ni et al., 2013). Cells were counted as positive if CD45 negative and either 
EpCAM or Vimentin positive. 
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Figure 3.1 Graphs to show the percentage retrieval of different numbers of two prostate 
cancer cell lines spiked into healthy volunteer whole blood when using the NICR assay. 20 
000 or 50 000 cells of each cell line were spiked into 2mls of whole healthy volunteer blood 
and the NICR Imagestream assay was used to process the sample. The number of cells from 
each cell line at the end were identified using size and fluorescence (Vimentin for PC3 and 
EpCAM for LNCaP). 
This experiment demonstrates a mean retrieval rate of 76.3% and 79.9% for the 20 000 and 
50 000 cell experiments for PC3, and 33.6% and 32.6% for the LNCaP arm.  
 
3.3 Antigen expression and choice of antibodies 
3.3.1 Fluorescence and primary vs secondary conjugation 
Before the final decision was made on which antigens to research for this study, the concept 
of using antibodies that were directly conjugated to fluorochromes versus a two-step 
primary and secondary application was explored. Whilst using unconjugated antibodies is 
cheaper, there is lack of quality control, and when faced with sampling tiny populations of 
cells the decision was made to use commercially conjugated antibodies where possible. 
3.3.2 Number of channels and choice of antigens 
As previously mentioned, the Imagestream has twelve channels in which to display images, 
and four lasers. Two of these channels display a brightfield image which can be used to 
assess cell morphology and gate based on whole cell or nuclear size criteria. Out of the 
remaining ten channels, six different fluorescently conjugated antibodies could be reliably 
used to identify different antigens as any more would risk significant spectral overlap. At 
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least one white cell marker would be necessary, in order to assist with gating strategy and 
elimination of leucocytes. A nuclear marker is also important as the FDA definition of a CTC 
clearly specifies criteria that identifies whole cells. This leaves the option of exploring a 
further four antigens. Whatever the combination of antibodies that makes up the final 
panel, it has to identify cells with the expected epithelial phenotype in addition to any new 
markers that are to be explored. In order to get robust data the choice was made not to 
explore a mesenchymal marker in this assay. Whilst it would be useful to ascertain how 
many cells had undergone EMT, adding an additional marker may compromise the data due 
to spectral overlap, and therefore this will be explored in chapter 4. A combination of 
antibodies that identifies the maximum number of phenotypically different cells whilst 
simultaneously being able to confidently exclude leucocytes is the ideal. The lasers available 




 405nm 488nm 561nm 642nm 
Example Dyes DAPI FITC PE APC 
 AF405 AF488 AF546 APC-Cy5.5 
 AF430 AF500 AF555 DyLight 649 
 Pacific Orange AF514 PE-Texas Red AF647 
 Marina Blue PE-Texas Red Spectrum 
Orange 
AF660 
 Pacific Blue PerCP PE-AF 647 AF680 
 Cascade Blue PerCP-Cy5.5 PE-AF 680 Draq5 
 DyLight 405 Draq5 Nile Blue Cy5 
 Qdot 525 - 800 PI Calcium Orange APC-Cy7 
Table 3.1 Laser wavelength and associated suggested fluorochromes for the Imagestream. 
3.3.3 The decision not to use a prostate specific antibody 
As discussed, the main reason for this project is to identify a new biomarker that could be 
used in metastatic disease. PSA is unreliable and would not add any additional information 
to the level obtained during serum sampling (bloods obtained for this study were taken at 
the same time as bloods required for clinical review, and therefore matched PSA results 
were obtained). Given that not all prostate cancers express PSA and those that do may not 
do so at a level that represents disease burden, PSA was excluded from the antibody panel. 
It was felt that whilst the presence of PSA could confirm a cell as a CTC, absence could not 
reliably exclude it. Because of the variance in expression of PSMA, and the mutations found 
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in the Androgen Receptor which would require using a number of different AR antibodies, 
these were also felt to be unhelpful. 
Due to the limited number of antigens that could be used in the panel, in the absence of 
having a prostate specific marker that could be used to positively identify the majority of 
prostate cells it was felt that using a prostate marker would not add to the understanding of 
cell phenotype and would restrict additional information that could be identified. 
3.3.4 Epithelial antigens 
The seminal papers in prostate cancer CTCs describe using EpCAM and CK as epithelial 
markers. Whilst EpCAM is a cell surface molecule, cytokeratins are cytoskeletal proteins. As 
the assay includes a permeabilisation step, this should not preclude the use of either. 
Cytokeratins do however vary between different tumours, and whilst prostate tumours 
should theoretically contain the same combination, there will undoubtedly be 
heterogeneity. Choosing a cytokeratin antibody which recognizes multiple cytokeratin 
epitopes would be optimal. 
3.3.5 Stem Cell antigens 
The need to identify somatic stem cells or differentiated progenitor cells as potentially the 
most lethal subpopulation of tumour cells has been discussed. Whilst there are several 
markers to be considered, the preliminary data showing survival outcomes related to Oct4, 
SOX2 and Nanog expression in prostate tissue is interesting (Hepburn et al., 2019), and it 
would be useful to look at individual expression and compare with combined expression of 
all three. For this reason, this combination of stem cell markers was used for this study. 
3.3.6 Overlap of expression  
The presence of mesenchymal stem cells in healthy adults to enable tissue repair must be 
acknowledged. These cells will be in the circulation and will therefore be detected when 
using stem cell antibodies. An increased number of these cells will potentially be released in 
response to cellular destruction caused by metastatic infiltration, so whilst they will not be 
CTCs per se, they may be clinically significant. Completely excluding these cells in the count 
is therefore not sensible and would also negate the use of stem cell antibodies. Therefore, a 
threshold must be considered either in terms of number of cells or fluorescence, so that 
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comparisons between stem cell expression in healthy blood and blood from patients with 
metastatic prostate cancer can be made. This is outlined during the next section. 
3.3.7 Heterogeneity of antigen expression within cell lines 
If looking for expression of proteins within a clinical sample, it must be anticipated that there 
will be phenotypical heterogeneity. Even within cell lines of an early passage it is likely that 
heterogeneity will exist, and the incidence of this would increase with the higher passage 
number of the cells. It is important to appreciate this when optimizing antibody 
concentrations and also in the interpretation of results. Similarly, distribution of cells 
throughout the cell cycle can influence expression of individual proteins. 
In order to demonstrate this, 10 000 cells from three prostate cancer cell lines were fixed, 
permeabilised and stained with a combination of epithelial and mesenchymal antibodies in 
addition to a nuclear marker. Cells were stained with EpCAM (conjugated to AF488), a pan-
Cytokeratin (conjugated to PE), Vimentin (conjugated to AF647) and DAPI as the nuclear 
marker and run through the Imagestream. This was repeated three times and a mean of the 
number was calculated (Table 3.2 and Figures 3.2 and 3.3). 
 
 Mean percentage of each cell type for each cell line 
Combination of antigens LNCaP PC3 CWR-22Rv1 
1. EpCAM+/CK+/Vim- 1.58 0.38 0.72 
2. EpCAM+/CK-/Vim- 97.04 0 96.86 
3. EpCAM+/CK-/Vim+ 0.12 0.08 0.60 
4. EpCAM-/CK+/Vim- 0.70 0.04 0.16 
5. EpCAM-/CK-/Vim+ 0.56 99.5 2.10 
Table 3.2 The prevalence of each combination of antigens expressed by three different 
prostate cancer cell lines; LNCaP, PC3 and CWR-22Rv1. All three cell lines were labelled with 
the three antigens EpCAM, CK and Vimentin and the percentage of total cells expressing 
each combination of antigens was recorded. 
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Figure 3.2 Imagestream images to demonstrate heterogeneity of antigen expression within 
prostate cancer cell lines. (Images 1, 2 & 3 are LNCaP cells, Image 4 is a CWR-22-Rv1 cell and 
Images 5 is a PC3 cell). 
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Figure 3.3 Graphs to show the percentage of each of the combinations of antigens expressed 
in each cell line. All cell lines were stained with EpCAM, Cytokeratin, Vimentin and the 
nuclear marker DAPI. Cells were processed on the Imagestream and the number of cells 
displaying fluorescence corresponding to each antigen, or combination of antigens, were 
recorded. LNCaP cells were predominantly EpCAM+/CK-/Vimentin-, PC3 cells were 
predominantly EpCAM-/CK-/Vimentin+ and CWR-22Rv1 cells were predominantly 
EpCAM+/CK-/Vimentin-. 
 
This experiment clearly demonstrates the heterogeneity between different prostate cancer 
cell lines. EpCAM+/CK-/Vimentin- cells are most prevalent in both LNCaP and CWR-22Rv1 
cell lines, whilst PC3 cells are predominantly EpCAM-/CK-/Vimentin+. This highlights the 
importance of looking for non-epithelial in addition to epithelial markers in any assay used to 
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3.3.8 Epithelial antigen expression in patient samples 
Before the final antibody panel was chosen, ten clinical samples were obtained from 
patients with end-stage prostate cancer (defined as being castrate resistant and on second 
line chemotherapy). Patients with such advanced disease were chosen due to the higher 
chance of having larger numbers of CTCs in their blood. These samples were processed using 
the NICR assay and stained with EpCAM (AF488), CK(PE), CD45 (PECy7) and Draq5 (nuclear 
stain). The aim of this experiment was to assess whether EpCAM or CK could be used 
independently as the sole epithelial marker. This would enable use of the three stem cell 
markers in combination, with one epithelial antigen as the fourth variable. 
Out of the 10 samples, 4185 cells in total were identified as potential CTCs (CD45- and 
Draq5+). 849 (20.2%) of these cells did not express either of the epithelial markers EpCAM or 












1 0 22 0 0 
2 0 0 0 5 
3 0 0 0 0 
4 111 1 2 381 
5 552 0 0 0 
6 107 0 0 330 
7 77 0 49 7 
8 44 1 5 0 
9 13 315 0 10 
10 50 1876 111 116 
Total 954 (22.9%) 2215 (52.9%) 167 (4.0%) 849 (20.2%) 
Table 3.3 The different combinations of antigens expressed in cells detected from the blood 
of patients with metastatic prostate cancer. All cells were labelled with EpCAM, CK, CD45 
and Draq5. To be considered a possible CTC cells had to be CD45- and Draq5+. Different 
combinations of EpCAM and CK expression were seen in all ten patients. The most common 
combination was EpCAM+/CK-, seen in 52.9% of patients. 
 
The following diagrams in Figure 3.4 demonstrate the combination of antigens from table 
3.3. Only 22.9% of cells can be defined as CTCs if using the FDA definition. EpCAM+ only cells 
were found in 5 of the samples compared to CK+ only cells in 4. These EpCAM+ only cells 
account for over half of the potential CTCs identified. Although there are a significantly 
higher number of EpCAM+ cells in total, this is skewed by one sample containing 84.5% of 
the total number of EpCAM cells. If this sample is removed and the remaining 9 samples are 
analysed, then the EpCAM+ only cells account for only 16.7% of the total population.  
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In this revised analysis almost double the proportion of cells are FDA-defined CTCs but there 
is also a higher proportion of non-epithelial cells (or at least, cells not expressing one or both 
of the two epithelial markers used in this experiment) compared to the first analysis. Whilst 
a proportion of these cells could be white cells that have not bound to the CD45 antibody, 
this should not account for 20-36% of the sample. This gives further evidence to support the 
theory that there is a significant proportion of cells without an epithelial phenotype, 
circulating in the blood of a patient with an epithelial tumour and these numbers are 
comparable with those found in the literature (Mego et al., 2011). 
Interestingly, the proportion of cells expressing CK only is at most 4%. Therefore, choosing to 
use EpCAM as the sole epithelial antibody would only result in the failed detection of a small 
percentage of cells. Due to heterogeneity between samples this number would vary but it is 
possible that cells that would have expressed CK may be detected by the presence of one or 
more of the stem cell markers.  
 
 
a) Combinations of antigens expressed in 
all ten clinical samples          
b) Combinations of antigens expressed in 
samples 1-9 
Figure 3.4 Venn Diagrams to demonstrate the combination of antigens expressed by cells 
detected in the blood of patients with metastatic prostate cancer. Diagram a) included all 
samples but diagram b) excludes sample 10 which had a very high number of cells found and 
could skew the data. The revised data without sample 10 shows that the majority of CTCs 
found in the 9 patients expressed both EpCAM and CK. 
3.3.9 Final antibody panel 
The final antibody combination has to be a compromise between what is commercially 
available, cost and avoiding spectral overlap. Despite using a pan-cytokeratin antibody which 
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should identify cytokeratins 4, 5, 6, 8, 10, 13 and 18 during the cell line and clinical 
experiments, EpCAM was found to be far more prevalent in the prostate cancer cell lines 
and the clinical samples compared to CKs and was therefore chosen as the epithelial marker. 
Inevitably there will be a proportion of prostate cancer cells in the samples that will evade 
detection due to antibody choice, but this is one of the limitations of any CTC work. The final 
list of antibodies and associated fluorochromes is outlined in Table 3.4. 
 
Antibody Fluorochrome Isotype Control Manufacturer 
EpCAM PE-Vio615 REA(S) Miltenyi Biotec 
Oct4 AF488 IgG1 BD Biosciences 
SOX2 AF555 IgG2a BD Biosciences 
Nanog Per-CP Cy5.5 IgG1 BD Biosciences 
CD45 PECy7 IgG1 BioLegend 
DAPI - - BioLegend 
 
Table 3.4 A list of chosen antibodies and the associated fluorochrome and isotype control 
used in the assay described in this chapter. 
 
The emission and excitation of the fluorochromes of the final panel of antibodies is 
demonstrated below in Figure 3.5. Some degree of spectral overlap will occur, but this will 
be minimised by careful compensation, using single colour controls. This will be explored in 
section 3.5. 
 
Figure 3.5 A graph to demonstrate the excitation (dotted line) and emission (solid block) 
wavelengths of the fluorochromes conjugated to the antibodies used in this assay (courtesy 
of BD Biosciences). 
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3.4 Optimisation of antibodies 
3.4.1 Antibody optimisation of EpCAM using cell lines 
Each optimisation concentration was repeated three times using 100 000 cells. Eppendorfs 
or FACS tubes contained the cells in 100µl of suspension. Therefore concentrations discussed 
are 1:500 (0.2µl), 1:200 (0.5µl), 1:100 (1µl), 1:75 (1.5µl) and 1:50 (2µl). 
EpCAM (PE-Vio615) was optimised using LNCaP cells (Figure 3.6). 100 000 cells were stained 
with increasing concentrations of antibody and compared to the same concentration of the 




      
Figure 3.6 Graphs to demonstrate LNCaP cells unstained (yellow), stained with isotype 
control (orange) and with increasing levels of antibody (red). Each volume of antibody was 
used to determine the lowest level that could be utilised by demonstrating a shift from the 
negative controls (unstained cells and isotype controls). 
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Figure 3.7 An Imagestream image demonstrating the cell membrane staining using the 
EpCAM antibody at a concentration of 1:200. 
 
There was no increased shift in fluorescence when using increasing concentrations, and the 
images obtained demonstrated appropriate staining (Figure 3.7). Therefore the EpCAM 
antibody was used at a concentration of 1:200. 
3.4.2 Antibody optimisation of Oct4, SOX2 and Nanog using cell lines 
Expression of Oct4, SOX2 and Nanog was much more difficult to ascertain as conventional 
cell lines did not express the stem cell antigens in sufficient, predictable quantities. 
Optimisation experiments were performed on cell lines LNCaP, PC3, SEM, TC71 and Y201 all 
without success. Mesenchymal stem cells were obtained from bone marrow (under ethical 
approval from North-East Newcastle and North Tyneside 1 Research Ethics Committee, REC 
no 17/NE/0361, Feb 2018) - please see appendix for ethics form) and whilst they did express 
the antigens (Figure 3.8), we were unable to culture them in sufficient quantities to perform 
reliable optimisation tests. 
 
Figure 3.8 Imagestream images to demonstrate expression of Oct4, SOX2 and Nanog in two 
different Mesenchymal Stem Cells. The first cell is only positive for Nanog but the second 
expresses all three stem cell antigens. 
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Optimisation for Oct4, SOX2 and Nanog was therefore performed using induced pluripotent 
stem (iPS) cells, (obtained from benign prostate tissue). This optimisation was conducted 
during a period of two months when the Imagestream was undergoing repair, and therefore 
conventional FACS was used to examine different antibody dilutions applied to iPS cells 
(Figure 3.9, unlabelled iPS cells; Figure 3.10 and 3.11, Oct4 antibody-labelled cells; Figure 




Figure 3.9 Unlabelled iPS cells gated based on size. Cells falling within this gate were counted 
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  c) 1:200      d) 1:500 
Figure 3.10 Graphs to demonstrate fluoresence in iPS cells only (black), cells with 
isotype control (red) and cells with Oct4 (AF488) at decreasing concentrations: a) 
1:50, b) 1:100, c) 1:200 and d) 1:500. The highest concentration shows a shift in 
fluorescence in the majority of cells labelled with the antigen compared to the 
isotype and unlabelled cells but the three lower concentrations show an overlap with 
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a) Cells only 
 
 
 b) 1:50      c) 1:100 
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   d) 1:200     e) 1:500 
Figure 3.11 Graphs to show the percentage of iPS cells that fell inside the positive gate, 
which was drawn by excluding the unlabelled cells as a negative control. The graphs show 
the fluorescence of the iPS cells with decreasing concentrations of Oct4 (AF488) antibody: b) 
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c) 1:200      d) 1:500 
Figure 3.12 Graphs to demonstrate fluoresence in iPS cells only (black), cells with isotype 
control (red) and cells with SOX2 (AF555) at decreasing concentrations: a) 1:50, b) 1:100, c) 
1:200 and d) 1:500. There is a clear shift in the cells labelled with the 1:50 concentration 
when compared to the unlabelled cells and isotype control, but an overlap with the negative 




a) Cells only 
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   b) 1:50      c) 1:100 
 
   d) 1:200     e) 1:500 
Figure 3.13 Graphs to show the percentage of iPS cells that fell inside the positive gate, 
which was drawn by excluding the unlabelled cells as a negative control. The graphs show 
the fluorescence of the iPS cells with decreasing concentrations of SOX2 (AF555) antibody: b) 
1:50, c) 1:100, d) 1:200 and e) 1:500. 
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  c) 1:200      d) 1:500 
Figure 3.14 Graphs to demonstrate fluoresence in iPS cells only (black), cells with isotype 
control (red) and cells with Nanog (PerCP Cy5.5) at decreasing concentrations: a) 1:50, b) 
1:100, c) 1:200 and d) 1:500. There is a larger overlap with the negative controls, even at the 
highest concentration, which was thought to be due to the pluripotency of the iPS cells. 
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a) Cells only 
 
 
b) 1:50      c) 1:100 
 
d) 1:200     e) 1:500 
Figure 3.15 Graphs to show the percentage of iPS cells that fell inside the positive gate, 
which was drawn by excluding the unlabelled cells as a negative control. The graphs show 
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the fluorescence of the iPS cells with decreasing concentrations of PerCP Cy5.5 antibody: b) 
1:50, c) 1:100, d) 1:200 and e) 1:500. 
  
 Percentage of iPS cells staining positive at each concentration (%) 
Concentration Oct4 SOX2 Nanog 
1:50 95.14 94.42 91.30 
1:100 91.93 93.88 45.40 
1:200 87.61 91.50 10.46 
1:500 65.20 90.12 1.22 
Table 3.5 A Table demonstrating the percentage of iPS cells staining positive for each 
antibody at increasing concentrations. 
 
There was a significant drop in the number of cells expressing both Oct4 and Nanog at lower 
concentrations of the antibody (Table 3.5). This could potentially be explained by the 
heterogeneity of the iPS cells, despite early passage. When looking at the Nanog experiment, 
there was evidence of a significant degree of overlap when using the isotype control at all 
concentrations (less so in the 1:50 concentration for which the opposite would be expected, 
but the number of cells seem to be lower which is an error of the experiment). A 
compromise needs to be reached and the benefit of ultimately using the ImagestreamX is 
that each positive image can be scrutinised visually, to ensure that the location of the 
positive stain is appropriate (in this case it should be nuclear).   
Based on these experiments, a concentration of 1:50 (2µl) was used for each of the 
antibodies Oct4, SOX2 and Nanog. 
3.4.3 Antibody optimisation of CD45 and DAPI 
DAPI and CD45 (PECy7) had been optimised by the NICR team and the concentrations of 
these were kept the same; 1:500 for DAPI and 1:50 for CD45.  
 
3.5 Cell size as an alternative means of detection 
3.5.1 Background 
As previously discussed, detection of CTCs based on size alone is difficult due to the size 
similarity between larger haematopoietic cells. Assuming CTCs are large means those 
becoming smaller whilst undergoing EMT may be missed (Yu et al., 2011). Selection methods 
using size-based criteria alone typically lead to a yield of less than 10% (Hao et al., 2018). The 
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NICR team who had done previous CTC work had used a gating strategy to capture cells 
based initially on size and then on fluorescence, to reduce the number of captured events 
and decrease file size. This was felt to be inappropriate in this assay as there is evidence 
from studies looking at cell size in different stages of prostate cancer that CTCs in patients 
with very advanced metastatic disease can be much smaller (Chen et al., 2015a). Despite cell 
lines being considerably larger than white blood cells, early experiments on the Imagestream 
using clinical samples detected a variation in size of possible prostate CTCs.  
3.5.2 Cell line size 
To identify prostate cell line cell size in comparison with white blood cells, 100 000 PC3 cells 
were spiked into 2mls of healthy volunteer blood. Two samples were prepared using the 
NICR Imagestream assay and the sample stained with Vimentin, CD45 and DAPI. Each sample 
was then run for ten minutes on either the Imagestream or conventional FACS. Fluorescence 
of Vimentin was used to identity true PC3 cells and these cells were then plotted with the 
white cells based on size (Figure 3.23). 
 
a) Imagestream Captured Cells     b) FACS Captured Cells 
Figure 3.16 Images to demonstrate PC3 cells when run in whole blood on a) the 
Imagestream (yellow events) and b) conventional FACS (blue events). (Blood cells are black) 
 
This experiment was then repeated with LNCaP cells, using EpCAM instead of Vimentin to 
identify the cell line (Figure 3.24). 
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a) Imagestream Captured Cells        b) FACS Captured Cells 
Figure 3.17 Images to demonstrate LNCaP cells when run in whole blood on a) the 




a) a PC3 cell from the Imagestream, demonstrating that it is negative for EpCAM and 
positive for Vimentin 
 
 
b) an LNCaP cell from the Imagestream, demonstrating that it is positive for EpCAM and 




c) a CD45+ white cell 
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Figure 3.18 Images taken from the Imagestream to demonstrate a) a PC3 cell, b) an LNCaP 
cell and c) a white cell 
 
From these graphs (Figures 3.23, 3.24) and images (Figure 3.25), it is clear that both PC3 and 
LNCaP cells are larger than the white blood cells. However, even with these cell lines there is 
a variation in size and some of the smaller cells were closer in size to the larger white cells.  
Gating based on size from this experiment could be appropriate, although careful re-
experimentation should be performed to calculate the percentage loss of cells if considering 
this method, and due to low numbers of expected CTCs in clinical samples it would have to 
be expected that smaller cells may get missed. In order to establish whether this would be a 
feasible strategy in the final Imagestream assay, CTC size in clinical samples must also be 
explored. 
3.5.3 Patient samples 
As patient samples are likely to be more heterogenous than cell lines, an observational 
experiment was performed on ten clinical samples that had been used at different stages 
during the optimization of the assay. Because these samples were run with different 
combinations of antibodies it was not possible to combine the data to look at overall size in 
graphical form. The following images were captured and show a representative variation in 





a) Two EpCAM positive cells 
 
b) an Oct4 positive cell 
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c) three SOX2 positive cells 
 
 
d) two Nanog positive cells 
 




f) a white cell 
Figure 3.19 Images taken from the Imagestream to show a variation in sizes of CTCs (a-e) in 
comparison with a white cell (f). 
 
Because the potential number of CTCs in clinical samples is so small, it was concluded that 
the variation in size of CTCs found in these ten samples precluded any elimination by gating 
based on size. Some of the CTCs found were smaller than the white cells, and whilst there 
were some larger cells, a significant population could be missed. 
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3.6  Final Assay and Gating Strategy 
3.6.1 Sample preparation 
The samples were collected from patients in EDTA blood tubes and processed within four 
hours. A combined fixation and lysis stage was performed followed by a white cell immuno-
magnetic depletion. Samples were then permeabilised before the addition of antibodies. 
3.6.2 Antibody selection 
The following antibodies were used for this assay: 
EpCAM (PE-Vio615) 1:200 
Oct4 (AF488) 1:50 
SOX2 (AF555) 1:50 
Nanog (PerCP-Cy5.5) 1:50 
CD45 (PECy7) 1:50 
DAPI (1:500) 
3.6.3 Imagestream Setup 
Laser settings were confirmed as per table 3.6 and single colour controls were processed at 
the start of each week to ensure accuracy and consistent staining of antibodies. 
3.6.4 Gating strategy for collection and analysis of an Imagestream file 
Samples were collected using a gate to exclude CD45 positive cells and events that were 
DAPI negative (presumed to be debris). The gates used were set up as a template and this 
was applied to all clinical samples processed. 
When analysing cells, all DAPI positive, EpCAM positive cells were visually inspected and 
included as positive events if staining was appropriate (cell membrane). DAPI positive cells 
displaying a threshold above 1.4e4 (Oct4 and SOX2) and 1.6e4 (Nanog) were also visually 
inspected and included if staining was appropriate (nuclear or cytoplasmic). Overall CTC 
count was recorded for each sample, in addition to the number of each combination of 
marker positive cells. 
 
  111 
3.7 Results by patient characteristic        
The following tables (Tables 3.6-3.12) show a summary of the number of cells detected by 
the assay described in this chapter, according to patient characteristics. Each cell expressing 
the combination of antigens expressed is recorded for each patient. 
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Patient 
No 

































   L  
1 48 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 41 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
3 43 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 52 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
5 38 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
Table 3.6 A table to show the number of cells expressing each antigen for blood taken from healthy volunteers when processed using the 
Imagestream assay. 
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Patient 
No 







































9.9 0 0 5 0 0 0 0 1 0 0 0 0 5 




9.5 0 1 7 0 0 2 0 1 5 0 0 0 16 




5.6 0 0 0 0 0 0 0 0 0 0 0 0 0 




7.9 0 0 0 0 0 0 0 0 0 0 0 0 0 




7.2 0 0 0 50 0 0 0 0 0 0 0 0 50 




4.4 0 0 0 0 0 0 0 0 0 0 0 0 0 
Table 3.7 A table to show the number of cells expressing each antigen for blood taken from patients with benign disease when processed using the 
Imagestream assay. 
  







































1 68 AS 5.3 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 72 AS 6.1 0 0 0 14 0 0 0 0 0 0 0 0 14 
3 76 WW 27.1 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 84 WW 18.1 0 0 3 0 0 0 0 0 0 0 0 0 3 
5 87 WW 86.0 1 0 0 1 0 0 0 0 0 0 0 0 2 
6 76 AS 37.4 0 0 1 0 0 0 0 0 0 0 0 0 1 







































1 77 New Diag 5.2 0 0 0 303 0 0 0 1 1 1 0 0 306 
2 68 New Diag 33.5 0 0 2 4 0 3 0 0 0 0 0 0 9 
3 65 New Diag 18.3 0 0 1 8 0 0 0 0 0 1 0 0 10 
4 74 New Diag 140.0 0 0 2 8 0 0 0 1 0 0 0 0 11 
5 68 New Diag 308.0 0 1 0 6 0 1 0 12 1 0 0 0 21 
6 62 New Diag 22.0 0 0 7 0 0 0 0 0 13 0 0 0 20 
7 68 New Diag 47.0 0 0 1 0 0 1 0 0 0 0 0 0 2 
8 69 New Diag 3.2 0 12 0 2 0 6 0 50 64 2 0 0 136 
Table 3.9 A table to show the number of cells expressing each antigen for blood taken from patients with new diagnosis metastatic disease when 
processed using the Imagestream assay. 
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1 69 Single agent 31.4 0 0 1 0 0 0 0 0 1 0 0 0 2 
2 82 Single agent 1.8 0 0 0 0 0 0 0 0 0 0 0 0 0 
3 71 Single agent 2.9 0 4 4 1 0 0 0 0 2 0 0 0 11 
4 92 Single agent 0.2 0 0 1 0 0 0 0 1 0 1 0 0 3 
5 91 Single agent 0.2 0 0 0 0 0 0 0 0 0 0 0 0 0 
6 82 Single agent 50.9 0 0 0 0 0 0 0 0 0 0 0 0 0 
7 87 Single agent 4.5 0 0 0 0 0 0 0 0 0 0 0 0 0 
8 66 Single agent 0.1 0 0 6 0 0 0 0 0 0 0 0 0 6 
9 71 Single agent 2020 0 0 34 3 0 3 0 3 0 1 1 0 45 
10 77 Single agent 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0 
11 59 Single agent 4.5 0 0 11 1 0 0 0 0 0 0 0 0 0 
12 63 Single agent 81.9 0 3 2 1 0 2 0 0 0 0 0 0 8 
13 67 Single agent 3.0 0 11 0 3 0 0 0 1 3 0 0 0 18 
Table 3.10 A table to show the number of cells expressing each antigen for blood taken from patients on single agent hormones when processed 
using the Imagestream assay. 
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Patient 
No 



































1 86 MAB 245.6 84 2 0 2 0 1 0 0 1 0 0 0 90 
2 84 MAB 61.4 1 0 0 1 0 0 0 0 2 0 0 0 4 
3 79 MAB 1.5 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 87 MAB 3.1 0 0 0 185 0 0 0 0 0 0 0 0 185 
5 82 MAB 24.0 0 2 5 0 0 0 0 0 1 0 0 0 8 
6 77 MAB 101.0 0 1 1 11 0 0 0 1 1 0 0 0 15 
7 78 MAB 1.5 0 0 0 0 0 0 0 0 0 2 0 0 2 
8 69 MAB 1.8 0 0 1 0 0 0 0 0 0 0 0 0 1 
9 86 MAB 12.6 0 0 2 0 0 0 0 0 0 0 0 0 2 
10 83 MAB 0.1 0 0 1 0 0 0 0 0 0 0 0 0 1 
11 83 MAB 23.4 0 1 0 2 0 0 0 0 0 0 0 0 3 
12 74 MAB 2.0 0 0 25 36 0 1 0 0 0 0 0 0 62 
13 96 MAB 34.6 0 2 57 0 1 0 0 0 0 2 0 0 62 
14 80 MAB 1.7 0 0 7 0 0 0 0 0 0 0 0 0 7 
15 73 MAB 5.5 0 0 40 1 0 0 0 0 0 0 0 0 41 
16 65 MAB 30.6 0 0 0 4 0 0 0 6 1 0 0 0 11 
Table 3.11 A table to show the number of cells expressing each antigen for blood taken from patients on maximum androgen blockade when 
processed using the Imagestream assay. 
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Pt 
No 
Age Treatment PSA  EpCAM+ Oct4+ SOX2+ Nanog+ EpCAM 
/ 
0/S/N 




















1 77 Enzalutamide 1875 4 0 2 0 0 8 0 0 0 0 1 0 15 
2 68 Docetaxel 0.8 0 0 0 14 0 0 0 0 0 0 0 0 14 
3 85 Dexamethasone 55.0 0 8 9 22 0 0 0 0 0 0 0 0 39 
4 69 Enzalutamide 380 11 0 1 3 0 0 0 1 3 0 0 0 19 
5 77 Dexamethasone 18.0 0 0 3 12 0 0 0 3 0 0 0 0 18 
6 61 Abiraterone 51.2 0 0 0 3 0 0 0 1 0 0 0 0 4 
7 60 Enzalutamide 0.7 0 1 0 68 0 0 0 9 0 0 0 0 78 
8 74 Dexamethasone 0.7 0 0 0 6 0 5 0 3 0 0 0 0 14 
9 73 Dexamethasone 23.0 0 0 5 4 0 0 0 3 0 0 1 0 13 
10 77 Docetaxel  433 0 2 66 5 0 0 0 0 0 0 0 0 73 
11 58 Enzalutamide 12.4 2 5 0 1 0 3 1 4 2 0 0 0 18 
12 87 Cabazitaxel 5.6 20 2 3 0 0 2 0 0 1 0 0 0 28 
13 70 Dexamethasone 228 0 0 3 12 0 0 0 3 0 0 0 0 18 
14 82 Enzalutamide 72.4 0 1 0 0 0 0 0 0 1 0 0 0 2 
15 74 Abiraterone 16.3 0 1 0 2 0 0 0 0 1 0 0 0 4 
16 74 Docetaxel 8.0 0 0 49 0 0 22 0 0 4 0 0 0 75 
17 72 Enzalutamide 586 20 1 0 0 0 1 0 1 0 0 0 0 23 
18 69 Radium 223 202 0 0 0 0 0 0 0 0 2 0 0 0 2 
19 80 Enzalutamide 2.2 0 0 2 10 0 0 0 0 0 0 0 0 12 
20 74 Enzalutamide 1.3 6 12 41 6 0 2 0 0 2 0 0 0 69 
21 76 Dexamethasone 0.8 0 0 5 0 0 0 0 0 0 0 0 0 5 
22 51 Enzalutamide 434 0 0 3 0 0 2 0 0 2 0 0 0 7 
23 58 Docetaxel 100 0 8 3 0 0 6 0 2 2 0 0 0 21 
24 76 Enzalutamide 4611 0 4 0 0 0 0 0 0 0 0 0 0 4 
25 77 Radium 223 29.2 2 0 10 0 0 2 1 0 10 0 0 0 25 
26 66 Enzalutamide 21.0 0 0 0 0 0 0 0 0 0 0 0 0 0 
27 72 Enzalutamide 532 0 0 0 2 0 0 0 0 0 0 0 0 2 
28 81 Radium 223 96.1 0 2 0 0 0 0 0 0 0 0 0 0 2 
29 78 Dexamethasone 10.5 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Table 3.12 A table to show the number of cells expressing each antigen for blood taken from 
patients with castrate resistant disease when processed using the Imagestream assay.  
 
3.8 Discussion 
The Imagestream offers a unique opportunity to sort cells using conventional FACS 
techniques in addition to visualising individual cell images, which gives it a unique advantage 
when testing the validity of a new assay. The ability to use up to six different fluorochromes 
has enabled a novel assay to be developed, looking at a combination of epithelial and stem 
cell markers, which has not been previously been conducted in prostate cancer CTCs.  
The decision not to include a prostate specific marker was made as it was not felt it could 
reliably identify prostate cancer cells. An alternative method would have been to have split 
each sample and run a different combination of epithelial, stem cell and prostate specific 
markers. This was considered but due to processing and analysis time it was felt that this 
would compromise the overall number of samples that could be obtained and processed, 
and could ultimately reduce the impact of any findings. The experiment looking at epithelial 
marker expression demonstrated that in up to 36% of the samples there were cells that 
were epithelial marker negative, which strengthens the argument for looking at alternative 
antigens. Although a mesenchymal marker could not be added in addition to the chosen 
combination, this will be explored in Chapter 4 and will address the population of cells that 
could be undergoing EMT. 
The cell line retrieval experiment to test the assay developed by the NICR team identified a 
considerable difference in retrieval between the two different cell lines. Whilst the PC3 
retrieval rate is higher than the mean rate for the previously tested cancer cells tested using 
the NICR assay (oesophageal, hepatocellular, ovarian and thyroid), the LNCaP numbers are 
lower. Cell fragility could account for the variation. Whilst cell lines are useful in assay 
development, heterogeneity between cell lines and clinical samples, and between each 
clinical sample will mean the actual retrieval rate of each clinical sample will be unknown. 
This would actually be the case for any assay using clinical samples on any platform, and as 
this study is not looking at enumeration but presence or absence of expression of markers, 
the results of this experiment are reassuring enough for this assay to be used for this study. 
The antibody optimisation was performed using cell lines to ensure reproducibility. As with 
any optimisation, the actual cells of interest in the clinical samples will express the antigens 
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differently compared to the cell lines or synthetic beads used during optimisation. This 
needs to be acknowleged but even if multiple cell lines are used and an average taken, this 
still won’t negate this, and indeed there is likely to be heterogeneity within the cell 
population of interest in the clinical sample. When looking at the presence of stem cell 
markers in healthy blood, there was an overlap between some of the CD45 negative / Nanog 
positive cells (presumed to be CTCs). This may mean a loss of potential CTCs if setting a 
threshold to exclude any white cells. Although a lower threshold could be used, and then 
cells could be visually inspected, because of the number of cells, this would be impractical. 
Setting the threshold at the decided level for Nanog is a limitation of this assay but a high 
number of false positives was felt to be worse than potentially missing a small number of 
cells.  
The Nanog results could also be affected by the Nanog optimisation. Even at the 1:50 
concentration, only 86% of the cell line was positive. Although this had been attributed to 
iPS cell heterogeneity, it could be that the antibody needed to be at a higher concentation. 
However, a 1:25 experiment was performed (results not shown) and there was too much 
overlap between the isotype control and antibody experiments. Therefore a compromise 
was reached, and ultimately it is hoped that only a small subset of CTCs are missed as a 
result of this. 
The gating strategy is important as whilst ideally as many cells as possible would be captured 
when running the experiments, the file size needs to be manageable. A small number of 
early experiments was lost due to the inability to open the file after an inappropriate gating 
strategy was employed. Visual inspection of cells not captured by the gates, or close to the 
threshold was performed prior to the final gate template being applied to ensure accuracy. 
This assay has been developed from an existing protocol used by colleagues looking at 
different cancers. Experiments looking at the pros and cons of different antibody 
combinations were used before deciding on the ultimate panel. Rigorous antibody 
optimisation and a personalised Imagestream set-up including careful fluorochrome choice, 
controls and gating have ensured that this new assay will detect as many CTCs as possible in 




  120 
Chapter 4. The role of multi-channel FACS in the detection and 
analysis of CTCs in metastatic prostate cancer 
 
Chapter Summary 
This chapter discusses the reason for exploring the role of a multi-channel FACS assay in the 
detection of CTCs from patients with metastatic prostate cancer. This novel assay 
development, using a combination of epithelial, mesenchymal and stem cell markers on the 
BD FACS Fusion is described. This includes the choice of antibodies used, cell line 
optimisation, gating strategies and options for downstream analysis. The pros and cons of 
this assay are also discussed, and the final assay outlined prior to the results, which can be 
found in Chapter 5. Because the FDA definition of a CTC does not include cells that express 
Oct4, SOX2 and Nanog, any cells described in this chapter that are EpCAM positive and/or 
express any of these three stem cell antigens are deemed putative CTCs. 
 
4.1 Platform choice 
4.1.1 Background 
Whilst the Imagestream offers the ability to visualise cells that have been sorted 
fluorescently, it does have limitations. The benefits of being able to visualise cells to ensure 
appropriate staining are huge, especially when developing a new assay. However, the 
number of lasers (4) limits the number of antigens that can be investigated, the running time 
of the sample is relatively long and laborious, file size means cells need to be gated before 
capture so the whole sample can’t be analysed, and the analysis itself is very time 
consuming. Samples are not retrievable so downstream analysis is not possible and when 
exploring the potential of a new assay to be used in clinical settings, few institutions will 
possess an Imagestream.  
In contrast, conventional FACS is a well-established method of cell sorting and most large 
institutions will have access to a machine, either in a hospital setting or related academic 
establishment. Processing and analysis of samples is relatively quick, and file size is not a 
limitation, so all data can be saved, with subsequent analysis used to eliminate unrequired 
information. The downside of FACS is the potential to have false positives. Debris or cells 
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that have stuck to the wrong fluorochrome can be included in gates that would give a 
disproportionately high number of positive events. Whilst it is possible to reduce this error 
to some degree (e.g. gating out doublets using size-based criteria) when looking at a small 
population of cells such as CTCs, this could lead to a significant over-estimation. One way to 
circumvent this is to use FACS cell sorting and downstream analysis on the cells. The 
population of interest could then undergo DNA or RNA extraction for sequencing, or be put 
onto a slide for conventional immuno-fluorescence. Whilst this would mean a considerable 
volume of work, during the development of the assay it would ensure validation, and a 
margin of error could be calculated for the over-estimation of CTC count. If acceptable, this 
downstream analysis could subsequently be negated.  
4.1.2 Choice of Platform 
Again, from a logistical perspective one of the available platforms at Newcastle University 
was chosen. The BD FACS Fusion has five lasers (UV 355 nm, Violet 405nm, Blue 488nm, 
Yellow/Green 561nm and Red 635 nm) which would comfortably allow ten fluorochromes to 
be used simultaneously, without any concern about significant overlap (Table 4.1). It has the 
option to sort into Eppendorfs, multi-well plates or onto slides. This was the chosen platform 
for development of this assay. 
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 Laser 
 UV 355nm 405nm 488nm 561nm 642nm 
Example 
Dyes 
BUV 395 BV421 FITC PE APC 
 DAPI V450 AF488 PE-Dazzle APC-Cy7 
 Hoechst 
Blue 
DAPI Brilliant Blue 
515 
AF555 APC-H7 
 BUV 737 Pacific Blue GFP PE-Cy7 AF647 
  BV510 YFP PE-Cy5.5 AF700 
  BV605 Zombie Green  Draq5 
  BV650 PerCP-Cy5.5   
  BV711    
  BV786    
Table 4.1 A Table to demonstrate the available lasers on the BD FACS Fusion at Newcastle 
University Medical School’s Flow Cytometry Core Facility, and the suggested fluorochromes 
(adapted from the Newcastle University FCCF website). 
 
4.2 Antigen expression and choice of antibodies 
4.2.1 Number of channels and choice of antigens 
Unlike in the Imagestream assay when the number of antigens was limited to six, the extra 
laser and lack of brightfield images gives the option for including an additional four 
antibodies. Choosing an antibody panel must take into account overlap of fluorescence, 
what is commercially available and the use of reliable fluorochromes where possible. 
Despite the antibody options in Table 4.1, not all fluorochromes give a consistent emission 
and are therefore less reliable than others.  
Some of the more common antigens are commercially available directly conjugated to a 
range of fluorochromes yet some of the rarer antigens are only available either 
unconjugated or conjugated to a limited number of fluorochrome types. Buying directly 
conjugated antibodies not only ensures consistency but reduces the error that could be 
introduced by adding a secondary fluorochrome. Although laser settings and antibodies 
should be routinely tested at regular intervals to ensure no fluorescent decay, when buying 
the antibody and fluorochrome to conjugate, the combined product must also be tested to 
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ensure consistency in fluorescence. This can be improved upon by using a conjugation kit, so 
that a stock of the combined antibody/fluorochrome can be made at any one time, but this 
can be expensive. 
The optimal final antibody panel was decided upon by finding directly conjugated antibodies 
for the rare antigens first, then choosing fluorochromes with minimal overlap for the more 
common antigens. Only one antibody (MT1-MMP) was not available as a commercial 
conjugate.  
4.2.2 The decision not to use a prostate specific antibody 
Although four extra channels were available to use in this assay compared to the previous 
assay on the Imagestream, again the decision was made not to include a prostate specific 
antibody. The reasons for this were the same as previously, in that heterogeneity of PSA and 
the Androgen Receptor (the most obvious choices to use as markers) in patients with 
advanced disease would not enable reliable identification of prostate cancer cells. Both 
EpCAM and Cytokeratin were included, so that the small proportion of EpCAM- epithelial 
cells could be correctly identified (and cells could therefore meet the FDA definition for a 
CTC). In addition to this, exploration of mesenchymal markers was desired and inclusion of 
Vimentin and MT1-MMP in this assay, the latter of which can induce epithelial to 
mesenchymal transition in prostate cancer cells, allowed a novel combination of epithelial, 
mesenchymal and stem cell markers to be studied; this had not been performed previously 
in metastatic prostate cancer.  
4.2.3 White cell markers 
The final additional channel was used for a second white cell marker. In the Imagestream 
assay, the thresholds for Oct4, SOX2 and Nanog in haematopoietic cells were found to be 
lower than in CTCs. Because visual inspection of these cells to confirm whether the ‘positive’ 
population are CTCs is not possible using this assay, it would not be possible to reliably 
repeat this experiment, and so a second white cell marker was chosen. Whilst the majority 
of haematopoietic cells would be positive for both markers, the use of a second marker 
would hopefully identify a small population of cells that didn’t bind to one of the white cell 
antibodies. Labelling as many cells as possible to exclude them as CTCs would make the 
assay more robust. 
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CD16 was chosen as the second white cell marker, used in addition to CD45. Whilst CD45 is 
also known as the common leucocyte antigen and is expressed on all human white cells 
(Altin and Sloan, 1997) CD16 is a surface marker found on macrophages, monocytes, 
neutrophils and natural killer cells (Janeaway, 2001). It would appear from looking at other 
studies in the literature, CD16 is often used as a second white cell marker to CD45 as 
combining the two antibodies will detect the highest number of white cells (Fujimoto et al., 
2000, Kahng et al., 2015). 
An experiment was performed to identify how distinct the white cell population using these 
two markers. 500 000 cells from each of three different cell lines (PC3, MCF7 and LNCaP) 
were added to 2mls of Healthy Volunteer Blood. Prior experimentation proved that none of 
these cell lines expressed CD45 or CD16. The blood then underwent lysis, fixation, 
permeabilisation and the following antibodies added: CD45 (BV786), CD16 (APC-H7), Pan-
cytokeratin (PECy7), EpCAM (BV650) and Vimentin (AF647). All antibodies were directly 
conjugated to the fluorochromes described. This was repeated three times and all three 
samples were then processed on the FACS Fusion (a-c) (Figure 4.1). 
 
a) Healthy Volunteer 1     b) Healthy Volunteer 2 
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c) Healthy Volunteer 3      
Figure 4.1 Three dot plots to show the CD45/CD16 negative population when three cell lines 
were added to blood from three healthy volunteers and stained with CD45 and CD16 
antibodies. The cells within the red gate are negative for both CD45 and CD16. 
 
From these graphs it is clear that the majority of the white cells are positive for both markers 
but that there are tails within the population, indicating that some white cells are only 
positive for one or the other. This demonstrates the importance of having two white cell 
markers. Exact proportions of unlabelled cells will be explored in the next section during the 
antibody optimisation. 
Although the cells within the gate are the negative population (PC3, LNCaP and MCF7 cells) 
there is a degree of overlap between these cells and the white cell population. Because each 
cell in this and the final assay will be exposed to a combination of antibodies it should be 
possible to determine if the cells here are white cells or not by looking at their fluorescence. 
However, this will be a limitation of the final assay as it will not be able to determine the 
difference between white cells that haven’t attached to either antibody, or CTCs that are 
negative for all the chosen markers. Because of the variation and number of different 
antibodies used it is hoped that this population will be very small. This will be explored in the 
next section. 
4.2.4 Epithelial antigens 
As already mentioned, because of the availability of additional channels, Cytokeratin was 
included in addition to EpCAM, so that cells displaying only one of these markers could still 
be detected, but also because those fulfilling full FDA criteria (EpCAM+/CK+/CD45- and 
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nucleated cells) could be counted. This would allow comparison of this assay with those in 
the literature. 
4.2.5 Mesenchymal antigens 
Whilst prostate cancer is of epithelial origin, the use of a mesenchymal antibody could help 
detect cells which have undergone epithelial to mesenchymal transition. There is the option 
of choosing an established mesenchymal marker such as N-cadherin or Vimentin (Armstrong 
et al., 2011, Satelli et al., 2017, Gravdal et al., 2007), or a marker more specific to EMT such 
as Twist1 or Zeb1 (Kong et al., 2011, Thiery and Sleeman, 2006, Christiansen and 
Rajasekaran, 2006). Given the propensity of prostate cancer to metastasize to bone, using a 
more unconventional marker such as membrane type-1 matrix metalloproteinase (MT1-
MMP) could potentially provide a greater understanding of disease pattern (Bonfil et al., 
2007) (Trudel et al., 2008). As the cellular results will be correlated with clinical data on 
disease progression, using this as a mesenchymal marker may provide new information. 
MT1-MMP has therefore been chosen as the mesenchymal marker so that its role as a 
potential biomarker in metastatic prostate cancer can be explored. 
4.2.6 Stem cell antigens 
The same three stem cell antigens that were used in the Imagestream assay were chosen for 
use in this FACS assay. This would enable comparison of the presence or absence of these 
markers using the two assays but would also hopefully identify a population of cells that 
might be both negative for epithelial and mesenchymal markers. 
4.2.7 Final antibody panel 
The following antibodies (Table 4.2) were chosen. All were directly conjugated to the 
associated fluorochrome except MT1-MMP. This was conjugated in the lab using a kit, and a 
stock solution made. The fluorescence of this was tested each time by both FACS and 
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Antibody Laser Fluorochrome Isotype 
Control 
Manufacturer 
EpCAM 405 670/30 BV650 IgG1 BD Biosciences 
Cytokeratin 561 586/15 PE Cy7 IgG1 2BScientific 
Vimentin 640 670/30 AF647 IgG1 Santa Cruz 
MT1-MMP 561 586/15 PE IgG1 Merck 
Millipore 
Oct4 405 450/50 BV421 IgG1 BD Biosciences 
SOX2 488 530/30 FITC REA 320 Miltenyi 
Nanog 488 530/30 PerCP Cy5.5 IgG1 BD Biosciences 
CD45 405 780/60 BV786 IgG1 BD Biosciences 
CD16 640 780/60 APC H7 IgG1 BD Biosciences 
Table 4.2 A table to list the antibodies, corresponding fluorochromes, and isotype controls 
chosen for this assay 
4.2.8 Overlap of expression 
Care was taken to ensure that the chosen fluorochromes had minimal overlap (Figure 4.2). 
By using the five lasers, and ensuring careful compensation, overlap or bleed between 
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Figure 4.2 Graphs to demonstrate the excitation (dotted line) and emission (solid block) 
wavelengths of the fluorochromes conjugated to the antibodies used in this assay (courtesy 
of BD Biosciences) 
 
 
4.3 Optimisation of antibodies 
4.3.1 Introduction 
All concentrations of antibodies were optimized based on concentrations recommended by 
the manufacturer. Set numbers of cells were used, and as the optimisation was performed 
on the Imagestream all cells were permeabilised in 100l of PermWash or suspended in 
100l of flow buffer if the antigen was on the cell membrane. They were then washed and 
resuspended in 200l of flow buffer and all processed on the Imagestream. 
4.3.2 White cell antigens 
The optimisation of the white cell antigens (CD45 and CD16) must be done per volume of 
cells rather than volume of blood, to account for the variability of the number of white cells 
in a patient’s blood. This is particularly relevant when considering patients who are 
immunocompromised, or those who may have an immune response (leucocytosis) to 
tumour growth or a specific treatment. 
Blood was obtained from three healthy volunteers and fixation and red cell lysis was 
performed. 106 cells were counted using the haemocytometer. Four separate volumes of the 
antibody were added to a standardised volume of cells in solution, and matching 
concentrations of the isotype control were added to matching blood samples. Cells with no 
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staining, cells with the isotype and cells with the antibody were then processed on the 
Imagestream. Results from all three samples were combined in the following graphs (Figure 
4.3). 
 
  a) 2.5µl                 b) 5µl 
 
  c) 7.5µl      d) 10µl 
 
Figure 4.3 Graphs to show the optimisation of the CD45 antibody - unstained white cells 
(yellow), white cells stained with the isotype control (orange) and white cells stained with 
CD45 (BV786) using four different volumes of the antibody (a-d). 
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There is a distinct shift in fluorescence between the isotype control and the cells stained 
with the antibody, even at the lowest concentration. Based on this, the lowest concentration 
could be used, but this was explored in more detail when looking at the proportion of 
unlabelled cells (cells that did not pick up the antibody). To look at the proportion of 
unlabelled cells in the sample with the antibody, gates were drawn over the negative 
population. Cells within this gate were counted and the percentage of unlabelled cells at 
each concentration can be seen in Figure 4.4 and Figure 4.5. Based on these results, a 
volume of 7.5µl was used per 106 white cells. 
 
   a) 2.5µl     b) 5µl 
 
   c) 7.5µl     d) 10µl 
Figure 4.4 Graphs to show the proportion of unlabelled cells in white blood cell samples 
stained with four different volumes of CD45 (BV786) when using 106 white cells. 
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Figure 4.5 A graph to show the percentages of unlabelled white cells at different volumes of 
antibody for CD45 (BV786) when using 106 white cells. 
 
The same protocol was repeated for optimisation of CD16. Cells obtained from healthy 
volunteers were prepared and 106 cells were counted prior to addition of either the 
antibody or isotype control. The cells were then processed on the Imagestream and the 
experiment repeated three times. The combined results are displayed in the following 
graphs (Figure 4.6). 
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  a) 1l                 b) 2.5l 
 
   c) 5l      d) 7.5l 
 
Figure 4.6 Graphs to show the optimisation of the CD16 antibody using unstained white cells 
(yellow), white cells stained with the isotype control (orange) and white cells with CD16 
(APC-H7) using four different volumes of the antibody (a-d). 
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There is not such a significant shift from the isotype control, and whilst present it appears 
that there is a higher proportion of unlabelled cells. This was explored in the same way as for 
the CD45 labelled cells. The following graphs (Figure 4.7) demonstrate the population of 
unlabelled cells in the arm of the experiment where CD16 (APC-H7) was added to the cells at 
different concentrations, which is further tabulated in Figure 4.8. 
 
  a) 1l                 b) 2.5l 
 
   c) 5l      d) 7.5l 
Figure 4.7 Graphs to show the proportion of unlabelled cells in white blood cell samples 
stained with CD16 (APC-H7) when using 106 cells. 
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Figure 4.8 A graph to show the percentages of unlabelled white cells at different volumes of 
antibody for CD16 (APC-H7) when using 106 white cells. 
 
In comparison to CD45, there are higher proportions of unlabelled white cells when using 
CD16. This is to be expected as not all white cells express the CD16 antigen. Using these 
results, 7.5l of the CD16 antibody per 106 white cells was chosen as the volume of antibody 
for this assay. This means 12.4% of cells will be unlabelled if using CD16 only. However only 
3.1% of cells are unlabelled from using the CD45 antigen alone. Whilst the experiment 
counting the total number of unlabelled white cells was not performed, it is hoped that a 
proportion of the 3.1% unlabelled cells will be detected by the addition of the CD16 
antibody, so that a gate such as the one used in Figure 4.1 can be used to select all non-
white cells, prior to further fluorescent analysis. 
4.3.3 Epithelial antigens 
The EpCAM antibody chosen for this assay is conjugated to a different fluorochrome (BV650) 
to that used in the Imagestream assay in Chapter 3, to fit into the final chosen panel. 
Optimisation therefore must be performed, and the chosen cell line was LNCaP. 100 000 
LNCaP cells were fixed, washed and resuspended in flow buffer. Four different volumes of 
the EpCAM (BV650) antibody were added to the cells, and the same volumes of the isotype 
controls were added to matched samples. Cells with no staining and the samples were then 
processed on the Imagestream. This was repeated three times and the results are displayed 
in the following graphs (Figure 4.9). 
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   a) 0.5l     b) 1l 
 
   c) 1.5l     d) 2l 
 
Figure 4.9 Graphs to show the optimisation of EpCAM (BV650) antibody using LNCaP cells. 
This shows unstained cells (yellow), LNCaP cells stained with the isotype control (orange) 
and LNCaP cells stained with EpCAM (BV650) (red) using four different volumes of the 
antibody (a-d). 
 
There is a distinct shift in fluorescence between the unstained cells, isotype control and the 
cells stained with the antibody, even at the lowest concentration (Figure 4.9). Therefore the 
0.5l volume was chosen. An Imagestream image of a cell stained using this antibody 
concentration is seen in Figure 4.10. 
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Figure 4.10 An Imagestream image of an LNCaP cell stained with EpCAM (BV650) when using 
0.5l, demonstrating cell membrane staining. 
 
The pan-cytokeratin antibody chosen for this assay is conjugated to PECy7 and was 
optimised using the MCF-7 cell line. Whilst this is a breast cancer cell line, over 99% of MCF-7 
cells express cytokeratin. 100 000 cells were fixed, permeabilised and stained with four 
increasing volumes of the cytokeratin (PECy7) antibody before being resuspended in 200l 
of flow buffer and processed on the Imagestream. Matched samples for cells only and cells 
stained with the isotype control were also run and each repeated three times. The results 
are displayed in the following graphs (Figure 4.11). 
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  a) 0.25l     b) 0.5l 
 
   c) 1l      d) 2l 
 
Figure 4.11 Graphs to show optimisation of the cytokeratin (PECy7) antibody using MCF-7 
cells. These graphs show  unstained MCF-7 cells (yellow), MCF-7 cells stained with the 
isotype control (orange) and MCF-7 cells stained with cytokeratin (PECy7) (red) using four 
different volumes of the antibody (a-d). 
 
When using higher volumes of the antibody (1l and 2l) the isotype control appears to 
overlap with the cells stained with the antibodies. This could be because it becomes sticky at 
higher concentrations but as a result the 0.5l volume of antibody was chosen for the final 
assay (Figure 4.12).  
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Figure 4.12 An Imagestream image of an MCF-7 cell stained with cytokeratin (PECy7) 
when using 0.5l, demonstrating cytoplasmic staining. 
 
4.3.4 Mesenchymal antigens 
The MT1-MMP antibody, conjugated to PE, had already been optimised by colleagues in the 
group for another workstream. 3l of antibody per 100 000 cells was used and this was the 
concentration used for this assay. 
Vimentin conjugated to AF647 was optimised using 100 000 PC3 cells. The cells were fixed 
and permeabilised followed by the addition of four different volumes of the antibodies. Cells 
were then resuspended in flow buffer and processed on the Imagestream, alongside 
matched samples with the Isotype control and PC3 cells only. This was repeated three times 
and the combined results are displayed in the following graphs (Figure 4.13). 
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  a) 0.5l     b) 1l 
 
   c) 2l      d) 3l 
 
Figure 4.13 Graphs to show the optimisation of the vimentin (AF647) antibody using PC3 
cells. These graphs show unstained cells (yellow), PC3 cells stained with the isotype control 
(orange) and PC3 cells stained with vimentin (AF647) (red) using four different volumes of 
the antibody (a-d). 
 
Similar to the cytokeratin antibody, at higher volumes there was an overlap between the 
isotype and antibody stained cells. Again, this could be due to the isotype being sticky at 
higher concentrations. The volume chosen for the final assay was 1l based on the results 
demonstrated in Figure 4.13. A cell stained with this concentration of antibody can be seen 
in Figure 4.14. 
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Figure 4.14 An Imagestream image of a PC3 cell stained with Vimentin (AF647) when using 
1l, demonstrating cytoplasmic and membrane staining 
4.3.5 Stem cell antigens 
The Stem Cell antigens needed to be optimised on iPS cells, as similar to before, because the 
mesenchymal stem cells harvested from bone marrow did not grow in sufficient quantities. 
Despite trials on several cell lines, positive staining was not seen. The same Nanog antibody 
that was used in the Imagestream assay was used in this assay, so optimisation was only 
necessary for Oct4 (BV421) and SOX2 (FITC). 100 000 iPS cells were fixed, permeabilised and 
stained with three increasing volumes of the two antibodies. Matched samples were stained 
with the paired isotype control for each antibody and the samples were all re-suspended in 
200l of flow buffer and processed on the Imagestream, alongside samples with unstained 
cells. The results can be seen in the following graphs (Figures 4.15, 4.16, 4.17 and 4.18). 
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   a) 0.5l     b) 1l 
 
    c)    2l 
Figure 4.15 Graphs to show the optimisation of Oct4 (BV421) antibody using iPS cells. These 
show unstained cells (yellow), iPS cells stained with the isotype control (orange) and iPS cells 
stained with Oct4 (BV421) (red) using three different volumes of the antibody (a-c). 
 
 
Figure 4.16 An Imagestream image of an iPS cell stained with Oct4 (BV421) when using 2l, 
demonstrating nuclear staining. 
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  a) 0.5l     b) 1l 
 
    c)    2l 
Figure 4.17 Graphs to show the optimisation of SOX2 (FITC) antibody using iPS cells. These 
graphs show unstained cells (yellow), iPS cells stained with the isotype control (orange) and 
iPS cells stained with SOX2 (FITC) (red) using three different volumes of the antibody (a-c). 
 
 
Figure 4.18 An Imagestream image of an iPS cell stained with SOX2 (FITC) when using 2l, 
demonstrating nuclear staining. 
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iPS cells can differentiate into any cell type depending on their culture environment so it is 
critical to use early passage cells if stem-like properties are still to be observed. By the 
nature of the way they are cultured and how often they have to be split, using cells in 
sufficient quantity meant that some cells are likely to have differentiated prior to the 
optimisation experiment. This could account for the overlap between the isotype control 
and the antibody stained cells during the Oct4 optimisation. There was a logarithmic 
increase in fluorescence using the 2l quantity yet the tail overlapped with the isotype 
staining. These cells could be cells that have lost their stem cell properties, or only weakly 
express them. The overlap could also be due to the stickiness of the isotype at higher 
concentrations. There wasn’t much change in isotype fluorescence between the 0.5l and 
1l volume but when using the 2l volume the cells stained with the isotype showed a 
higher fluorescence. For these two reasons, a higher volume of antibody was not chosen and 
2l of both Oct4 (BV421) and SOX2 (FITC) were used for this assay (Figures 4.15 and 4.17, 
respectively). 
4.3.6 DAPI 
DAPI concentration was kept the same as for the Imagestream assay in chapter 3 at 1:500 
(or 0.2l). 
 
4.4 Optimisation of an assay to use on a conventional FACS machine with 
sorting capabilities 
 
4.4.1 Collection and storage of blood from patients and healthy volunteers 
4 ml of blood collected in K2EDTA tubes from the patients described in Chapter 3 was used 
for this assay. Consent was obtained from all patients and blood was transported from the 
hospital to the lab at room temperature in a Biohazard UN3373 marked container. Because I 
performed the collection and processing for both assays, and the first stage needed to be 
performed within four hours from blood harvest, the decision was made to use the same 
blood preparation protocol as per the Imagestream assay. 
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4.4.2 Preparation of blood samples 
The BD PhosFlow FixLyse Buffer was immediately applied to the blood to allow cellular 
fixation and lysis of erythrocytes. Immunomagnetic white cell depletion was performed prior 
to permeabilisation. Antibody staining with the antibodies described in the previous section 
was then applied, before washing and resuspension in FACS tubes using 200l of flow buffer. 
Samples were processed the same day on the BD FACS Fusion, to ensure no degradation of 
fluorescence. 
4.4.3 Optimisation of cell sorting and post-sort storage 
A gating strategy was optimised based first on forward and side scatter, to eliminate cell 
debris and doublets, and then on negative fluorescence for both CD16 and CD45 as per 
Figure 4.1. Cells within the gate shown in this figure were assumed to be the potential CTC 
population and were collected in a sterile Eppendorf, suspended in two drops of flow buffer. 
The sorted cell population was then frozen in a -80C freezer, which is kept locked under 
HTA guidelines. All flow data was saved (including the non-sorted population) for analysis. 
 
4.5 Controls, gating strategies and analysis 
4.5.1 Single colour controls and laser set-up 
As per the Imagestream assay in Chapter 3, in order to determine the laser settings to 
enable minimal bleed but detect cells expressing each fluorochrome, flow cytometry 
compensation beads (Ultracomp ebeads, Thermofisher Scientific) were stained with each 
antibody (LNCaP cells were used for DAPI). Beads with no staining were run using each laser, 
and then the beads stained with each antibody were processed. If a high level of bleed was 
detected between one laser and another, the laser setting was reduced. All samples were 
run initially to determine rough laser settings, and then processed again using final settings 
once adjustments had been made. 
These laser settings were then used each time the experiment was run to ensure 
comparable data (Figure 4.19). Single colour controls were repeated every four weeks or 
every time a new antibody vial was purchased, to minimise variation.
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Figure 4.19 A compensation matrix created on the BD FACS Fusion when running each 
sample. Any significant overlap would show in red. 
4.5.2 Gating Strategies 
For each antibody, cells expressing the antigen were stained with the antibody in question 
and processed alongside cells with the isotype control and cells with no staining. Gates were 
first drawn based on forward and side scatter to exclude debris and doublets, and then 
drawn to enable inclusion of cells that had a higher fluorescence than the cells with the 
isotype (Figures 4.20 – 4.26). 
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c) LNCaP cells with EpCAM (BV421)   d) Fluorescence on LNCaP unstained cells 
(black), cells with isotype control (red) 




e) Gate used to identify EpCAM positive CTCs 
Figure 4.20 Graphs to show the fluorescence of a) LNCaP cells with no staining, b) staining 
with the isotype control, c) staining with the EpCAM antibody, d) combined data and e) the 
final gate used for the assay. This final gate was drawn to include any cells expressing higher 
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 a) MCF-7 cells only         b) MCF-7 cells with Isotype control 
 
 
c) MCF-7 cells with CK (PECy7) 
    
    
    
    
 d) Fluorescence on MCF-7 
unstained cells (black), cells with 
isotype control (red) and cells with 
 CK (PECy7) (blue). 
 
e) Gate used to identify Cytokeratin positive CTCs
  148 
Figure 4.21 Graphs to show the fluorescence of MCF7 cells with a) no staining, b) staining 
with the isotype control, c) staining with the cytokeratin antibody, d) combined data and e) 
the final gate used for the assay. This final gate was drawn to include any cells expressing 
higher fluorescence than the isotype control. 
 
 
 a) PC3 cells only   b) PC3 cells with Isotype control 
 
 
 c) PC3 cells with Vimentin (AF647)
     
     
             
d) Fluorescence on PC3 cells only 
(black), cells with isotype control (red) 
and cells with Vimentin (AF647) (blue). 
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  e) Gate used to identify Vimentin positive CTCs 
Figure 4.22 Graphs to show the fluorescence of PC3 cells with a) no staining, b) staining with 
the isotype control, c) staining with the Vimentin antibody, d) combined data and e) the final 
gate used for the assay. This final gate was drawn to include any cells expressing higher 





 a) PC3 cells only       b) PC3 cells with Isotype control 
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 c) PC3 cells with MT1-MMP (PE)
             
     
             
d) Fluorescence on PC3 cells only 
(black), cells with isotype control (red) 
and cells with MT1-MMP (PE) (blue). 
 
 
 e) Gate used to identify MT1-MMP positive CTCs 
Figure 4.23 Graphs to show the fluorescence of PC3 cells with a) no staining, b) staining with 
the isotype control, c) staining with the MT1-MMP antibody, d) combined data and e) the 
final gate used for the assay. This final gate was drawn to include any cells expressing higher 





 a) iPS cells only         b) iPS cells with isotype control 
 
 
        c) iPS cells with Oct4 (BV421)
     
     
     
             
d) Fluorescence on iPS unstained cells 
(black), cells with isotype control (red) 








e) Gate used to identify Oct4 positive CTCs 
Figure 4.24 Graphs to show the fluorescence of iPS cells with a) no staining, b) staining with 
the isotype control, c) staining with the Oct4 antibody, d) combined data and e) the final 
gate used for the assay. This final gate was drawn to include any cells expressing higher 












        
 c) iPS cells with SOX2 (FITC) 
     
     
             
d) Fluorescence on iPS cells only 
(black), cells with isotype control (red) 
and cells with SOX2 (FITC) (blue). 
 
 
e) Gate used to identify SOX2 positive CTCs 
Figure 4.25 Graphs to show the fluorescence of iPS cells with a) no staining, b) staining with 
the isotype control, c) staining with the SOX2 antibody, d) combined data and e) the final 
gate used for the assay. This final gate was drawn to include any cells expressing higher 











c) iPS cells with Nanog (PerCP Cy5.5) d) Fluorescence on iPS unstained cells 
(black), cells with isotype control (red) 





e) Gate used to identify Nanog positive CTCs 
Figure 4.26 Graphs to show the fluorescence of iPS cells with a) no staining, b) staining with 
the isotype control, c) staining with the Nanog antibody, d) combined data and e) the final 
gate used for the assay. This final gate was drawn to include any cells expressing higher 
fluorescence than the isotype control. 
 
4.5.3 Healthy Volunteer controls 
Blood from five male healthy volunteers was processed as part of this assay. Because the 
volunteers were from the lab staff, age-matched controls were not possible. The possibility 
of obtaining blood from age-matched patients with no history of prostate cancer, or any 
other cancer (e.g. from a non-oncology clinic) was explored, but the original ethical approval 
did not allow this. 
In order to exclude potential white blood cells expressing Oct4, SOX2 and Nanog, additional 
gates were used to identify whole cells and the CD45/CD16 negative population first, and 




Figure 4.27 A graph to demonstrate the gating of whole CD45-/CD16- cells, which should 
contain predominantly non-white blood cells. A gate was drawn round the population that 
was negative for both antigens and this was the gate used to capture putative CTCs. 
 
Further thresholds for Oct4, SOX2 and Nanog based on expression in the healthy volunteer 
bloods were not applied as without imaging or further cell characterization it was not 
possible to accurately determine which cells were definitely white blood cells. Expression of 
all antigens but particularly Oct4, SOX2 and Nanog in these healthy volunteer samples was 
noted and will be discussed in Chapter 5. 
 
4.6 Downstream analysis 
 
4.6.1 Immunofluorescence 
Unlike with the Imagestream where any population of interest could be visualised, the 
validity of the sorted population needed to be tested to ensure that the cells within this 
population are indeed what they are supposed to be. One method of doing this would be to 
sort directly onto a microscope slide and use standard immunofluorescence to visualise the 
cells. This would require a microscope with the same lasers as the FACS machine, because 




In order to test this concept, 100 000 of each of LNCaP, PC3 and MCF-7 cells were spiked into 
2mls of healthy volunteer blood. The cells were processed using the assay described in 
section 4.4 but because the microscope available did not have the same laser configuration, 
iPS cells were not included and the antibodies used were EpCAM, Cytokeratin, Vimentin, 
MT1-MMP, CD45 and DAPI.  Cells were sorted based first on size (using forward and side 
scatter to remove doublets and debris) and then by the population that was negative for 
both CD45 and CD16. For technical reasons, cells were not sorted directly onto microscope 
slides and instead were collected into three different Eppendorfs: i) EpCAM+ only, ii) 
EpCAM+/CK+ and iii) Vimentin+/MT1-MMP+. This was based on the presumption that cells 
in i) were LNCaPs, cells in ii) MCF-7s and cells in iii) PC3s. The cells were then mounted on 
microscope slides using DAPI mounting media. Due to the potential of fluorescence 
degradation, the cell sort was performed in the dark, as was the mounting of cells onto the 
slides. Cells were imaged in the Bioimaging facility at Newcastle University using the Nikon 
AR1 confocal microscope with the following lasers: 405nm, 488nm, 561nm, 647nm (Figure 
4.28). 
    
a) EpCAM+/DAPI+      b) CK+/DAPI+         c) Vimentin+/DAPI+ 
Figure 4.28 Immunofluorescence images to demonstrate three cells sorted on the BD FACS 
Fusion based on negative expression of CD45/CD16. These cells were cell lines spiked in 
healthy volunteer blood and stained with EPCAM, Cytokeratin, Vimentin, MT1-MMP. CD45 
and DAPI. Cell a) was positive for EpCAM, cell b) was positive for Cytokeratin and the cells in 
c) were positive for Vimentin. 
 
As Figure 4.28 demonstrates, it was possible to detect some of the sorted cells. However, 
the cells were very sparse and this was despite spiking with 100 000 of each cell of the three 
cell lines, with the potential of 300 000 cells to sort. In a clinical sample, the expected CTC 
population would be much lower, so the feasibility of this option is limited. It was time-
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consuming to set up each slide with the lasers, and during the setting-up there was the risk 
of bleaching the samples. Though the process was repeated three times it was only possible 
to image one set of slides because of these time constraints, and because the experiment 
yielded a poor number. The decision was made not to repeat this experiment as it was felt 
unlikely to be possible to replicate it using clinical samples. Cells expressing MT1-MMP were 
also not imaged due to the laser overlap with the cells expressing Cytokeratin. Reassuringly, 
there were no white cells detected, which for this one experiment demonstrated a pure sort. 
However, if considering this method as an option, the purity of the sort would need to be 
investigated in more detail. 
4.6.2 DNA extraction for PCR and sequencing 
Because imaging the sorted cells proved difficult, the decision was made to sort the cells and 
use a DNA amplification kit to get enough DNA from the small sorted cell population. This 
would enable a PCR to be performed to look for prostate specific mutations, or to send the 
cells directly for sequencing. The anticipated sorted cell population in the clinical assay 
would have fewer than 1000 cells, so the REPLI-g Mini kit (Qiagen) was chosen for this 
purpose. Due to time constraints this assay was not tested prior to the collection of clinical 
samples. The clinical samples were sorted and frozen at -80C for analysis following the 
collection of all samples. 
Approximately halfway through the collection of clinical samples, it became apparent that 
using this (or similar products) on fixed cells would give a falsely elevated reading of DNA. To 
test this theory, 1000 cells from three different cell lines underwent DNA extraction and 
amplification using this kit. Each cell line had two arms; fixed and unfixed. DNA levels were 
then measured for both using the Qubit (Thermofisher Scientific). The results are displayed 




Figure 4.29 A graph to demonstrate DNA yield from 3 different cells lines using either fixed 
or unfixed cells. 1000 cells from three different cell lines underwent DNA extraction and 
amplification, before DNA levels were measured on the Qubit. This was to determine 
whether fixation gave a false estimation of DNA quantity. 
 
In all three cell lines, higher values of DNA were obtained in the fixed samples compared to 
the unfixed samples. Because the fixative used was paraformaldehyde (similar to the fixative 
in the FixLyse buffer used in the final assay) this causes protein crosslinking, which would 
need to be reversed in order to obtain accurate results. This can be possible e.g. when 
looking at tissue sections, but the temperatures required to do this are very high and tissue 
sections will contain a much greater number of cells. The high temperatures risk damaging 
the cells, and when faced with a very low number to start with the risk of cell loss is very 
high. Fixation using coagulants such as methanol or ethanol would not cause this problem, 
but because over half of the clinical samples had been collected and processed by this stage 
it was felt that such a significant change to the assay could alter retrieval rates and therefore 
results.  
Cells from the clinical samples were therefore sorted using the assay as described in section 
1.4 but no post-sort analysis has been performed. Data obtained from this experiment must 
therefore be validated by comparing the results from clinical samples with the results from 
healthy volunteer controls. The sorted cells have been kept for all patients and controls and 









































































4.7 Results by patient characteristic 
The following tables (Tables 4.3-4.9) show a summary of the number of cells detected by the 
assay described in this chapter, according to patient characteristics. Each cell expressing the 
different antigens expressed is recorded for each patient. Combinations of antigens were 
not recorded as without visual inspection of the cells, as in the Imagestream assay, it was 














Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 48 Healthy 
Volunteer 
N/A 2 11 1 7 10 21 838 890 
2 41 Healthy 
Volunteer 
N/A 0 9 8 6 9 15 1082 1129 
3 43 Healthy 
Volunteer 
N/A 0 6 6 0 3 1 943 959 
4 52 Healthy 
Volunteer 
N/A 2 8 7 3 4 21 900 945 
5 38 Healthy 
Volunteer 
N/A 1 2 0 3 3 7 423 439 
Table 4.3 A table to show the number of cells expressing each antigen that were found in the blood 
from each healthy volunteer. 
Patient 
No 
Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 




9.9 1 0 0 16 159 5 18 199 




9.5 8 0 1 4 225 2 0 240 




5.6 1 25 25 0 13 4 399 1047 




7.9 1 30 30 2 6 452 1434 1925 




7.2 1 64 64 89 17 11 112 318 




4.4 0 17 17 122 22 29 203 393 
Table 4.4 A table to show the number of cells expressing each antigen that were found in the blood 






Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 68 AS 5.3 3 191 47 5320 152 13 7 5732 
2 72 AS 6.1 5 0 1 5888 153 53 3 6103 
3 76 WW 27.1 0 31 25 0 21 132 170 379 
4 84 WW 18.1 0 30 0 2 61 42 790 925 
5 87 WW 86.0 4 0 3 321 15 130 745 1218 
6 76 AS 37.4 2 0 16 0 329 0 813 347 
Table 4.5 A table to show the number of cells expressing each antigen that were found in the blood 




Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 77 New Diag 5.2 1 0 8 25 157 12 0 203 
2 68 New Diag 33.5 0 0 0 24 174 3 1 202 
3 65 New Diag 18.3 29 0 19 2 117 54 269 490 
4 74 New Diag 140.0 0 2 2 45 0 73 3213 3335 
5 68 New Diag 308.0 1 4 4 42 13 33 4085 4182 
6 62 New Diag 22.0 1 117 8 1687 3 1 396 2213 
7 68 New Diag 47.0 3 51 7 82 1 0 365 509 
8 69 New Diag 3.2 2 244 0 254 53 7 1641 2201 
Table 4.6 A table to show the number of cells expressing each antigen that were found in the blood 














Pt Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 69 Single agent 31.4 2 16 1 27 36 0 8 90 
2 82 Single agent 1.8 0 11 13 46 166 43 2 281 
3 71 Single agent 2.9 0 0 0 6 118 6 0 130 
4 92 Single agent 0.2 0 0 3 17 158 15 6 199 
5 91 Single agent 0.2 0 30 3 0 8 22 122 185 
6 82 Single agent 50.9 0 97 2 1 13 302 921 1336 
7 87 Single agent 4.5 8 12 3 251 62 8 179 523 
8 66 Single agent 0.1 2 4 0 87 9 12 74 188 
9 71 Single agent 2020 5 8 14 11 0 6 450 494 
10 77 Single agent 0.1 17 11 2 4 58 1 7 100 
11 59 Single agent 4.5 22 15 4 2 21 195 864 1123 
12 63 Single agent 81.9 199 1515 2 9 7 0 8245 9977 
13 67 Single agent 3.0 2 28 1813 904 1 14 116 2878 
Table 4.7 A table to show the number of cells expressing each antigen that were found in the blood 






Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 86 MAB 245.6 88 2 1 151 118 8 44 412 
2 84 MAB 61.4 11 0 1 777 16 16 0 821 
3 79 MAB 1.5 0 3 26 152 160 26 0 367 
4 87 MAB 3.1 0 616 13 389 160 25 12 1215 
5 82 MAB 24.0 1 1 6 36 119 5 1 169 
6 77 MAB 101.0 1 0 0 19 123 8 1 152 
7 78 MAB 1.5 0 7 5 21 117 6 0 156 
8 69 MAB 1.8 0 0 2 19 434 3 24 482 
9 86 MAB 12.6 15 0 4 9 172 23 1 224 
10 83 MAB 0.1 1 0 0 3 90 1 1 96 
11 83 MAB 23.4 0 13 1 2 10 22 164 212 
12 74 MAB 2.0 16 1 5 982 0 0 80 1084 
13 96 MAB 34.6 18 10 2 3 44 180 475 732 
14 80 MAB 1.7 7 10 9 1 29 20 54 130 
15 73 MAB 5.5 12 1 4 4 30 63 245 359 
16 65 MAB 30.6 0 6 1 44 3 21 588 663 
Table 4.8 A table to show the number of cells expressing each antigen that were found in the blood 






Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 77 Enzalutamide 1875 8 417 13 94 62 5 2243 2842 
2 68 Docetaxel 0.8 0 0 0 353 164 1 56 574 
3 85 Dexamethasone 55.0 2 18 6 360 116 42 1 545 
4 69 Enzalutamide 380 109 10 6 13 1 162 532 833 
5 77 Dexamethasone 18.0 17 2 5 4 492 307 639 1466 
6 61 Abiraterone 51.2 0 2 4 83 3 36 1247 1375 
7 60 Enzalutamide 0.7 0 2 3 52 231 0 3001 3289 
8 74 Dexamethasone 0.7 0 2 2 368 18 8 1352 1750 
9 73 Dexamethasone 23.0 858 1176 25 19 4 58 9339 11479 
10 77 Docetaxel  433 555 697 1 3 1 114 3583 4954 
11 58 Enzalutamide 12.4 0 83 14 490 7 178 547 1319 
12 87 Cabazitaxel 5.6 1 44 6 224 8 0 384 667 
13 70 Dexamethasone 228 3 126 10 483 18 0 1059 1699 
14 82 Enzalutamide 72.4 10 211 24 610 5 1 1336 2197 
15 74 Abiraterone 16.3 0 122 5 22 13 21 3763 3946 
16 74 Docetaxel 8.0 0 331 7 18 7 16 4751 5130 
17 72 Enzalutamide 586 9 326 13 22 7 6 4482 4865 
18 69 Radium 223 202 43 395 0 10 0 21 1528 1997 
19 80 Enzalutamide 2.2 2 6382 1 15 3 4 3326 9733 
20 74 Enzalutamide 1.3 5 207 2 6 4 2 3597 3823 
21 76 Dexamethasone 0.8 1 0 0 1 0 0 187 189 
22 51 Enzalutamide 434 5 721 0 5 0 15 6278 7024 
23 58 Docetaxel 100 3 138 3 134 1 14 2602 2895 
24 76 Enzalutamide 4611 5 6142 0 70 124 0 6697 13038 
25 77 Radium 223 29.2 2 131 0 159 62 2 2059 2415 
26 66 Enzalutamide 21.0 43 60 28 196 2 5 4593 4927 
27 72 Enzalutamide 532 3 231 8 303 2 14 774 1335 
28 81 Radium 223 96.1 4 28 5 187 0 156 1543 1923 
29 78 Dexamethasone 10.5 3 47 5 232 0 340 1381 2008 
Table 4.9 A table to show the number of cells expressing each antigen that were found in the 





Unfortunately, despite careful panel planning, there was too much overlap between DAPI 
and Oct4 (BV421). The decision was made to exclude DAPI from the panel and rely on 
forward and side scatter to identify whole cells rather than debris. Although this meant that 
the FDA criteria for a CTC could not be fulfilled using this assay, it was decided that re-
arranging the panel and undergoing further optimisation of antibodies conjugated to new 
fluorochromes would delay the collection of clinical samples and the ability to test the assay. 
Although this is a flaw of this assay, the identification of cell-sized, marker positive cells was 
felt to be sufficient. 
When using gates to include or exclude populations found on FACS these will rarely be 100% 
pure. There is always likely to be a slight overlap in fluorescence and this can be explained in 
part by cellular heterogeneity – some cells will only weakly express an antigen in comparison 
to others. The gate used to determine the negative white cell population in the optimisation 
experiment (Figure 4.1) could be made bigger and could include more cells as there is an 
overlap between that and the white cell population. This gate was manipulated many times 
in order to include as many potential CTCs as possible, without the need to study an 
unnecessarily large population. The experiment described in section 4.3.2 to determine the 
percentage of white cells not detected by each antibody demonstrated that only 3.1% of 
white cells were not detected by the CD45 antibody, and 12.4% by the CD16 antibody. The 
experiment looking at the number not detected by either was not performed, but by looking 
at Figure 4.1 there are cells that are positive for each antibody but not for both, so a 
proportion of the 3.1% not detected by CD45 will have been excluded by being positive for 
CD16. It will never be possible to get 100% purity; using additional white cell markers would 
help but would be at the expense of one of the markers of interest, but even then, there 
would never be 100% antigen binding. It is hoped that the use of these two white cell 
markers will identify a practical proportion of white cells, to eliminate them from the 
potential CTC population. 
The optimisation experiments for the epithelial, mesenchymal and stem cell markers all used 
100 000 cells. This number was chosen so that a reliable number of cells would be stained, 
but a number far greater than the potential number of CTCs in the samples would be used. 
This would ensure that any antibody quantity would be more than enough to bind with 
antigens expressed by CTCs.  
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As discussed, the overlap between the iPS cells stained with the isotype and those stained 
with the antibody could be due to the iPS cells losing their stem-cell properties as they start 
to differentiate, despite lowest passage cells being used at all times. However, on a few of 
the other antibodies (Vimentin, Cytokeratin) there was overlap of the isotype and antibody 
stained cells, particularly at higher concentrations. This could be because the isotype 
becomes stickier when more is used. 
The gates used in section 4.5 are again not 100% discriminatory and when compared to the 
isotype stained cells in optimisation, most do include very small proportions of the isotype 
stained cells. This could mean false positives in the final assay. Despite meticulous 
optimisation and choosing antibody concentrations that stain the maximum number of cells 
without providing excess that could bind inappropriately, this is inevitable. In all cases except 
that of Vimentin, less than 1% of the isotype-stained cells could be found in the gate used to 
identify the antibody stained population, and 1.55% of the Vimentin isotype-stained cells 
were in this gate. It is hoped that this leaves an acceptable degree of uncertainty.  
A major flaw of this assay was the inability to test its validity using downstream analysis and 
was in part due to trying to process samples for both this and the Imagestream assay 
simultaneously. Because on average four or five blood samples were collected at each clinic, 
processing time was high, and using the same fix/lyse process meant simultaneous 
processing could occur more quickly. Fixing the cells was important due to the length of the 
protocol. It would not have been possible to perform red cell lysis, white cell depletion, 
incubate with the antibodies and run the samples on the FACS sorter on the same day as 
collection, due to the clinic timings and time taken to obtain the samples. Fewer samples 
could have been obtained but the impact of any observational study would be reduced by a 
lower sample number. This however has to be balanced against the need for reliable data – 
there is little point having a large study if the data is meaningless.  
The concern about using FACS is the purity and sensitivity of detecting small cell populations, 
such as CTCs. As the Imagestream has demonstrated, even when using size-based criteria to 
eliminate debris, some cell shaped events (possibly dead cells or larger debris) can bind to 
antibodies inappropriately and until they are further scrutinised (e.g. by imaging) they would 
appear as a false positive. In the assay described in this chapter the inability to use DAPI, and 
therefore identify whole cells, in addition to the inability to perform downstream analysis 
has further added to this concern. But when reviewing the literature, multiple studies do use 
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flow cytometry for the detection of CTCs and report detection rates as sensitive as 3 cells in 
2mls of blood (Lu et al., 2015)  or 1 in a million cells (Carpenter et al., 2014, Gorner et al., 
2015). In this assay the use of two white cell markers in addition to the prior immuno-
magnetic depleting of white cells are both important ways of identifying a purer population, 
and using male controls to compare results against is also a strength. In addition to this, 
because the FACS assay is being run in parallel to the Imagestream assay, data obtained 
from both can be compared up to a point. Although the FACS assay uses additional markers, 
the stem cell markers are explored in both, and so any marked differences in detection 
would potentially be a sign of the FACS assay being inaccurate. 
Creating a new assay involves many processes, and the development of this one was more 
challenging than first anticipated, in part due to the number of markers that were being 
investigated. The benefit of using FACS for CTC detection is the fact that most clinicians 
considering such an assay for a clinical trial would have access to a platform, which would 
increase the uptake of any trial participation. Whilst FACS sorting is relatively expensive, 
straight-forward FACS processing is inexpensive, and these are both important factors to 
consider when thinking about a new assay for clinical use. Rigorous optimisation was 
adopted during the development and whilst downstream analysis was not performed to test 
the validity, it is hoped that the process was scrupulous enough that the data obtained, as 





Chapter 5. The clinical significance of CTCs detected by 
Imagestream and FACS 
Chapter Summary 
This chapter contains the results of the patient blood samples that were processed using 
both the Imagestream and FACS assays, described in Chapters 3 and 4 respectively. Patients 
have been grouped according to the treatment they were on at the time of blood sampling, 
and clinical data for PSA and ALP was recorded. Statistical analysis has been performed to 
determine whether significant differences in CTC count and antigen expression are 
demonstrated and whether there was any correlation shown between CTC count and the 
clinical parameters. Any cell described as a CTC in this chapter is a putative CTC as expression 
of Vimentin, MT1-MMP, Oct4, SOX2 and Nanog is not included in the FDA definition of a 
CTC. 
 
5.1 Clinical Data 
 
5.1.1 Demographics of patients 
Blood was obtained from 88 male patients at the Freeman Hospital, Newcastle upon Tyne 
between August 2017 and April 2018.  Six samples were lost when the Imagestream crashed 
during processing and there were problems with two different samples during FACS 
processing. For two further patients it was not possible to obtain any clinical data. In total 
therefore there are 78 patients who had blood processed on both platforms with matched 
clinical data. Age range was from 58-96 with a median age of 75 and a mean of 74. Men with 
different stages of prostate cancer were subjects for this study, ranging from those referred 
with a suspicion of prostate cancer but who subsequently were found to have benign 
prostate conditions, to those with castrate resistant disease (Figure 5.1). The latter was 
defined by the need for a second line agent following a rising PSA, or increase in radiological 
burden of disease despite maximum androgen blockade. Because not all patients had up-to-
date imaging at the time of blood sampling and there were often no pathology results, 




The original aim of the study was to identify a biomarker to predict who would respond to 
androgen deprivation therapy and who would benefit from initial treatment with what are 
known as second line agents (e.g. abiraterone or enzalutamide). Because of this, ideally 
patients with a new diagnosis of metastatic disease before the commencement of any 
treatment would be chosen. However, patients were chosen with different stages of 
diseases so that CTCs would be more likely to be detected. Not all patients with early 
metastatic disease would have high levels of CTCs in their blood, which would make 
commenting on the significance of the presence or absence of specific markers in their blood 
difficult. At this stage of the study, patients with a high metastatic burden were chosen in 
addition to those with early metastatic disease, so that a comparison could be made. If the 
findings were found to be significant then further studies recruiting larger numbers of 
untreated patients with metastatic disease could be performed. 
The patients with benign prostatic disease were included as an age-matched control 
comparison.  
Although patients on active surveillance are deemed curative and those on watchful waiting 
are considered palliative, they were classified together for the purpose of this study as the 
patients are not on treatment. The decision for patients to decline treatment is made on an 
individual basis with the aim of reducing treatment associated toxicity (Heidenreich A., 
2013). Those on active surveillance have a defined investigation schedule (including biopsy, 
imaging and PSA testing) whereas those on watchful waiting will have an individualised 
schedule based on symptoms. Treatment for patients in either group can be started once 
progression is identified. In theory the patients in both of these groups should have stable 
disease and the assumption has been made that any CTCs present should not express 
markers associated with aggressive disease. In terms of overall CTC count, those on watchful 
waiting could have metastatic disease and therefore could have a higher CTC count, but 
because numbers of patients sampled in each category were small, they were classified 
together. 
It is not possible to say until several months after their blood was taken whether their 
disease was static at the time of the sampling for this study, as subsequent PSA results may 
indicate disease progression. Presence of CTCs and certain markers expressed by those CTCs 
may be more sensitive than PSA rises. This will be explored in more detail when comparing 
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the interval PSAs of patients in each treatment group, but in comparison to the patients with 
end-stage disease, it would be expected that patients on active surveillance and watchful 
waiting would have both a lower CTC number and a lower number of markers associated 
with aggressive disease. Figure 5.1 outlines the number of patients at each stage of disease. 
Seven patients who had a new diagnosis of metastatic disease but who were completely 
treatment naïve were included in this study. Six of these had radiological evidence of 
metastatic spread to either lymph nodes or bones, and the seventh was treated as a 
presumed metastatic diagnosis due to his PSA and the clinical examination of his prostate, 
despite no confirmed radiological evidence of spread. 
Those patients on androgen deprivation therapy could be further divided into those on 
single hormonal agents, or those on maximum androgen blockade, as demonstrated in 
Figure 5.2. The latter consists of the addition of an anti-androgen following previous medical 
or surgical castration. Those on maximum androgen blockade could have well controlled, 
static disease. But again, subsequent clinical follow-up would identify those who had disease 
that quickly progressed after the time of sampling, and this will be demonstrated in more 
detail later in this chapter. One of the patients on maximum androgen blockade and four of 
the patients on single hormonal therapy had received up-front chemotherapy at the time of 
starting hormonal therapy, due to recent changes in the guidelines (Heidenreich A., 2013). 
Patients classified for the purpose of this study as having castrate resistant disease were all 
on a second line agent (e.g. dexamethasone, enzalutamide, abiraterone). Because clinical 
trials such as STAMPEDE (2019) have changed the order of treatment in recent years, further 





Figure 5.1 A graph to demonstrate the breakdown of patients used in this study by stage of 
disease. The majority have metastatic disease, either newly diagnosed, on hormone 
suppression, or are on second line therapy for castrate resistant disease. 
 
 
Figure 5.2 A graph to demonstrate the type of hormone therapy patients were on. Thirteen 
patients were on single hormone agents compared to sixteen patients who were on 





































































































5.1.2 Healthy volunteer controls 
Five male healthy volunteers from the NICR donated blood to process on the Imagestream 
and FACS. There is no matched clinical data for these volunteers as ethical approval for this 
was not obtained, but the CTC results can be compared with the patient samples as none of 
the patients were known to have any existing malignancies. It was felt necessary to have 
some controls with no known prostate disease, as although prostate cancer has not been 
diagnosed in the benign patient cohort, there may be small foci of cancer that have not been 
detected by the existing methods. 
5.1.3 Clinical blood results 
For the purpose of this study, the ‘time of sampling’ is used to describe the time that blood 
was sampled from the patient for the Imagestream and FACS assays. Ethical approval had 
been obtained prior to starting the project and did not permit serial sampling for lab work, 
or any additional clinical blood tests that were not required for clinical purposes. Bloods 
obtained for routine clinical use could however be used so data was collected from patients 
at both the time of obtaining blood for the assays described in Chapters 3 and 4, and six 
months later. 
All patients attending prostate cancer clinics in the UK currently undergo interval PSA 
testing. As previously discussed, despite its flaws, this is the most reliable biomarker 
currently available and monitoring the PSA of an individual can usually indicate the response 
to different treatments. Actual PSA value is not usually helpful but a trend for an individual 
patient is more indicative of disease progression. 
PSA alone is not sufficiently reliable for disease monitoring, especially in castrate resistant 
disease (Payne and Cornford, 2011) due to evidence of metastatic disease spread despite a 
stable PSA (Pezaro et al., 2014). For this reason, regular imaging (CT and/or bone scan) and 
repeat blood tests including a Full Blood Count, ALP and Liver profile are recommended even 
if the patient has no symptoms. Frequency of these investigations will vary between units, 
but evidence suggests this should be every 6 months for metastatic disease (Gillessen et al., 
2016).  
Alkaline Phosphatase (ALP) monitoring can be useful because abnormal bone tissue 
formation, which can occur when bone metastases are present, can lead to elevated ALP 
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production. This membrane-bound glycoprotein is predominantly produced in the liver but 
can also be produced by other organs such as bone, pancreas and kidney (Sharma et al., 
2014). An increase in ALP might therefore indicate to the clinician that bone metastases are 
forming, or increasing in burden, and may warrant earlier radiological imaging and a possible 
change of treatment. A normal ALP will vary between labs but at the Freeman Hospital the 
normal value is 30-130 IU/l.  
Because the patients have all had a variety of follow-up tests and scans, and data was 
collected at a relatively early time-point for follow-up, the decision was made to note PSA 
and ALP for each patient at the time of sampling and after a six-month interval as these 
provided the most complete data sets. Although this is only a crude measure, it would be 
expected that patients with benign disease would have a lower PSA and ALP than those with 
castrate resistant disease. In addition, those with treatment-controlled disease (e.g. those 
on hormones) would be expected to have a lower PSA and ALP than those with newly 
diagnosed metastatic disease, or those on treatment who are becoming resistant. These 
results can then be compared to CTC count and antigens expressed in the next sections, as a 
method of correlating the CTC results with disease severity. Figure 5.3 shows the number of 






a) PSA            b) ALP 
Figure 5.3 Graphs to show a) PSA level and b) ALP level at the time of blood sampling for all 
patients at each stage of the disease (the bar denotes the median). Those with metastatic 
disease have a higher median level of PSA and ALP. 
 
Disease Stage Median PSA at 
sampling  
Mean PSA at 
sampling (+SD) 
Range 
Benign 7.2 7.1 (2.2) 4.4-10.0 
Surveillance 21.1 28.7 (27.7) 5.3-86.0 
New diagnosis 
metastatic 
33.5 81.7 (109.5) 3.2-308.0 
Hormones – 
single agent 
3.8 162.5 (535.4) 0.02-2020.0 
Hormones – MAB 9.1 34.3 (62.3) 0.02-245.6 
Castrate resistant 29.2 338.2 (901.1) 0.7-4611 
Table 5.1 A Table to show the Median and Mean PSA for patients in each disease stage 
























































































































































Disease Stage Median ALP at 
sampling 
Mean ALP at sampling 
(+SD) 
Range 
Benign 62.5 63.3 (4.2) 59-69 
Surveillance 73.0 81.4 (36.6) 49-144 
New diagnosis 
metastatic 
73.5 147.2 (193.8) 37-541 
Hormones – 
single agent 
81.5 91.2 (39.1) 55-188 
Hormones – 
MAB 
84 123.2 (100.1) 48-410 
Castrate 
resistant 
95 180.5 (215.8) 50-835 
Table 5.2 A Table to show the median and mean ALP for patients in each disease stage 
category at the time of sampling. The median for patients in all categories was within the 
normal range. 
 
As expected, the graphs in Figure 5.3, and the data in Tables 5.1 and 5.2 depict the 
generalized pattern that both PSA and ALP are higher as disease is more advanced. From the 
standard deviation it is clear that there is a greater variation in PSA results in those patients 
with newly diagnosed metastatic disease, single-agent hormones and castrate-resistant 
disease compared to those with benign disease, undergoing surveillance and on maximum 
androgen blockade.  
In order to demonstrate this more closely, PSA and ALP at both sampling time and six-month 
interval were plotted for each group (Figures 5.4 – 5.8). These data were limited by the fact 
that not all patients had PSA measured at six months (e.g. those in the benign and 
surveillance groups – due to clinical need this may be monitored at 9 or 12 months) and ALP 
was not measured for every patient (e.g. no patient in the benign group had ALP measured 


































a) PSA     b) ALP 
Figure 5.4 Graphs to show a) PSA and b) ALP at the time of sampling and at a six-month 
interval for patients with benign disease (the bar denotes the median) N.B. No six-month 
ALPs were recorded for these patients. Each coloured dot represents one patient so the 
corresponding value at 6 months can be seen. A black coloured dot at baseline means there 
was no 6-month sample recorded. The median PSA did increase only two patients had PSAs 
taken at six months and both had negative prostate biopsies. 
 
Only two patients in this group had PSA taken at six months, and none had ALP measured. 
The ALP for all patients was within the normal range at the time of sampling. A modest rise 
in PSA was seen for the two patients with serial PSA samples but biopsies of both of these 
patients were negative, so it can be assumed that all patients within this category had 
benign disease. 
It was not possible to perform statistical evaluation on the PSA or ALP progression due to 



















































































a) PSA     b) ALP 
Figure 5.5 Graphs to show a) PSA and b) ALP at the time of sampling and after six months for 
patients on surveillance (the bar denotes the median). Each coloured dot represents one 
patient so the corresponding value at 6 months can be seen. A black coloured dot at baseline 
means there was no 6-month sample recorded and vice versa. There was no significant PSA 
increase at six months (p=0.32). As only one patient had an ALP taken at sampling time no 
comparison could be made. 
 
All patients within the Surveillance group had ALPs within the normal range. The median 
PSAs at sampling time and at six months are very similar (Figure 5.5).  
The Wilcoxon matched pairs signed rank test was used to identify whether any significant 
change in PSA occurred over 6 months. This showed a p-value of 0.32 which demonstrates 
no significant change. It was not possible to do this for the ALP due to only having one value 













































































a) PSA     b) ALP 
Figure 5.6 Graphs to show a) PSA and b) ALP at the time of sampling and after a six-month 
interval for patients with newly diagnosed metastatic disease (the bar denotes the median). 
Each coloured dot represents one patient so the corresponding value at 6 months can be 
seen. A black coloured dot at baseline means there was no 6-month sample recorded. All 
patients showed a PSA response to treatment but this was not found to be significant 
(p=0.06). ALP increased marginally at 6 months but this was also not significant (p=0.81). 
 
The patients within the Newly Diagnosed Metastatic Disease group are of particular interest 
because they presented with metastatic disease and at the time of sampling were treatment 
naïve. Interestingly the patient with the lowest PSA had the highest ALP and had a significant 
bony burden of metastatic disease. All patients showed a PSA response to treatment (i.e. 
PSA decreased at 6 months) but the median ALP increased by 11.0IU/l (Figure 5.6). This was 
not found to be a statistically significant increase when the Wilcoxon matched pairs signed 
rank test was used (p = 0.81). The same test was used to determine a significant difference 
in PSA change which was also not found to be significant (p = 0.06) despite a median 










































































a) PSA     b) ALP 
Figure 5.7 Graphs to show a) PSA and b) ALP at the time of sampling and after six months for 
patients on single hormonal agents (the bar denotes the median). Each coloured dot 
represents one patient so the corresponding value at 6 months can be seen. A black 
coloured dot at baseline means there was no 6-month sample recorded. The median PSA 
and ALP changes were not significant (p=0.57 and p=0.31 respectively). 
 
The median PSA for patients in the Single Hormonal Agent group decreased by 0.04ng/ml 
but this was not found to be significant (Wilcoxon matched pairs signed rank test p = 0.57). 
Median ALP rose by 8.5IU/l but this was also not significant (p = 0.31) (Figure 5.7). 
One patient was a particular outlier whose PSA and ALP rose dramatically during the six- 
month period. Despite then being started on a second line agent at six months, he died 
shortly afterwards. There was also one death in this group during the six months, but from a 












































































a) PSA     b) ALP 
Figure 5.8 Graphs to show a) PSA and b) ALP at the time of sampling and after six months for 
patients on maximum androgen blockade (the bar denotes the median). Each coloured dot 
represents one patient so the corresponding value at 6 months can be seen. A black 
coloured dot at baseline means there was no 6-month sample recorded. Both median PSA 
and ALP decreased but this was not significant (p=0.08 and 0.75 respectively). 
 
The data for the Maximum Androgen Blockade group was slightly skewed as two of the 
patients with higher PSA and ALP results at sampling time had died from the disease by the 
six-month point, and therefore no blood results were available. They account for the two 
highest ALP results at sampling (Figure 5.8). Of the surviving fourteen patients, four had a 
PSA that almost doubled during the six months, indicating that their disease could now be 
castrate resistant.  
Median PSA decreased by 2.11ng/ml which was not found to be significant (p = 0.08) and 
















































































a) PSA     b) ALP 
Figure 5.9 Graphs to show a) PSA and b) ALP at the time of sampling and after six months for 
patients with castrate resistant disease (the bar denotes the median). Each coloured dot 
represents one patient so the corresponding value at 6 months can be seen. A black 
coloured dot at baseline means there was no 6-month sample recorded. Median PSA 
decreased but this was not significant (p=0.36) and median ALP rose was also not significant 
(p=0.98). 
 
PSA level in the Castrate Resistant Disease group was both on average higher and with a 
greater range, indicating that some of the patients in this group had end stage disease (no 
further treatment options). The two patients with the highest PSA results at time of sampling 
had died by the six-month point, and a further death occurred within this group, all from 
prostate cancer related causes.  
Median PSA decreased by 0.43ng/ml which was not significant (p = 0.36) and median ALP 
increased by 3IU/l which was also not significant (p = 0.98) (Figure 5.9). 
None of the different groups showed a significant increase or decrease in PSA or ALP during 
the six-month period, as demonstrated in Table 5.3. This could be due to low numbers in 




Disease stage p-value for 
change in 
PSA over 6 
months 
Median of 
difference in PSA 
(range) 
p-value for 
change in ALP 
over 6 months 
Median of 
difference in ALP 
over 6 months 
(range) 
Benign - - - - 





0.06 -14.28 (-297.2 – 
+2.4) 
0.81 +11.0 (-470.0 – 
+24.0) 
Hormones – single 
agent 
0.57 -0.04 _-245.6 - 
+113.7) 
0.31 +8.5 (-336.0 - 
+52.0) 
Hormones – MAB 0.08 -2.11 (-2007.1 - 
+9619.1) 




0.36 -0.43 (-431.6 - 
+1174.8) 
0.98 -3.0 (-726- +496) 
Table 5.3 A table to demonstrate the median change in PSA and ALP values for the different 
treatment groups and their significance (using the Wilcoxon matched pairs signed rank test). 





5.1.4 Number of deaths 
 
Figure 5.10 Number of prostate cancer-related deaths. There were six deaths in total and all 
deaths were in patients with advanced disease. 
 
During the first six months after sampling, six patients died from prostate cancer-related 
causes, and one further patient from a non-associated cause (Figure 5.10). These patients all 
had metastatic disease at the time of their death, so their CTC antigen expression was 
analysed with both the FACS and Imagestream techniques. 
 
5.2 Results of Imagestream detected CTCs 
 
5.2.1 Definition of CTC data recorded 
The total number of CTCs for each patient was recorded, in addition to the different 
combinations of antigens expressed by each CTC. For the purpose of this study a CTC was 
counted as a CD45 negative cell that expressed one or more of the following markers: 
EpCAM, Oct4, SOX2 and/or Nanog. The fluorescence thresholds described in Chapter 3 for 
Oct 4, SOX2 and Nanog were applied and only cells that expressed Oct4, SOX2 and Nanog 







































































5.2.2 Total CTC count 
The total numbers of CTCs detected using the Imagestream platform are displayed in the 
following graph (Figure 5.11), and the median and mean are displayed in Table 5.4. The 
newly diagnosed metastatic group had two patients with high CTC counts, and the patients 
on maximum androgen blockade and those who were castrate resistant showed higher 
counts than the other treatment groups. There was one outlier in the benign group who had 
50 CTCs (all Nanog positive). None of the healthy volunteers had any CTCs detected. 
 
 
Figure 5.11 A graph to show the total number of putative CTCs found from patients within 
each treatment group, using the Imagestream. The most CTCs were found in patients with 





















































































Disease stage (n=) Median CTC count Mean CTC count 
(+SD) 
Range 
Healthy volunteers (5) 0 0 0 
Benign (6) 3 12 (19.7) 0-50 
Surveillance (6) 2 3 (5.4) 0-14 
New diagnosis 
metastatic (8) 
16 64 (106.6) 2-305 
Hormones – single 
agent (13) 
2 7 (12.6) 0-45 
Hormones – MAB (16) 8 31 (49.6) 0-185 
Castrate resistant (29) 14 21 (23.5) 0-75 
Table 5.4 A table to demonstrate the median and mean (+SD) no of CTCs detected via the 
Imagestream for patients at each disease stage.  
 
Tables 5.5 – 5.11 list the total number of putative CTCs expressing each antigen detected on 








































   L  
1 48 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 41 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
3 43 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 52 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 
5 38 Healthy 
Volunteer 
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 




















































9.9 0 0 5 0 0 0 0 1 0 0 0 0 5 




9.5 0 1 7 0 0 2 0 1 5 0 0 0 16 




5.6 0 0 0 0 0 0 0 0 0 0 0 0 0 




7.9 0 0 0 0 0 0 0 0 0 0 0 0 0 




7.2 0 0 0 50 0 0 0 0 0 0 0 0 50 




4.4 0 0 0 0 0 0 0 0 0 0 0 0 0 









































1 68 AS 5.3 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 72 AS 6.1 0 0 0 14 0 0 0 0 0 0 0 0 14 
3 76 WW 27.1 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 84 WW 18.1 0 0 3 0 0 0 0 0 0 0 0 0 3 
5 87 WW 86.0 1 0 0 1 0 0 0 0 0 0 0 0 2 
6 76 AS 37.4 0 0 1 0 0 0 0 0 0 0 0 0 1 







































1 77 New Diag 5.2 0 0 0 303 0 0 0 1 1 1 0 0 306 
2 68 New Diag 33.5 0 0 2 4 0 3 0 0 0 0 0 0 9 
3 65 New Diag 18.3 0 0 1 8 0 0 0 0 0 1 0 0 10 
4 74 New Diag 140.0 0 0 2 8 0 0 0 1 0 0 0 0 11 
5 68 New Diag 308.0 0 1 0 6 0 1 0 12 1 0 0 0 21 
6 62 New Diag 22.0 0 0 7 0 0 0 0 0 13 0 0 0 20 
7 68 New Diag 47.0 0 0 1 0 0 1 0 0 0 0 0 0 2 
8 69 New Diag 3.2 0 12 0 2 0 6 0 50 64 2 0 0 136 
Table 5.8 A table to show the number of cells expressing each antigen for blood taken from patients with new diagnosis metastatic disease when 







































1 69 Single agent 31.4 0 0 1 0 0 0 0 0 1 0 0 0 2 
2 82 Single agent 1.8 0 0 0 0 0 0 0 0 0 0 0 0 0 
3 71 Single agent 2.9 0 4 4 1 0 0 0 0 2 0 0 0 11 
4 92 Single agent 0.2 0 0 1 0 0 0 0 1 0 1 0 0 3 
5 91 Single agent 0.2 0 0 0 0 0 0 0 0 0 0 0 0 0 
6 82 Single agent 50.9 0 0 0 0 0 0 0 0 0 0 0 0 0 
7 87 Single agent 4.5 0 0 0 0 0 0 0 0 0 0 0 0 0 
8 66 Single agent 0.1 0 0 6 0 0 0 0 0 0 0 0 0 6 
9 71 Single agent 2020 0 0 34 3 0 3 0 3 0 1 1 0 45 
10 77 Single agent 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0 
11 59 Single agent 4.5 0 0 11 1 0 0 0 0 0 0 0 0 0 
12 63 Single agent 81.9 0 3 2 1 0 2 0 0 0 0 0 0 8 
13 67 Single agent 3.0 0 11 0 3 0 0 0 1 3 0 0 0 18 
Table 5.9 A table to show the number of cells expressing each antigen for blood taken from patients on single agent hormones when processed using 













































1 86 MAB 245.6 84 2 0 2 0 1 0 0 1 0 0 0 90 
2 84 MAB 61.4 1 0 0 1 0 0 0 0 2 0 0 0 4 
3 79 MAB 1.5 0 0 0 0 0 0 0 0 0 0 0 0 0 
4 87 MAB 3.1 0 0 0 185 0 0 0 0 0 0 0 0 185 
5 82 MAB 24.0 0 2 5 0 0 0 0 0 1 0 0 0 8 
6 77 MAB 101.0 0 1 1 11 0 0 0 1 1 0 0 0 15 
7 78 MAB 1.5 0 0 0 0 0 0 0 0 0 2 0 0 2 
8 69 MAB 1.8 0 0 1 0 0 0 0 0 0 0 0 0 1 
9 86 MAB 12.6 0 0 2 0 0 0 0 0 0 0 0 0 2 
10 83 MAB 0.1 0 0 1 0 0 0 0 0 0 0 0 0 1 
11 83 MAB 23.4 0 1 0 2 0 0 0 0 0 0 0 0 3 
12 74 MAB 2.0 0 0 25 36 0 1 0 0 0 0 0 0 62 
13 96 MAB 34.6 0 2 57 0 1 0 0 0 0 2 0 0 62 
14 80 MAB 1.7 0 0 7 0 0 0 0 0 0 0 0 0 7 
15 73 MAB 5.5 0 0 40 1 0 0 0 0 0 0 0 0 41 
16 65 MAB 30.6 0 0 0 4 0 0 0 6 1 0 0 0 11 
Table 5.10 A table to show the number of cells expressing each antigen for blood taken from patients on maximum androgen blockade when 






Age Treatment PSA  EpCAM+ Oct4+ SOX2+ Nanog+ EpCAM 
/ 
0/S/N 




















1 77 Enzalutamide 1875 4 0 2 0 0 8 0 0 0 0 1 0 15 
2 68 Docetaxel 0.8 0 0 0 14 0 0 0 0 0 0 0 0 14 
3 85 Dexamethasone 55.0 0 8 9 22 0 0 0 0 0 0 0 0 39 
4 69 Enzalutamide 380 11 0 1 3 0 0 0 1 3 0 0 0 19 
5 77 Dexamethasone 18.0 0 0 3 12 0 0 0 3 0 0 0 0 18 
6 61 Abiraterone 51.2 0 0 0 3 0 0 0 1 0 0 0 0 4 
7 60 Enzalutamide 0.7 0 1 0 68 0 0 0 9 0 0 0 0 78 
8 74 Dexamethasone 0.7 0 0 0 6 0 5 0 3 0 0 0 0 14 
9 73 Dexamethasone 23.0 0 0 5 4 0 0 0 3 0 0 1 0 13 
10 77 Docetaxel  433 0 2 66 5 0 0 0 0 0 0 0 0 73 
11 58 Enzalutamide 12.4 2 5 0 1 0 3 1 4 2 0 0 0 18 
12 87 Cabazitaxel 5.6 20 2 3 0 0 2 0 0 1 0 0 0 28 
13 70 Dexamethasone 228 0 0 3 12 0 0 0 3 0 0 0 0 18 
14 82 Enzalutamide 72.4 0 1 0 0 0 0 0 0 1 0 0 0 2 
15 74 Abiraterone 16.3 0 1 0 2 0 0 0 0 1 0 0 0 4 
16 74 Docetaxel 8.0 0 0 49 0 0 22 0 0 4 0 0 0 75 
17 72 Enzalutamide 586 20 1 0 0 0 1 0 1 0 0 0 0 23 
18 69 Radium 223 202 0 0 0 0 0 0 0 0 2 0 0 0 2 
19 80 Enzalutamide 2.2 0 0 2 10 0 0 0 0 0 0 0 0 12 
20 74 Enzalutamide 1.3 6 12 41 6 0 2 0 0 2 0 0 0 69 
21 76 Dexamethasone 0.8 0 0 5 0 0 0 0 0 0 0 0 0 5 
22 51 Enzalutamide 434 0 0 3 0 0 2 0 0 2 0 0 0 7 
23 58 Docetaxel 100 0 8 3 0 0 6 0 2 2 0 0 0 21 
24 76 Enzalutamide 4611 0 4 0 0 0 0 0 0 0 0 0 0 4 
25 77 Radium 223 29.2 2 0 10 0 0 2 1 0 10 0 0 0 25 
26 66 Enzalutamide 21.0 0 0 0 0 0 0 0 0 0 0 0 0 0 
27 72 Enzalutamide 532 0 0 0 2 0 0 0 0 0 0 0 0 2 
28 81 Radium 223 96.1 0 2 0 0 0 0 0 0 0 0 0 0 2 




Table 5.11 A table to show the number of cells expressing each antigen for blood taken from 
patients with castrate resistant disease when processed using the Imagestream assay. 
 
 The Welch’s ANOVA test was performed to determine whether there was a significant 
difference in number of CTCs detected between patients in each disease stage (p = 0.02). 
The Mann Whitney test was then performed between the different groups to see which CTC 
counts were significantly different based on disease stage. The p-values from this test are 
displayed in Table 5.12. 
Disease stage groups Benign Surv NDM HSA HMAB CR 
Benign  - 0.81 0.09 0.89 0.23 0.15 
Surveillance 0.81 - 0.01 0.87 0.06 0.07 
Newly diagnosed 
metastatic 
0.09 0.01 - 0.01 0.22 0.48 
Hormones – single 
agent 
0.89 0.87 0.01 - 0.05 0.06 
Hormones – MAB 0.23 0.06 0.22 0.05 - 0.57 
Castrate resistant 0.15 0.07 0.48 0.06 0.57 - 
Table 5.12 A table to demonstrate the p-values when comparing CTC counts between the 
different disease stage groups when using the Mann Whitney test. There is a significant 
difference in CTC counts between the newly diagnosed metastatic group and those 
undergoing surveillance and on single-agent hormones. There is also a significant difference 
between those on single-agent hormones and those on maximum androgen blockade. 
 
These results show that there is a significant difference between CTC counts from the 
Imagestream assay between patients in the following disease stages: 
1) Newly diagnosed metastatic and a) surveillance, and b) hormones – single agent 
2) Hormones – single agent, and hormones – maximum androgen blockade 
These results would suggest that those on surveillance and single-agent hormones had more 
stable disease than those who had newly diagnosed metastatic disease and also those on 
maximum androgen blockade. This is unsurprising from a clinical perspective but reassuring 
that the assay confirms what would be predicted. 
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The p-values were very close to being significant between those on surveillance and those 
with castrate resistant disease and those on maximum androgen blockade. This may have 
become significant if using higher numbers of patients in each group. 
5.2.3 CTC count and PSA 
Although we know PSA is not a reliable predictor of disease progression, CTC count obtained 
from the Imagestream assay was plotted against PSA for patients in all groups, to determine 
whether there was a correlation, both at baseline (Figure 5.12) and six-month interval 
(Figure 5.13). 
 
Figure 5.12 A graph to show baseline PSA and CTC count using the Imagestream assay (the 



















































Figure 5.13 A graph to show PSA at 6 months and CTC count using the Imagestream assay 
(the line demonstrates linear regression) r2 = 0.0035 therefore there is no correlation. 
 
The r2 values for the correlation between baseline PSA and CTC count is 0.007 and 0.0035 for 
PSA after 6 months, which suggests no correlation. 
5.2.4 CTC count and ALP 
Whilst ALP is not a standardised biomarker in prostate cancer, it is recommended to check 
ALP at intervals as discussed earlier in this chapter. ALP at baseline (Figure 5.14) and also 
after 6 months was correlated to CTC count for all patients (Figure 5.15). 
 
Figure 5.14 A graph to show ALP at baseline and CTC count using the Imagestream assay (the 

























Figure 5.15 A graph to show ALP after 6 months and CTC count using the Imagestream assay 
(the line demonstrates linear regression) r2 = 0.008 therefore there is no correlation. 
 
The r2 values for the correlation between CTC count and ALP at baseline and after 6 months 
are 0.11 and 0.008 respectively which means there is no correlation at either time-point. 
 
5.2.5 Antigen expression 
Cells were examined for the expression of antigens and all combinations were recorded. 
































Figure 5.16 A graph from the full patient group (n = 78) to show how many CTCs are 
expressed including each antigen combination. The most common antigens were SOX2 and 
Nanog. 
 
To look at this in more detail, this data was then broken down into treatment type. See 























































































Figure 5.17 A graph to show how many CTCs expressed each antigen combination in patients 
with benign disease. Very few CTCs were found in this group, but the majority expressed 
SOX2, Nanog or a combination of Oct4 and SOX2. 
 
 
Figure 5.18 A graph to show how many CTCs expressed each antigen combination in patients 































































































































































Figure 5.19 A graph to show how many CTCs expressed each antigen combination in patients 
with newly diagnosed metastatic disease. More of the CTCs from this group expressed the 
three stem cell markers, either alone or in combination. 
 
 
Figure 5.20 A graph to show how many CTCs expressed each antigen combination in patients 






































































































































































Figure 5.21 A graph to show how many CTCs expressed each antigen combination in patients 
on maximum androgen blockade. SOX2 and Nanog were again commonly expressed, and 
one patient had high numbers of EpCAM+ cells. 
 
 
Figure 5.22 A graph to show how many CTCs expressed each antigen combination in patients 
with castrate-resistant disease. Several patients had CTCs with each of the individual 


































































































































































In order to examine the significance of different antigen expression between patients in each 
group, the Kruskal-Wallace test was performed. This compared the numbers of CTCs 
expressing each antigen combination for each disease stage. The results are displayed in 
Table 5.13. 
Antigen(s) Kruskal-Wallace statistic p-value 
EpCAM 7.52 0.28 
Oct4 6.94 0.33 
SOX2 6.26 0.40 
Nanog 11.12 0.08 
EpCAM/Oct4/Sox2/Nanog 4.19 0.65 
Oct4/SOX2/Nanog 10.70 0.09 
EpCAM/Oct4 3.78 0.71 
Oct4/Nanog 9.95 0.13 
Oct4/SOX2 8.05 0.23 
EpCAM/Nanog 5.39 0.50 
SOX2/Nanog 4.93 0.55 
Table 5.13 A table demonstrating the Kruskal-Wallace statistic which shows the significance 
of the number of CTCs displaying each antigen combination for the different disease groups.  
P > 0.05 for each antigen or antigen combination therefore there was no significant 
difference found. 
 
These results show that the actual number of CTCs expressing each antigen combination is 
not significant between patients at the different disease stages. (If there had been 
significance, then a t-test would have been used to determine the disease stages between 
which there was a significant difference.) 
In order to look at this data in a different way, the odds ratio of whether the three stem cell 
antigens were present or absent in different groups was explored. The patients in the 
surveillance group were chosen as the comparison group (Table 5.14) because aside from 
one patient with 14 Nanog positive cells, there were minimal numbers of each of the 
antigens present. The healthy volunteer or benign groups were not chosen as the 
comparator group as none of the former had any Oct4 / SOX2 /Nanog cells, and the latter 
had only one patient with any. This would mean the statistical test would require 
202 
 
adjustment, which would make it less accurate, especially when dealing with low numbers of 
patients in each group.  
Patient Oct4 SOX2 Nanog 
1 0 0 0 
2 0 0 14 
3 0 0 0 
4 0 3 0 
5 0 0 1 
6 0 1 0 
Table 5.14 A table to list the number of CTCs expressing each stem cell antigen for each 
patient in the surveillance group. 
 
When looking at Oct4 (Table 5.15), although the odds ratios are all greater than 1 apart from 
the healthy volunteer group, this cannot be interpreted as a positive association as none of 
the p-values show significance. All categories have lower numbers of Oct4 positive cells 
present than absent, so the odds ratios are confusing. Low numbers could account for this. 
a) Oct4 
Disease Stage Present Absent Odds Ratio p-value z statistic 
Surveillance 0 6 - - - 
Healthy volunteer 0 5 0.16 0.28 1.08 
Benign 1 5 3.55 0.46 0.73 
New diagnosis metastatic 2 6 5.00 0.33 0.98 
Hormones – single agent 3 10 4.33 0.36 0.92 
Hormones – MAB 5 11 6.21 0.24 1.18 
Castrate resistant 12 16 9.84 0.13 1.51 
Table 5.15 A table to demonstrate the number of CTCs that had Oct4 present or absent for 
patients in each disease group compared to the CTCs in the surveillance disease group. 
There is no significant difference found. 
 
For SOX2 (Table 5.16), there are low odds ratios for the healthy volunteer and benign 
disease groups, which would imply that the presence of the antigen is not likely in these 
groups when compared to the surveillance group. This would be expected, although in both 
cases, the p-value does not show significance. Again, this could be explained by a small 
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number of patients in these groups and the significance might be proven with a larger 
sample size. All of the other groups have odds ratios greater than 1, which would suggest 
that presence of SOX2 is more likely in these groups compared to the surveillance group, but 
the p-values are not significant.  
b) SOX2 
Disease Stage Present Absent Odds Ratio p-value z statistic 
Surveillance 2 4 - - - 
Healthy volunteer 0 5 0.16 0.28 1.08 
Benign 0 5 0.16 0.28 1.08 
New diagnosis metastatic 5 3 3.33 0.29 1.06 
Hormones – single agent 7 6 2.33 0.41 0.82 
Hormones – MAB 9 7 2.57 0.35 0.94 
Castrate resistant 15 14 2.14 0.41 0.81 
Table 5.16 A table to demonstrate the number of CTCs that had SOX2 present or absent for 
patients in each disease group compared to the CTCs in the surveillance disease group. 
There is no significant difference found. 
 
When looking at Nanog (Table 5.17), there are also odds ratios of less than 1 for the healthy 
volunteer and benign groups, but both have p-values greater than 0.05. All other groups 
have odds ratios greater than 1, the highest of which is for the newly diagnostic metastatic 
group. Six patients in this group had cells that expressed Nanog compared to two of the 
surveillance group, in comparison to Nanog-absent cells in two of the newly diagnostic 
metastatic group and four in the surveillance group. Although the p-value is 0.13 and 





Disease Stage Present Absent Odds Ratio p-value z statistic 
Surveillance 2 4 - - - 
Healthy volunteer 0 5 0.16 0.28 1.08 
Benign 1 5 0.40 0.51 0.66 
New diagnosis metastatic 6 2 6.0 0.13 1.55 
Hormones – single agent 5 8 1.25 0.83 0.22 
Hormones – MAB 8 8 2.00 0.49 0.69 
Castrate resistant 15 14 2.14 0.42 0.81 
Table 5.17 A table to demonstrate the number of CTCs that had Nanog present or absent for 
patients in each disease group compared to the CTCs in the surveillance disease group. 
There is no significant difference found. 
 
5.2.6 Antigen expression in patients that died 
Whilst the follow-up for this study is so far at a relatively early stage, the expression of 
antigens in patients that had died during this time would also be of interest. The odds ratios 
for presence or absence of stem cell antigen expression in those patients who had died 
compared to those who were still alive at six months is demonstrated in the Table 5.18. 
Antigen / Alive vs Dead Present Absent Odds Ratio p-value z statistic 
Oct4 Alive 21 51 - - - 
Oct 4 Dead 2 4 1.21 0.83 0.22 
SOX2 Alive 38 34 - - - 
SOX2 Dead 1 5 0.18 0.12 0.54 
Nanog Alive 35 37 - - - 
Nanog Dead 2 4 0.53 0.48 0.71 
Table 5.18 A table to demonstrate the odds ratios of each stem cell antigen being present or 
absent in the patients that had died in comparison to the patients still alive (using the results 
from the Imagestream assay). The presence of each antigen does not correlate with the 
survival of patients during the time frame studied. 
 
Unfortunately, none of these odds ratios is significant. The value obtained for the Oct4 
antigen is confusing because it is greater than 1 despite there being fewer Oct4-positive 
patients who died compare to Oct4-negative patients. With such a high p-value this isn’t 
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significant anyway. Because only six patients had died within the timeframe, these results do 
not necessarily mean that there is no association, and it would be valuable to repeat this 
analysis in future, once more patients have died from prostate-related causes. 
 
5.3 Results of FACS detected CTCs 
5.3.1 Definition of CTC data recorded 
Without the additional validation of a downstream assay to identify the FACS sorted 
population, it is not known whether the CD45-/CD16- population that were sorted are all 
CTCs. It is likely that they contain some white cells (debris based on size was gated out). 
Although there is antigen data which could be used in conjunction, cells were not examined 
for dual expression of antigens (due to the large number of antigens examined). For 
example, a cell expressing EpCAM might also express CK and therefore counting the number 
of cells expressing each antigen for each patient might result in counting the same cell more 
than once. 
Therefore, for the purpose of this study, the CTC count for the FACS assay describes those 
cells which are CD45-CD16 negative. 
5.3.2 Total CTC count 
The total numbers of CTCs detected using FACS are displayed in the following graph (Figure 
5.23), and the median and mean are displayed in Table 5.19. The patients with benign 
disease had a higher median number of CTCs than the patients with castrate-resistant 




Figure 5.23 A graph to show the total number of CTCs found from patients within each 
treatment group, using FACS. This shows that those with newly diagnosed metastatic disease 
had the highest number of putative CTCs but there is no significant difference between the 
patients in different groups (p=0.36). 
 
Disease Stage Median CTC sort 
no 
Mean CTC sort no 
(+SD) 
Range 
Healthy volunteers 404 413 (195.6) 172-677 
Benign 1152 1243 (737.1) 481-2363 
Surveillance 873 2181 (2313.1) 467-5500 
New diagnosis 
metastatic 
1747 1903 (1911.0) 168-6059 
Hormones – single 
agent 
1448 1542 (1120.1) 111-3389 
Hormones – MAB 1163 3019 (4857.0) 72-20000 
Castrate resistant 799 1267 (1309) 128-5286 
Table 5.19 A table to demonstrate the median and mean (+SD) no of CTCs detected via FACS 































































































Tables 5.20 – 5.26 list the total number of putative CTCs expressing each antigen detected on the FACS, according to patient characteristic. 







Age Treatment PSA EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 48 Healthy 
Volunteer 
N/A 2 11 1 7 10 21 838 890 
2 41 Healthy 
Volunteer 
N/A 0 9 8 6 9 15 1082 1129 
3 43 Healthy 
Volunteer 
N/A 0 6 6 0 3 1 943 959 
4 52 Healthy 
Volunteer 
N/A 2 8 7 3 4 21 900 945 
5 38 Healthy 
Volunteer 





Age Treatment PSA EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-MMP Total 
1 73 New patient – 
negative 
biopsy 
9.9 1 0 0 16 159 5 18 199 
2 79 New patient – 
negative 
biopsy 
9.5 8 0 1 4 225 2 0 240 
3 67 New patient – 
negative 
biopsy 
5.6 1 25 25 0 13 4 399 1047 
4 68 New patient – 
negative 
biopsy 
7.9 1 30 30 2 6 452 1434 1925 
5 67 New patient – 
negative 
biopsy 
7.2 1 64 64 89 17 11 112 318 
6 70 New patient – 
negative 
biopsy 
4.4 0 17 17 122 22 29 203 393 








Age Treatment PSA EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 68 AS 5.3 3 191 47 5320 152 13 7 5732 
2 72 AS 6.1 5 0 1 5888 153 53 3 6103 
3 76 WW 27.1 0 31 25 0 21 132 170 379 
4 84 WW 18.1 0 30 0 2 61 42 790 925 
5 87 WW 86.0 4 0 3 321 15 130 745 1218 
6 76 AS 37.4 2 0 16 0 329 0 813 347 







Age Treatment PSA EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 77 New Diag 5.2 1 0 8 25 157 12 0 203 
2 68 New Diag 33.5 0 0 0 24 174 3 1 202 
3 65 New Diag 18.3 29 0 19 2 117 54 269 490 
4 74 New Diag 140.0 0 2 2 45 0 73 3213 3335 
5 68 New Diag 308.0 1 4 4 42 13 33 4085 4182 
6 62 New Diag 22.0 1 117 8 1687 3 1 396 2213 
7 68 New Diag 47.0 3 51 7 82 1 0 365 509 
8 69 New Diag 3.2 2 244 0 254 53 7 1641 2201 





Pt Age Treatment PSA EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 69 Single 
agent 
31.4 2 16 1 27 36 0 8 90 
2 82 Single 
agent 
1.8 0 11 13 46 166 43 2 281 
3 71 Single 
agent 
2.9 0 0 0 6 118 6 0 130 
4 92 Single 
agent 
0.2 0 0 3 17 158 15 6 199 
5 91 Single 
agent 
0.2 0 30 3 0 8 22 122 185 
6 82 Single 
agent 
50.9 0 97 2 1 13 302 921 1336 
7 87 Single 
agent 
4.5 8 12 3 251 62 8 179 523 
8 66 Single 
agent 
0.1 2 4 0 87 9 12 74 188 
9 71 Single 
agent 
2020 5 8 14 11 0 6 450 494 
10 77 Single 
agent 
0.1 17 11 2 4 58 1 7 100 
11 59 Single 
agent 
4.5 22 15 4 2 21 195 864 1123 
12 63 Single 
agent 
81.9 199 1515 2 9 7 0 8245 9977 
13 67 Single 
agent 
3.0 2 28 1813 904 1 14 116 2878 
Table 5.24 A table to show the number of cells expressing each antigen that were found in 






Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 86 MAB 245.6 88 2 1 151 118 8 44 412 
2 84 MAB 61.4 11 0 1 777 16 16 0 821 
3 79 MAB 1.5 0 3 26 152 160 26 0 367 
4 87 MAB 3.1 0 616 13 389 160 25 12 1215 
5 82 MAB 24.0 1 1 6 36 119 5 1 169 
6 77 MAB 101.0 1 0 0 19 123 8 1 152 
7 78 MAB 1.5 0 7 5 21 117 6 0 156 
8 69 MAB 1.8 0 0 2 19 434 3 24 482 
9 86 MAB 12.6 15 0 4 9 172 23 1 224 
10 83 MAB 0.1 1 0 0 3 90 1 1 96 
11 83 MAB 23.4 0 13 1 2 10 22 164 212 
12 74 MAB 2.0 16 1 5 982 0 0 80 1084 
13 96 MAB 34.6 18 10 2 3 44 180 475 732 
14 80 MAB 1.7 7 10 9 1 29 20 54 130 
15 73 MAB 5.5 12 1 4 4 30 63 245 359 
16 65 MAB 30.6 0 6 1 44 3 21 588 663 
Table 5.25 A table to show the number of cells expressing each antigen that were found in 






Age Treatment PSA  EpCAM CK Oct4 SOX2 Nanog Vimentin MT1-
MMP 
Total 
1 77 Enzalutamide 1875 8 417 13 94 62 5 2243 2842 
2 68 Docetaxel 0.8 0 0 0 353 164 1 56 574 
3 85 Dexamethasone 55.0 2 18 6 360 116 42 1 545 
4 69 Enzalutamide 380 109 10 6 13 1 162 532 833 
5 77 Dexamethasone 18.0 17 2 5 4 492 307 639 1466 
6 61 Abiraterone 51.2 0 2 4 83 3 36 1247 1375 
7 60 Enzalutamide 0.7 0 2 3 52 231 0 3001 3289 
8 74 Dexamethasone 0.7 0 2 2 368 18 8 1352 1750 
9 73 Dexamethasone 23.0 858 1176 25 19 4 58 9339 11479 
10 77 Docetaxel  433 555 697 1 3 1 114 3583 4954 
11 58 Enzalutamide 12.4 0 83 14 490 7 178 547 1319 
12 87 Cabazitaxel 5.6 1 44 6 224 8 0 384 667 
13 70 Dexamethasone 228 3 126 10 483 18 0 1059 1699 
14 82 Enzalutamide 72.4 10 211 24 610 5 1 1336 2197 
15 74 Abiraterone 16.3 0 122 5 22 13 21 3763 3946 
16 74 Docetaxel 8.0 0 331 7 18 7 16 4751 5130 
17 72 Enzalutamide 586 9 326 13 22 7 6 4482 4865 
18 69 Radium 223 202 43 395 0 10 0 21 1528 1997 
19 80 Enzalutamide 2.2 2 6382 1 15 3 4 3326 9733 
20 74 Enzalutamide 1.3 5 207 2 6 4 2 3597 3823 
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21 76 Dexamethasone 0.8 1 0 0 1 0 0 187 189 
22 51 Enzalutamide 434 5 721 0 5 0 15 6278 7024 
23 58 Docetaxel 100 3 138 3 134 1 14 2602 2895 
24 76 Enzalutamide 4611 5 6142 0 70 124 0 6697 13038 
25 77 Radium 223 29.2 2 131 0 159 62 2 2059 2415 
26 66 Enzalutamide 21.0 43 60 28 196 2 5 4593 4927 
27 72 Enzalutamide 532 3 231 8 303 2 14 774 1335 
28 81 Radium 223 96.1 4 28 5 187 0 156 1543 1923 
29 78 Dexamethasone 10.5 3 47 5 232 0 340 1381 2008 
Table 5.26 A table to show the number of cells expressing each antigen that were found in 
the blood from each patient with castrate resistant disease.  
 
The Kruskal-Wallace test was performed to ascertain whether there was a significant 
difference in the number of CTCs detected for patients with each disease stage. The Kruskal-
Wallace statistic was 6.67 and the p-value was 0.36, demonstrating no significant difference 
in CTC count using the FACS assay, for patients at different disease stages. 
 
5.3.3 CTC count and PSA 
Although the CTC count data from this FACS assay appears to be unreliable, CTC count and 
PSA, both at baseline and after six months, were correlated for all patients, regardless of 
disease stage (Figures 5.24 and 5.25).  
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Figure 5.24 A graph to show baseline PSA and CTC count using the FACS assay (the line 
demonstrates linear regression) r2 = 0.01 therefore there is no correlation with CTC count 




Figure 5.25 A graph to show PSA after six months and CTC count using the FACS assay (the 
line demonstrates linear regression) r2 = 0.0001 therefore there is no correlation with CTC 
count and PSA at 6 months. 
 
The r2 values for both time-points were 0.01 and 0.0001 respectively, indicating no 

























































































5.3.4 CTC count and ALP 
The same was done for CTC count and ALP, both at baseline and after six months, and the 




Figure 5.26 A graph to show ALP at baseline and CTC count using the FACS assay (the line 
demonstrates linear regression) r2 = 0.02 therefore there is no correlation between CTC 













































































Figure 5.27 A graph to show ALP after six months and CTC count using the FACS assay (the 
line demonstrates linear regression) r2 = 0.006, therefore there is no correlation between 
CTC count and ALP at 6 months. 
 
No correlation was seen between CTC count and ALP at either baseline or after six months, 
demonstrated by the r2 values of 0.02 and 0.006 respectively.  
5.3.5 Antigen expression 
Cells were examined for the expression of antigens. Unlike for the Imagestream results, 
combinations of antigens were not recorded due to the risk of counting cells twice. Figure 
5.28 illustrates the frequency of expression of each antigen. Each dot represents one 
patient. 
 
Figure 5.28 A graph to show how many CTCs expressed each antigen using the FACS assay. 
MT1-MMP was expressed by the largest number of patients and all antigens were detected 
on CTCs. 
 
To look at this in more detail, this data was then broken down into treatment type (Figures 

















































Figure 5.29 A graph to show how many CTCs expressed each antigen in the healthy 
volunteers. A higher than expected number of cells expressed each antigen aside from 
EpCAM. High numbers of MT1-MMP+ cells were detected. This suggests that the criteria 
used to determine what a positive event is was not strict enough – this could be due to 
gating error or have occurred during the optimisation of the antibody. 
  
 
Figure 5.30 A graph to show how many CTCs expressed each antigen in patients with benign 
disease. Most patients had low numbers of cells expressing each antigen but there are 






















































































Figure 5.31 A graph to show how many CTCs expressed each antigen in patients undergoing 
surveillance. Similar to the previous groups, low numbers of EpCAM+ cells and high numbers 
of MT1-MMP cells were detected. The median number of cells expressing the stem cell 
markers was higher than the previous two groups. 
 
 
Figure 5.32 A graph to show how many CTCs expressed each antigen in patients with newly 
diagnosed metastatic disease. Higher numbers of cells expressing all antigens were detected 































































































Figure 5.33 A graph to show how many CTCs expressed each antigen in patients on single-
agent hormones. There were small numbers of patients expressing multiple cells with each 
of the stem cell antigens but the majority of patients had low numbers of these cells. 
 
 
Figure 5.34 A graph to show how many CTCs expressed each antigen in patients on 
hormones – maximum androgen blockade. The median number of cells expressing Nanog 




























































































Figure 5.35 A graph to show how many CTCs expressed each antigen in patients with 
castrate-resistant disease. This group of patients had higher median numbers of cells 
expressing all antigens. 
 
From these graphs, what is most concerning is the high numbers of ‘CTCs’ in the healthy 
volunteers and patients with benign disease, particularly the no of cells expressing MT1-
MMP. This could indicate a problem with the MT1-MMP antibody leading to a lot of false 
positives, or detection of white cells expressing MT1-MMP. 
In order to examine the significance of different antigen expression between patients in each 
group, the Kruskal-Wallace test was performed. This compared the numbers of CTCs 


















































Antigen(s) Kruskal-Wallace statistic p-value 
EpCAM 4.11 0.66 
Cytokeratin 19.87 0.03 
Oct4 1.85 0.93 
SOX2 12.58 0.05 
Nanog 15.85 0.01 
Vimentin 0.65 0.22 
MT1-MMP 34.64 <0.001 
Table 5.27 A table demonstrating the Kruskal-Wallace statistic which shows the significance 
of the number of CTCs displaying each antigen for the different disease groups. The p-value 
is less than 0.05 (and therefore significant) for numbers of cells expressing cytokeratin, 
SOX2, Nanog and MT1-MMP. 
 
Unlike in the Imagestream assay, there was a significant difference found in the number of 
antigens expressed for four of the antigens (Cytokeratin, SOX2, Nanog and MT1-MMP). 
Although the MT1-MMP results should be interpreted with a high level of suspicion, instead 
of odds ratios, Mann-Whitney tests were performed between the different disease groups 
for each of the four antigens to show which groups showed significant differences (Tables 






HV Benign Surv NDM HSA HMAB CR 
Healthy volunteer - 0.40 >0.99 0.65 0.15 0.17 0.04 
Benign  0.40 - 0.98 >0.99 0.85 0.22 0.04 
Surveillance >0.99 0.98 - 0.77 0.85 0.75 0.04 
Newly diagnosed 
metastatic 
0.65 >0.99 0.77 - 0.51 0.68 0.04 
Hormones – single 
agent 
0.15 0.85 0.85 0.51 - 0.01 0.03 
Hormones – MAB 0.17 0.22 0.75 0.68 0.01 - 0.002 
Castrate resistant 0.04 0.04 0.04 0.04 0.03 0.002 - 
Table 5.28 A table demonstrating the p-values when the Mann-Whitney test was performed 
to analyse the significance of the difference of numbers of cells expressing Cytokeratin 
between each disease group (p-values in bold denote significance). 
 
b) SOX2 
Disease stage groups HV Benign Surv NDM HSA HMAB CR 
Healthy volunteer - 0.45 0.12 0.02 0.11 0.05 0.01 
Benign  0.45 - 0.62 0.24 0.78 0.32 0.05 
Surveillance 0.12 0.62 - 0.57 0.65 0.95 0.37 
Newly diagnosed 
metastatic 
0.02 0.24 0.57 - 0.17 0.33 >0.99 
Hormones – single 
agent 
0.11 0.78 0.65 0.17 - 0.50 0.06 
Hormones – MAB 0.05 0.32 0.95 0.33 0.50 - 0.27 
Castrate resistant 0.01 0.05 0.37 >0.99 0.06 0.27 - 
Table 5.29 A table demonstrating the p-values when the Mann-Whitney test was performed 
to analyse the significance of the difference of numbers of cells expressing SOX2 between 






Disease stage groups HV Benign Surv NDM HSA HMAB CR 
Healthy volunteer - 0.02 0.01 0.43 0.10 0.01 0.90 
Benign  0.02 - 0.78 0.51 0.59 0.58 0.05 
Surveillance 0.01 0.78 - 0.55 0.37 0.68 0.02 
Newly diagnosed 
metastatic 
0.43 0.51 0.55 - 0.98 0.36 0.36 
Hormones – single 
agent 
0.10 0.59 0.37 0.98 - 0.14 0.07 
Hormones – MAB 0.01 0.58 0.68 0.36 0.14 - 0.01 
Castrate resistant 0.90 0.05 0.02 0.36 0.07 0.01 - 
Table 5.30 A table demonstrating the p-values when the Mann-Whitney test was performed 
to analyse the significance of the difference of numbers of cells expressing Nanog between 
each disease group (p-values in bold denote significance). 
 
d) MT1-MMP 
Disease stage groups HV Benign Surv NDM HSA HMAB CR 
Healthy volunteer - 0.08 0.18 0.52 0.04 0.01 0.10 
Benign  0.08 - 0.70 0.36 0.84 0.24 0.01 
Surveillance 0.18 0.70 - 0.85 0.59 0.05 0.03 
Newly diagnosed 
metastatic 
0.52 0.36 0.85 - 0.38 0.05 0.08 
Hormones – single 
agent 
0.04 0.84 0.59 0.38 - 0.12 0.01 
Hormones – MAB 0.01 0.24 0.05 0.05 0.12 - <0.001 
Castrate resistant 0.10 0.01 0.03 0.08 0.01 <0.001 - 
Table 5.31 A table demonstrating the p-values when the Mann-Whitney test was performed 
to analyse the significance of the difference of numbers of cells expressing MT1-MMP 
between each disease group (p-values in bold denote significance). 
 
In order to consider the results of the FACS assay as reliable, there should be a significant 
difference found between the number of cells expressing each antigen in the healthy 
volunteer group and all other patients. Unfortunately, the Cytokeratin results only show a 
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significant difference between one of the patient groups, SOX2 and Nanog between three of 
the six patient groups, and MT1-MMP between two patient groups. This means that the 
healthy volunteers, who have no known prostate cancer, are just as likely to have the same 
number of cells expressing the different antigens as those in the patient groups. Although 
there are some significant differences between patient groups for each of these four 
antigens, these results are meaningless if the control group is also testing positive. 
This could in part be due to low numbers of healthy volunteers in particular, but also low 
numbers in the treatment groups, but it could also be a reflection of the inaccuracy of the 
assay. 
5.3.6 Antigen expression in patients that died 
Similar to the Imagestream assay, the expression of antigens in patients that had died during 
the study time was explored. The odds ratios for presence or absence of stem cell antigen 
expression in the six patients who had died compared to those who were still alive at six 
months is demonstrated in Table 5.32. 
Antigen / Alive vs Dead Present Absent Odds ratio p-value z statistic 
Oct4 alive 59 13 - - - 
Oct 4 dead 3 3 0.22 0.08 1.73 
SOX2 alive 68 4 - - - 
SOX2 dead 6 0 0.85 0.92 0.10 
Nanog alive 65 7 - - - 
Nanog dead 5 1 0.54 0.60 0.53 
Table 5.32 A table to demonstrate the odds ratios of each stem cell antigen being present or 
absent in the patients that had died in comparison to the patients still alive (using the results 
from the FACS assay). There was no significance found to the presence of each stem cell 
antigen and whether the patient died during the study timeframe. 
 
Although all of the odds ratios are less than 1, suggesting that the presence of each antigen 
is not associated with death, none of these odds ratios are significant. Again, this could be 
because only six patients had died within the timeframe, and it would be valuable to repeat 
this analysis in future, once more patients have died from prostate cancer related causes. 
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5.4 Statistical comparison of Imagestream-detected and FACS-detected CTCs 
Comparison of the two techniques is not really possible in terms of antigen expression, as 
different antigen combinations were used for both techniques. Because the same amount of 
blood was used for both assays from matching patients, and the samples were prepared in 
the same way, CTC count from the Imagestream, and the sorted cell population (which 
although not verified as pure CTCs are the closest comparable numbers of CTCs) from the 
FACS assay should show a correlation (Figure 5.36). 
 
Figure 5.36 A graph to show the correlation between CTC count as detected by the 
Imagestream assay, and sorted cell population from the FACS assay (the line denotes linear 
regression) r2 = 0.0003, therefore there was no correlation between the number of putative 
CTCs detected using the two different methods. 
 
This graph shows that the cell numbers identified as CTCs by the Imagestream, and the 
CD45-/CD16- population sorted via FACS do not correlate. It would be expected that the 
FACS sorted population would be less pure and contain white cells that have not picked up 
the antibody, but this error should affect all samples and therefore be negated. Because 
there was no significant difference between CTC counts for patients in the different disease 
groups using the FACS assay, whereas there were using the Imagestream assay, this suggests 
that the FACS assay is likely to be the method which is the more unreliable of the two, 









































This work is an observational study, rather than a clinical trial, which means that only a 
limited number of conclusions can be drawn. Because patients were not randomised to 
different treatment types, they have all received slightly different treatments or had them at 
different time-points. Due to the relatively fast-changing treatment regimes, a consequence 
of the findings of existing clinical trials, patients will not have necessarily received 
medications in the same order, and some with more recent diagnoses may have had 
completely new treatments. 
Ethical approval was already obtained prior to the start of this study, and it was only once 
the collection of patient samples commenced that it became clear that additions to this 
approval would have been useful. Serial blood samples for CTC counts would have been 
beneficial so that a change in both count and antigen expression could be correlated with 
clinical findings. However, in reality this would have meant ongoing work beyond the time 
that was funded for this study and would have meant a further funding application. Whilst 
this is still possible now, it might be more useful to reflect on what has been learnt from this 
data and design a more optimal investigation, with a new ethics application, as this is likely 
to provide more useful information than continuing to add to the existing data. 
Categorising the patients into the different disease stages / treatment groups was done 
based on the assumption that patients in these categories would have different expected 
CTC findings. If a larger cohort had been studied, or longer timeframes explored, this may 
not be necessary, and disease progression could be correlated with CTC findings and 
extrapolated back to look at treatments. There are many ways to analyse this data but for 
the purpose of this study it was felt this might be useful. 
Because the blood sampling, consent, transportation, processing and analysis were 
performed by a single person, this limited the number of patients that could be included in 
the study. The collection and processing phase lasted approximately six months and it took 
this long to obtain blood from 88 patients. No more than five patients could be targeted 
from any clinic due to the time taken to consent and sample the blood. Depending on the 
day of the clinic only five samples could be run per week due to the FACS assay requiring 
staff from the facility to run the sort (during working hours only). If blood was obtained on a 
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Monday, a second clinic could be targeted on a Wednesday or Thursday but clinics on 
Fridays could not be utilised.  
Clinic lists were obtained prior to the day the patient attended, and notes were accessed to 
see which patients would be appropriate. Some patients declined consent, for a small 
number it was not possible to obtain blood due to vascular access, and some patients were 
not approached when it was clear that they were unwell, or their disease had progressed to 
the terminal phase. Therefore, despite best intentions and careful planning, on some 
occasions only two patients were consented from a clinic. Working as part of a bigger team 
and being able to access multiple clinics a week would help mitigate some of these factors 
and would enable more patients to be included in the study within the same time frame.  
The decision to correlate CTC count for both assays with PSA and ALP was made because of 
limited other means of predicting disease progression. As discussed in Chapter 1, it is known 
that PSA is not a reliable marker of advancing disease (Lucia et al., 2008, Thompson et al., 
2004), hence the need for a new biomarker, and there was incomplete data for ALP. But in 
the short time-frame there were not enough patients with radiological investigations to use 
those as a marker of progression. The fact that there was no median change in PSA or ALP in 
any of the groups between the baseline level and the levels six months later could be due to 
the short time frame, the low number of patients in each group or the fact that they are 
both unreliable biomarkers. As further time has now passed, it would be possible to obtain 
PSA and ALP results for all patients a year after their original samples and it would be 
interesting to see if this longer time frame would produce a more significant outcome. 
Percentage change of PSA and ALP might be more relevant than the actual change in the 
values. Another option would be to wait a little longer (e.g. two years) and collect death data 
to allow the Kaplan-Meier estimator to be calculated. As the original study on which this 
work was based looked at survival based on Oct4/SOX2/Nanog expression in prostate tissue 
this would be a useful comparison. This work is planned once the relevant time period has 
elapsed. 
When looking at the data from the two assays, the Imagestream data appears to be more 
reliable as none of the healthy volunteers had CTCs detected. Because cells could be 
examined visually once gating had been used to sort into different populations it is 
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unsurprising that this method was more likely to be accurate than the FACS assay for looking 
at small cell populations such as CTCs.  
For the Imagestream results, the patients in the benign group had a higher median and 
mean number of CTCs than the surveillance group, which is unexpected. It is possible that 
these patients might have had small foci of cancer that had not been detected, and longer-
term follow-up, including data on disease progression would be interesting. With such low 
numbers though, the significance of this difference is questionable. In the original seminal 
papers on CTCs a count of >2 CTCs was considered diagnostic, meaning that 1-2 CTCs could 
be found in healthy volunteers (possibly contaminants or false positives) (Allard et al., 2004). 
The mean number of putative CTCs found in the benign patients on Imagestream was 
affected by one particular sample in which there was a high number of Nanog positive cells. 
It is possible that these were false positives and that each of the other samples contained a 
small number of cells that, allowing for a small margin of error, should be ignored.  
A significant difference in overall CTC count was found between the newly diagnosed 
metastatic patients and those on both surveillance and single-agent hormones, and between 
those on single agent hormones and maximum androgen blockade. Significance was not 
found but the p-value was close to 0.05 for patients undergoing surveillance in comparison 
to those with both castrate-resistant disease and on maximum androgen blockade, and 
larger numbers in the groups may have led to this becoming significant. Whilst these results 
do not prove anything new, they do help to validate the results obtained using this assay and 
mean that the antigen data can be interpreted with some reassurance of accuracy. 
Unfortunately, the antigen expression on CTCs from patients in each group was not 
statistically significantly different when comparing each group all together, or when looking 
at the odds ratio of the antigens being present or absent. This lack of difference in antigen 
expression is surprising given that the counts are significantly different between the groups, 
but could be explained by the relatively low numbers of CTCs to start with, that means each 
antigen or combination of antigens is expressed in even lower numbers. The odds ratio could 
be worked out between all of the groups, but given that the surveillance group had the 
lowest number of CTCs (while still having counts greater than 0) a difference is unlikely to be 
shown. There was also no difference when looking at the odds ratio of the three stem cell 
antigens being present in patients who were alive versus those who were dead. Looking at 
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this odds ratio over a longer time period may be helpful as a higher number of patients will 
have died, and this work is planned alongside the Kaplan-Meier work.  
When looking at the FACS results, the CTC count itself is likely to have a higher degree of 
error, in that rather than looking at antigen positive cells, all CD45-/CD16- cells were 
counted. As explained, it was felt that this was most accurate, given the inability to validate 
the cells further. But what is concerning, and means the results for the antigen expression 
for this assay must be interpreted with caution, is that there is no significant difference in 
CTC counts between any of the groups, including the healthy volunteers. 
A difference in antigen expression for the FACS assay was found to be significant for four of 
the antigens, but the majority were not significantly different to the healthy volunteer 
control group. This data should therefore be interpreted with a high index of suspicion. Odds 
ratios for the different antigens were not calculated for the FACS assay but given the 
relatively high number of cells expressing antigens, and the low numbers of patients in each 
group, it is unlikely to have yielded any significant differences.  
The odds ratios looking at the presence or absence of the three stem cell antigens were also 
not found to show an association in those patients who were dead or alive. Whilst low 
numbers of early deaths could be blamed, given the other findings from this assay it is more 
likely to be due to unreliable data. 
The results from the Imagestream assay are disappointing in that antigen expression on CTCs 
at this stage does not appear to be significant. However the data may yet predict survival if 
correlated to prostate cancer related deaths and/or disease progression over a longer time-
frame. The FACS assay appears to have a high degree of error and the results at this stage 
indicate that reliable data is unlikely to be generated from this arm of the work. Some 
groups have had success isolating CTCs using conventional FACS such as the one in this 
assay. But given the availability of FACS machines and the relative ease at which high 
throughput of samples can be processed, the fact that the literature is not full of studies 






Chapter 6. The use of CTCs to develop different models for target 
discovery 
Chapter Summary 
This chapter explores the potential use of CTCs once they have been extracted and cultured. 
Different models are explored based on the physical and chemical properties of the CTCs. 
These include experiments looking at the stiffness of different cells, their chemokine 
expression, and a CDX mouse model, the latter two of which have not been previously 
investigated in prostate cancer. (It should be noted that where the term CTC is used that 
these cells are deemed putative CTCs as they do not fulfil the criteria set by the FDA). 
 
6.1 Rationale for attempting to use CTCs for target discovery 
During the process of optimising the FACS and Imagestream assays, review of the literature 
revealed that there had been successful attempts to culture CTCs (Hwang et al., 2017, 
Cayrefourcq et al., 2015, Zhang et al., 2013, Hamilton et al., 2016, Kolostova et al., 2014, 
Kolostova et al., 2015, Kulasinghe et al., 2016), albeit at extremely low frequency of success. 
Some of these cells were then used for downstream models, such as circulating tumour cell 
derived xenograft (CDX) mouse models (Hodgkinson et al., 2014, Morrow et al., 2016). 
Discussion with colleagues within the Institute working in different fields (pharmacy, drug 
discovery and bio-engineering) led to the ideas described in this chapter regarding different 
uses for CTCs.  Because of the high numbers of samples collected for the FACS and 
Imagestream assays, an attempt at culturing was made. The following experiments were 
conducted, in order to explore the possibility of utilising CTCs in a different way for clinical 
benefit such a drug discovery. 
 
6.2 Comparison of different techniques for CTC extraction from whole blood 
6.2.1 Background 
The methods used to extract CTCs for the Imagestream and FACS assays had used an initial 
fixation step. Whilst this worked well for the Imagestream assay and would have worked for 
the FACS assay had there not been the issue with the sorted population, it would not enable 
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cell culture. Different methods of CTC extraction were already in existence or became 
commercially available during the course of this project. These were compared using cell 
lines spiked in blood to see which yielded the highest retrieval count.  
Three different experiments were performed using increasing numbers of spiked cells (1000, 
10 000 and 100 000 cells) in 2mls of blood. Each was repeated three times and performed 
for two different cell lines, PC3 and U2OS. Cell lines were harvested and counted using a 
haemocytometer before being added to the blood. Blood containing spiked cells was then 
processed using each method and cell retrieval was measured by running the cells on the 
Imagestream. This was to ensure that white cells were not falsely increasing retrieval 
numbers and, although there would have been a degree of cell loss, as this method was 
applied to all arms of the experiment it was felt that this would not affect the comparative 
numbers. The cells of interest were resuspended in Robosep buffer and stained with 
CD45(PECy7), Vimentin (AF647) and DAPI (for PC3s) or CD45(PECy7), CD44(FITC) and DAPI 
(for U2OS).  
For this experiment I am grateful to Maria Georgiou (technician in the Rankin group) for her 
assistance in preparing and running some of the samples. 
6.2.2 Density centrifugation 
The Stem Cell Technologies Rosette-Sep Anti-CD36 CTC Enrichment kit was chosen for this 
experiment. This particular preparation was used due to its use in the successful retrieval 
and subsequent CDX mouse model created from a patient with small cell lung cancer that 
was discussed in the seminal paper on CTC CDX models (Hodgkinson et al., 2014). 
Density centrifugation is one of the most basic cell separation techniques available and can 
be performed on a bench-top centrifuge using standard Falcon tubes (Kitz et al., 2018). It 
works on the assumption that CTCs will have a density lower than 1.077g/ml (Alunni-
Fabbroni and Sandri, 2010). In its most basic form, this method can be performed solely 
using a density gradient medium, which will cause cells with different densities to separate 
into different layers when the tube is spun in a high-speed centrifuge. The top layer is usually 
plasma, followed by the CTC layer, and then the layer containing the white cells, leaving the 
red cells at the bottom of the flask (Lowes and Allan, 2014). The plasma layer can be 
carefully pipetted off and discarded, revealing the CTC layer. An obvious weakness of this 
technique is cell contamination between the layers, either due to inadequate separation 
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during the centrifugation stage, or manual mixing at the pipetting stage. It assumes CTC cell 
density will be universally different to cells found in the blood, which although is true of 
larger CTCs, smaller ones can often be denser (van der Toom et al., 2016). One strength of 
the method is that it does not rely on carcinoma cell markers, and the CTC antigen 
heterogeneity will not matter. Various kits are commercially available that include 
antibodies targeted at white cells, to reduce the contamination between the white cell layer 
and the CTCs. 
The Rosette-Sep kit contains a cocktail of antibodies that targets the white cell population 
(CD2, CD16, CD19, CD36, CD38, CD45 and CD66b) in addition to glycophorin A on red blood 
cells. Blood is incubated with this cocktail at room temperature and then mixed with the 
Lymphoprep density gradient medium prior to centrifugation. The results of the density 
centrifugation experiment for the two different cell lines using the three different cell 
numbers spiked in 2ml of blood are shown in Figure 6.1. A prostate and osteosarcoma cell 
were used to complement work conducted by other members of the group, looking into CTC 




Figure 6.1 A graph to show the mean number of cells retrieved (n = 3) when using the 
density centrifugation method. The cells were counted on the ImagestreamX. 1.27%, 2.20% 
and 0.78% of the PC3 cells were retrieved when 1000, 10 000 and 100 000 cells were spiked 
respectively. 0.67%, 0.70% and 0.50% of the U2OS cells were retrieved when 1000, 10 000 


























As expected, increasing numbers are retrieved when higher numbers are spiked into the 
blood, although the variability, demonstrated by the standard deviation, is much higher in 
the 100 000-cell arm of the experiment. PC3 retrieval is slightly better, possibly because the 
cells are less fragile compared to the U2OS. 
6.2.3 Magnetic Separation 
This principle uses magnetically conjugated antibodies against either white cell antigens or 
CTC antigens which are commercially available in cocktails that are mixed directly with 
whole blood, followed by magnetic beads which bind to the relevant antibodies. The blood is 
then processed through a magnet for either negative or positive selection. For positive 
selection (e.g. antigen that will be positive on the CTC population) the cells that are 
magnetically selected are retained in the tube for further analysis whereas for negative 
selection (e.g. white cell antigens) the magnetically selected cells are discarded. 
Two different commercial kits were used, which both use the same principle of negative 
selection. The first of these was a single white cell marker kit (CD45) from Miltenyi Biotec 
and the second was the Stem Cell Technologies Easy Sep CTC Human enrichment kit which 
contains antibodies to multiple white cell markers. This method also included an initial red 
cell lysis step using density centrifugation prior to the application of the magnetically 
labelled micro-beads. The micro-bead cocktail was then combined with the remaining blood 
components and incubated prior to being passed through magnetic filters. 
The results of this first magnetic separation experiment for the two different cell lines using 




Figure 6.2 A graph to show the mean number of cells retrieved (n = 3) with the first magnetic 
separation kit (Miltenyi) using CD45 as a single marker. The cells were counted on the 
ImagestreamX. 1.03%, 0.25% and 1.22% of the PC3 cells were retrieved when 1000, 10 000 
and 100 000 cells were spiked respectively. 2.60%, 0.85% and 2.76% of the U2OS cells were 
retrieved when 1000, 10 000 and 100 000 cells were spiked respectively. 
 
 
This experiment needed repeating several times to get accurate results as the red cell lysis 
did not work particularly well. Even when running the sample through the Imagestream 
there was clear evidence of remaining erythrocytes. This was the only method in which 
there was a higher retrieval rate of U2OS compared to PC3 cells, and there was not a 
proportionally higher number retrieved in the 100 000 spiked-cell arm.  
The second magnetic separation method used a multiple white cell marker cocktail. The 
Stem Cell Technologies Easy Sep CTC Human enrichment kit contains a combination of anti-
white cell antibodies (CD2, CD14, CD16, CD19, CD45, CD61, CD66b) and Glycophorin A to 
target erythrocytes. There is no initial red cell lysis or density centrifugation step and the 
cocktail is applied to whole blood. 
The results of this second magnetic separation experiment for the two different cell lines 


































Figure 6.3 A graph to show the mean number of cells retrieved (n = 3) with the second 
magnetic separation kit (Stem Cell Technologies) using multiple white cell markers. The cells 
were counted on the ImagestreamX. 7.30%, 8.52% and 13.64% of the PC3 cells were 
retrieved when 1000, 10 000 and 100 000 cells were spiked respectively. 6.23%, 3.70% and 




Because a higher number of white cell antibodies was used in this cocktail, it might be 
expected that a lower number of cells would be retrieved due to cell line cells possibly 
adhering to more of the white cells remaining on the magnet. However, a higher proportion 
of cells were retrieved from both cell lines at all three concentrations, when compared to 
the previous two methods. 
6.2.4 Physical Properties (Parsortix) 
The final method chosen for this experiment was retrieval based on physical properties. The 
NICR has a Parsortix machine which works by passing whole blood through a cassette 
containing multiple filters at a constant pressure of 99bar (Miller et al., 2018). It assumes 
that CTCs will be both bigger and less deformable (due to a higher nuclear: cytoplasmic ratio) 
than the leucocytes and erythrocytes (Kitz et al., 2018, Miller et al., 2018). By using a 
combination of buffers and priming fluids, the blood is drawn through the machine and the 
cassette is used to filter out unwanted cells. The CTCs are then collected in an Eppendorf. 
This method had been used successfully to separate CTCs from whole blood in patients with 




































Benefits of this method include the lack of antigen labelling and the consequent potential for 
heterogeneous CTC populations to be identified. Small CTCs might be missed however, and 
the filters can clog easily. 
The results of this physical separation experiment for the two different cell lines using the 
three different cell numbers spiked in 2ml of blood are demonstrated in Figure 6.4. 
 
 
Figure 6.4 A graph to show the mean number of cells (n = 3) retrieved when using the 
Parsortix machine. The cells were counted on the ImagestreamX. 2.97%, 0.99% and 0.67% of 
the PC3 cells were retrieved when 1000, 10 000 and 100 000 cells were spiked respectively. 
0.63%, 0.29% and 0.19% of the U2OS cells were retrieved when 1000, 10 000 and 100 000 




The actual numbers of cells retrieved were comparable to the density centrifugation method 
and the magnetic separation method using the Miltenyi kit. There were issues with filter 
clogging during a couple of the experiments and this meant eight repeats were required in 
order to get a full set of results. Again, the U2OS retrieval is lower in comparison to the PC3 





























6.2.5 Overall retrieval and choice of method 
In order to compare the numbers of cells retrieved some basic statistics were performed to 
compare the methods. The following table (Table 6.1) and graph (Figure 6.5) outline the 
mean number of cells retrieved using each method, for each cell line and at each quantity. 
 
 Percentage recovery 
No of cells 
spiked 
1000 10 000 100 000 
Cell line PC3 U2OS PC3 U2OS PC3 U2OS 
Density 
centrifguation 
1.27 0.67 2.20 0.70 0.78 0.50 
Magnetic 
sep’n (M kit) 
1.03 2.60 0.25 0.85 1.22 2.76 
Magnetic 
sep’n (STC kit) 
7.30 6.23 8.52 3.70 13.64 6.55 
Physical 
(Parsortix) 
2.97 0.63 0.99 0.29 0.67 0.19 
Table 6.1 A table demonstrating the percentage of cells retrieved using each method, for 
each cell line at each different quantity. (M = Miltenyi and STC = Stem Cell Technologies). 
The Stem Cell Technologies kit enabled the highest percentage of cells to be recovered when 





Figure 6.5 A graph to show the mean number of cells retrieved for each cell line, using each 
method when 1000 cells were spiked. (STC = Stem Cell Technologies). The Kruskal-Wallis test 
showed a significant difference when all four techniques were compared for the PC3 cells (p 
= 0.004) and U2OS cells (p = 0.03). Further analysis with the Mann-Whitney test, comparing 
each individual technique did not reveal a significant difference. 
 
The Kruskal-Wallis test was performed which showed a significant difference when 
comparing all four methods for both PC3 (p = 0.004, Kruskal-Wallis statistic = 9.0) and U2OS 
(p = 0.03, Kruskal-Wallis statistic = 9.1) for the 1000 cell experiment.  The Mann-Whitney test 
was then performed to demonstrate whether there was a significant difference between 
each of the individual values (performed separately for each different cell line) but this did 
not reveal any significant differences between methods.  
Although the Stem Cell Technologies kit appears to produce a higher retrieval rate, the 
Mann-Whitney test shows that the numbers retrieved are not significantly different from 
any of the other methods. This could be due to low numbers of repeats, and overall low cell 
numbers too.  
The Kruskal-Wallis test was repeated to compare the retrieval rate of all four methods for 
the 10 000-cell experiments. For the PC3 arm the p-value was 0.001 (Kruskal-Wallis statistic 









































































number of cells retrieved using each method for the 10 000-cell experiment is shown in the 
following graph (Figure 6.6).  
 
 
Figure 6.6 A graph to show the mean number of cells retrieved for each cell line, using each 
method when 10 000 cells were spiked. (STC = Stem Cell Technologies). The Kruskal-Wallis 
test showed a significant difference when all four techniques were compared for the PC3 
cells (p = 0.001) and U2OS cells (p = 0.006). Further analysis with the Mann-Whitney test, 
comparing each individual technique did not reveal a significant difference. 
 
The Mann-Whitney test was then performed to demonstrate whether there was a significant 
difference between each of the individual values (performed separately for each different 
cell line) but despite the results shown in Figure 6.6 showing a higher retrieval rate for the 
Stem Cell Technologies kit, these figures are not significant and there were no significant 
differences between methods.  
For the final arm of the experiment (100 000 spiked cells) the Kruskal-Wallis test was 
performed for each cell line separately, to investigate whether there were significant 
differences between the four methods. For the PC3 cells, the p-value was 0.001 (Kruskal-













































































8.7). The mean number of cells retrieved using each method for the 100 000-cell experiment 
is shown in the following graph (Figure 6.7). 
 
 
Figure 6.7 A graph to show the mean number of cells retrieved for each cell line, using each 
method when 100 000 cells were spiked. (STC = Stem Cell Technologies). The Kruskal-Wallis 
test showed a significant difference when all four techniques were compared for the PC3 
cells (p = 0.001) and U2OS cells (p = 0.006). Further analysis with the Mann-Whitney test, 
comparing each individual technique did not reveal a significant difference. 
 
None of the individual methods for the 100 000-cell spiked experiment showed a significant 
difference in retrieval rate when the Mann-Whitney test was performed, despite there being 
higher overall numbers retrieved. Again, this could be due to only repeating each method 
three times.  
Although the statistical analyses do not demonstrate a significant difference in retrieval rate, 
the multiple magnetic marker kit from Stem Cell Technologies was chosen as the method of 
choice for extracting CTCs from clinical samples.  
The Density Centrifugation method had been used before by different groups to obtain 



















































































model (Hodgkinson et al., 2014). However, when this method was attempted here, there 
were technical difficulties preventing contamination of cells from other layers while 
obtaining the purified enriched cell layer. This is likely to have improved with use but as 
overall numbers were lower than with the magnetic kit from STC, the decision was made not 
to use this method. 
There were often issues with the red cell lysis using the Miltenyi kit, and this arm of the 
experiment had to be repeated eight times in order to obtain the ultimate sample free of red 
cells. It also only used one white cell marker to extract white cells from the cell pellet, and 
there were many more white cells seen on the subsequent Imagestream analysis. As 
discussed later in section 6.3.2, white cells grow prolifically in culture and could potentially 
starve CTCs of nutrients. For this experiment the white cells were gated out of the analysis, 
but if the cells of interest were being transferred straight to a culture medium, not only 
could they be deprived of nutrients but it would be more difficult to discern which cells were 
CTCs and which were white cells when planning ongoing CTC specific experiments. 
The Parsortix was discounted as the machine itself was situated in non-sterile conditions in 
the NICR. This meant that subsequent attempts at culture ended up in infection. Preliminary 
discussions were made about transferring the machine into a tissue culture hood, but lack of 
resources and the fact that others using this machine did not require sterile conditions 
meant that this did not occur. In addition, the two cell lines used for the spiking experiment 
both have cells much larger than white blood cells. If these cell lines still didn’t result in 
significantly higher retrieval numbers compared to other methods, it raises concern that 
small CTCs from clinical samples may be completely missed. 
Because the Stem Cell Technologies kit uses multiple magnetic markers against white cells, it 
would be expected to have potentially one of the lower yields of CTCs. However, possibly 
because it did not involve a separate red cell lysis phase (which could have fragmented some 
of the cells), the cell retrieval was higher, even if not significant. It was a much purer sample 
too, with very few white cells seen on the Imagestream. 
This chosen method resulted in cells within a gelatinous-looking suspension. This was spun 
down and whilst no visible pellet was seen, the majority of the gelatinous material was 
discarded (presumed to be plasma and platelets) and media was used to resuspend any cells 
that remained, before transfer to a 24-well plate for incubation.  
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6.3 Optimisation of Cell Culture 
6.3.1 Background 
In order to perform downstream experiments that could be repeated, CTCs obtained would 
ideally need to be expanded by growing in culture. Harvested numbers from each patient 
are likely to be small and, although concern about differentiation must be considered, even 
one or two cell passages are likely to increase cell numbers to the required amount. Ideally, 
sequencing at every passage would be performed to look at differentiation but for logistic 
and financial reasons this would not always be possible. 
6.3.2 Different culture media 
On reviewing the literature, there were several groups who had successfully managed to 
culture CTCs but very few who had managed to keep these cells alive beyond 14 days. For 
those with longer term success, media choice varied between specific stem cell media 
(Hwang et al., 2017) and basic RPMI (Kolostova et al., 2014, Kolostova et al., 2015, Hamilton 
et al., 2016, Yu et al., 2014) or DMEM (Zhang et al., 2013, Cayrefourcq et al., 2015, 
Kulasinghe et al., 2016). Some added varying quantities of insulin (Cayrefourcq et al., 2015, 
Zhang et al., 2013), antibiotics (Drost et al., 2016, Hamilton et al., 2016, Zhang et al., 2013) 
and steroids (Drost et al., 2016, Zhang et al., 2013) and all used different quantities of 
growth factors and foetal bovine serum (Cayrefourcq et al., 2015, Drost et al., 2016, 
Hamilton et al., 2016, Kolostova et al., 2014, Kolostova et al., 2015, Kulasinghe et al., 2016, 
Yu et al., 2014, Zhang et al., 2013). 
Due to the stage of the project, there was limited time to set up experiments to try and 
compare the different media and additives. Because of this, and to reduce the risk of 
introducing infection by adding several individual components, the Lonza Mesenchymal 
Stem Cell Growth Medium Bulletkit was chosen. This contains a basal media that is 
specifically designed to promote stem cell growth without encouraging differentiation. It 
also contains a pre-determined cocktail of growth supplements and set volumes of L-
glutamine and antibiotics. Once combined, the full media can be stored at 4°C for up to six 
months. 
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6.3.3 Normoxic versus hypoxic conditions for cell culture 
Some of the studies that looked at successful CTC culture described maintaining cell culture 
under hypoxic conditions (Cayrefourcq et al., 2015, Kulasinghe et al., 2016). These groups 
varied the oxygen tension and found that the CTCs proliferated more quickly under hypoxic 
conditions. It is established that under hypoxic conditions, hypoxia inducible factor 1 alpha 
(HIF-1) is induced (Liao et al., 2007). In turn this targets pro-metastatic genes such as 
GLUT1 and LOX, which promote tumour growth and metastasis (Semenza et al., 1996, 
Sowter et al., 2001).  
A hypoxic incubator and tissue culture hood are available in the NICR, but at the time of the 
planned experiments they were undergoing repair and were not available for a period of 
two months. Cells obtained from patient samples were therefore kept under normoxic 
conditions for the purposes of this experiment. 
6.3.4 Testing the media and culture conditions on cancer cell lines 
Before using precious clinical samples, two cancer cell lines were spiked into whole blood, 
selected using the Stem Cell Technologies multiple-magnetic white cell marker kit described 
in section 6.2 and maintained in the Lonza Mesenchymal Stem Cell culture described in 
section 6.3.2. This was to ascertain whether the method of cell retrieval would be viable to 
use on clinical samples (in terms of incidence of infection and other practical logistics). 1000 
PC3 or U2OS cells were spiked in to 2ml of healthy volunteer blood and the kit was used as 
described earlier. The resultant cell suspension was spun down, and cells resuspended in 
2ml of the Lonza media. This cell suspension was then divided into six and added to a six-
well plate with each well containing 2ml of the media. Each cell line experiment was 
repeated three times. The incubation procedure followed the method described for cell line 
culture in Chapter 2 and media was changed every third day. After six days they were 
sufficiently confluent to transfer to T75 flasks and after sixteen days they were still viable 
and had required two further 1:20 passages. The following images (Figures 6.8 and 6.9) were 
taken at sixteen days. 
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Figure 6.8 Microscope images of the three flasks containing PC3 cells at day 16 (x40 
magnification). 
 
Figure 6.9 Microscope images of the three flasks containing U2OS cells at day 16 (x40 
magnification). 
 
This experiment demonstrates that the CTC selection kit and media are both suitable for the 
selection and maintenance of cancer cell lines in culture. Whilst anticipated CTC numbers 
will often be much lower, and CTC proliferation may not be as successful in these conditions, 
there were no significant difficulties encountered, and the morphology of the cells showed 
that they were the cell lines and not white cells. It was therefore felt that this method would 
be suitable to use with clinical blood samples. 
6.3.5 Testing the media and culture conditions on white blood cells 
Low numbers of CTCs were anticipated from the selection method in the clinical samples, 
and therefore retrieved cells were put directly into culture, rather than sorting them further 
via another method such as FACS. Because the sample was unlikely to be 100% pure and was 
likely to contain some white cells, an experiment to determine whether or not white blood 
cells would survive in the culture conditions was performed. This was done to ascertain a) 
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whether they would survive and b) their proliferation rate. If they died under these 
conditions then we could be confident that any surviving cells were a pure CTC population, 
and similarly if they proliferated quickly, the slow growth of any cells from the clinical 
samples is more likely to indicate CTCs rather than white cells. 
Images were taken at day 1 (Figure 6.10) and day 13 (Figure 6.11). 




Figure 6.11 Microscope images of the three flasks containing white cells at day 13 (x20 
magnification). 
 
Despite the white cells being sparsely distributed in the original well, by day 10 they would 
have been confluent enough to transfer to a T75 flask, and at day 13 they were clearly over 
confluent. This experiment proves that white cells do survive in the culture environment and 
that they proliferate very quickly. By using the multiple-white cell antibody cocktail in the 
Stem Cell Technologies CTC kit it is hoped that very few white cells will be present in the cell 
suspension that is ultimately put into culture. 
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6.4 Using clinical samples for CTC culture 
6.4.1 The first clinical sample 
4ml of blood was obtained from a patient with end stage castrate resistant prostate cancer. 
The patient had multiple bony and lymph node metastases and had received treatment for 
both a spinal cord compression and pathological fractures. The blood was processed under 
sterile conditions using the Stem Cell Technologies Mesenchymal Stem Cell kit and incubated 
in the Lonza Mesenchymal Stem Cell media in a 12-well plate under the standard incubation 
conditions described in Chapter 2. Media was changed every second day and images taken 
at day 7 (Figure 6.12), day 13 (Figure 6.13), day 17 (Figure 6.14) and day 32 (Figure 6.15). 
 
Figure 6.12 Microscope images of three of the wells from patient CTC-JARO-110 at day 7 
(x20 magnification). The cells were very sparse. 
 
 
Figure 6.13 Microscope images of three of the wells from patient CTC-JARO-110 at day 13 




Figure 6.14 Microscope images of three of the wells from patient CTC-JARO-110 at day 17 




Figure 6.15 Microscope images of three of the wells from patient CTC-JARO-110 at day 32 
(x20 magnification). There was an increase in confluence from day 13. 
 
 
The different magnifications were used to demonstrate the overall confluence in the well 
and the individual cell morphologies. 
Because the cells had not proliferated as quickly as the white cells in the experiment in 
section 6.3.5 but had grown in number, it was assumed that these cells were CTCs. The cells 
were trypsinised on day 33 and half were put back into fresh media for ongoing culture 
whilst the other half was processed on the Imagestream. The results of this experiment are 
discussed in section 6.5.2. 
Due to the relatively long time that it takes to expand these cells in culture, at this stage the 
decision was made to obtain further clinical samples for this purpose to enable potential 
CTCs to grow for use in further experiments. 
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6.4.2 Clinical samples and the lessons learnt from attempted CTC culture 
Blood from twenty-five patients with castrate resistant prostate cancer was obtained using 
the same method as with the first sample. Media was changed every second day but, despite 
performing this in sterile conditions and using vacutainers rather than needles to harvest the 
blood, by the end of week four, sixteen samples had to be discarded due to infection. Some 
of these infections were obviously bacterial but some were likely to be fungal (due to spores 
seen under microscopic examination). The media already contained an antibiotic 
combination of penicillin and streptomycin, so nystatin was added to the full media. Four 
further samples succumbed to infection over the next six weeks, which meant that there 
were six remaining, including the original patient’s. These were maintained in culture for the 
next six months, and due to slow growth only required passage approximately every two 
months. 
During the harvest process from the initial CTC selection kit, the resultant cell suspension 
was very gelatinous. Initially, because no cell pellet was seen and there was concern about 
fragmenting the low numbers of cells had centrifugation been performed, this gelatinous 
material containing the potential CTCs was put directly into media. This was contrary to 
what was performed in the cell-line experiment, but there had been a visible cell pellet in 
that. Unfortunately, this then formed a jelly-like substance in the wells of the plate. Although 
some cells could be seen adhering to the bottom of the plate, there were also some cells 
within this jelly-like material. This material could not be aspirated and instead had to be 
manually removed using a pipette and sterile forceps in order to change the media. After 
this happened to the first six samples (all but one of which succumbed to infection) the 
decision was made to spin the collection tube from the CTC kit, and discard the majority of 
the supernatant before resuspending.  
Because so many of the samples were lost to infection, it was not possible to determine 
whether all contained cells that could have been CTCs. However, patients with the highest 
clinical burden of disease were targeted, and paired samples on the Imagestream showed all 
had CTCs detected via the method described in Chapter 3.  
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6.5 Proving the authenticity of the cells from clinical samples in culture 
6.5.1 Background 
Although the cells grown in culture were growing very slowly, and this is contrary to the 
white cells that grew much more rapidly, it cannot be assumed that this feature alone means 
that they are CTCs. Sequencing the cells would be the gold standard but this is technically 
difficult and expensive (involving DNA extraction from a small cell number followed by 
transporting the cells to a different institute). In addition, because of the slow growth of the 
cells in culture, when passaging them any cells taken out for analysis will mean a lower 
number of cells remaining for further culture and expansion. 
The following methods of cell analysis were attempted in order to determine what the cells 
actually were. 
6.5.2 Antigen expression 
For the first patient sample that was cultured (CTC-JARO-110), the cells were trypsinised on 
day 33 (the day after the image in Figure 6.15 was taken). One third of the cells were put 
back into culture, a third were used for the experiment described in section 6.8 and a third 
were prepared to run on the Imagestream. The latter sample was spun at 400g and 
resuspended in 4% Paraformaldehyde for twenty minutes for fixation. The 
paraformaldehyde was then washed off and the cells were permeabilised and stained with 
the following antibodies, in line with the Imagestream method described in Chapter 3: CD45 
(PECy7), EpCAM (PE-Vio 615), Oct4 (AF488), SOX2 (AF555), Nanog (PerCP-Cy5.5) and DAPI. 
All cells were subsequently resuspended in 200µl of Robosep buffer and run through the 
Imagestream. 
A basic plot looking at cell size was performed and the results are shown in Figure 6.16. This 
shows a small number of much larger cells than would be expected if white cells only were 
present in the sample. 
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Figure 6.16 A graph to show cell area against cell circularity for all cells processed during this 
experiment. The gate is used to identify cells that are larger than the majority of white cells 
are expected to be. This shows that there are several cells that are larger than the majority 
of white cells and these could be potential CTCs. 
 
 
To identify cells that were not white cells, the intensity of CD45 for all cells was plotted. This 
revealed three distinct populations (Figure 6.17).  
 
Figure 6.17 A graph to show the intensity of CD45 for all cells processed during this 
experiment. There are three distinct populations of cells although population 1 is likely to be 
debris or cells with non-specific staining as the intensity of the CD45 expression is very low. 
Cells in population 2 were smaller white cells than those in population 3. 
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When the individual cells in each of these populations were looked at more closely, cells 
within population 2 and population 3 were predominantly white cells that stained positive 
for CD45 (Figure 6.18). The variation in intensity between population 2 and population 3 was 
broadly explained by the size of the white cell. 
 
Figure 6.18 An Imagestream image of a typical cell seen in population 2 and population 3. 
 
 
The cells within population 1 were a mixture of large cells with large nuclei, very few of 
which were positive for the other antigens, and a large number of small, Nanog+ cells (Figure 
6.19). 
 
a) An EpCAM+/DAPI+ cell 
 
 
b) A DAPI+ cell 
 
 
c) A small Nanog+/DAPI+ cell 
Figure 6.19 Imagestream images to show examples of some of the cells seen within 
population 1 in Figure 6.17. Cell a) expressed EpCAM and no CD45 so could be a putative 
CTC. Cell b) had no EpCAM, stem cell or CD45 expression so could either be a white cell that 
didn’t express or stain positive for CD45, or a putative CTC which was negative for the 
markers of interest. Cell c) was a Nanog positive cell but expressed Nanog at a level higher 
than normal white cells, so could be a putative CTC. 
 
All of the cells from the whole population that were DAPI+/CD45- were counted as potential 
CTCs. An intensity plot of Nanog for all of these cells was then performed (Figure 6.20). This 
was to establish whether the Nanog+ cells expressed Nanog at an intensity over the 
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threshold set in Chapter 3, which was higher than the intensity at which white cells 
expressed it. 
 
Figure 6.20 A graph to show the intensity of Nanog for all DAPI+/CD45- cells processed 
during these experiments. The majority of the cells expressed Nanog at a much higher level 
than is normally expressed in white cells, so these could represent putative CTCs. 
 
From this graph, the majority of the possible CTCs expressed Nanog at a level much higher 
than is normally expressed in white cells. The cells in gate A when visualised appeared much 
larger than the Nanog+ cells in Figure 6.19c. Additionally, they did not obviously visually 
express Nanog. An example of one of these cells is seen in Figure 6.19b. This result means 
that we can say with some degree of confidence that the small cells seen in Figure 6.19c are 
not white cells, with the inference that they are CTCs. All CD45-/DAPI+ cells were highlighted 
on the original plot of cell size (Figure 6.21).  
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Figure 6.21 A graph to show the area against circularity plot but with the possible CTCs 
(CD45-/DAPI+ cells) highlighted in yellow. There is a considerable overlap in size between 
those cells that were negative for CD45 and white cells expressing CD45. As Nanog 
expression in the CD45- cells is high, we can be reasonably confident that these cells are not 
white cells but that they could be putative CTCs. 
 
This graph demonstrates that whilst some of the larger cells do appear to be CTCs, some 
were bits of debris that did not contain nuclei. What is particularly fascinating about this plot 
is that the majority of the CD45-/DAPI+ cells were of a similar size compared to white cells. 
Because we have looked at Nanog expression in these cells we can be reasonably confident 
that they are not just white cells that have lost CD45 expression but could be small CTCs. In 
total there were 818 possible CTCs out of a total of 6680 events (cells/debris).  
Whilst this data is reassuring, it is not conclusive and so other methods were conducted. 
6.5.3 Real Time qPCR 
A real-time quantitative PCR experiment was attempted to look at gene copy number of 
PSA, ARV7 and TMPRSS2 in the DNA from cells from five of the patients with cells in culture. 
The cells were trypsinised and DNA extraction and amplification were performed using the 
Qiagen Repli-g Mini kit. PC3 cells were also used as a control for this experiment. DNA 
quantity was measured using the Qubit (ThermoFisher Scientific) and was sufficient to 
proceed with the experiment. Unfortunately, the dissociation curves for all three genes at all 
concentrations showed multiple peaks. The housekeeper gene did amplify successfully so 
there may have been a problem with the primers for the three genes of interest. This 
happened again when the experiment was repeated, but because the cells were so slow to 
grow it was not possible to obtain further cells at this stage for analysis using this method. 
6.5.4 SNP Array 
A different approach was attempted; a SNP Array to detect single nucleotide polymorphisms 
that commonly occur in prostate cancer within the cells in culture. This was initially 
performed on cells belonging to three of the patients, and subsequently for the remaining 
three patients. PC3 cells were used as a control on both occasions. DNA was extracted and 
amplified using the Repli-g Mini kit (Qiagen) and measured using the Qubit to ensure 
adequate quantities. The DNA was then transferred on ice to a different department within 
the university for the SNP Array to be performed.  
 255 
Unfortunately, in the first instance, despite the Qubit measuring adequate levels of DNA in 
all but one of the samples (>500µg), the SNP wasn’t possible as they couldn’t detect 
sufficient quantities of DNA. For the second set of patients, the flasks containing the cells 
were transferred directly to the department for the DNA extraction to be performed there. 
Unfortunately, again not enough DNA was extracted; the SNP was run anyway but failed. 
6.5.5 Whole-exome sequencing 
As a final attempt to determine the validity of the cells in culture, DNA was extracted from 
the cells of three patients and one cell line control and sent for whole-exome sequencing. 
Instead of extracting the DNA from cells in culture, it was performed on thawed samples that 
were frozen when passaged (passage 3 for CTC-JACH-73, passage 4 for CTC-JEWR-124 and 
passage 5 for CTC-JARO-110). This was done purely for time reasons as the cells take so long 
to grow in culture. The DNA extraction and amplification were performed by my colleague, 
Justin Englebert, using the Repli-G mini kit (Qiagen). Cells were transported in suspension on 
ice to another institution within the university. I am grateful to Justin Englebert, (technician 
in the Rankin group) for his help with the DNA extraction. 
The DNA quantities and exome quality control data from the samples are shown in Table 6.2. 
A lower percentage of duplications (% dups) is preferable as higher numbers suggest an 
enrichment bias. Although we were advised by the sequencing team that an M seq number 
above 20 is preferable they were confident that they had enough DNA. However, when they 
attempted interpretation of the sequencing there had not been enough DNA from the 
patient samples. There was sufficient DNA from the two cell lines (U2OS cells were also sent 
as a positive control for some osteosarcoma patient cells) so the issue here may have been 
short DNA fragments from the patient samples, rather than an overall lack of DNA. 

















% Dups %GC M seqs 
CTC-JACH-73 8.96 896 15 59.73 76.5–79 57.00 6.9–7.1 
CTC-JARO-110 18.1 1810 15 120.67 56.0–57.9 45 23.1–23.7 
CTC-JEWR-124 4.92 492 15 32.80 75.1–77.4 54.00 7.2–7.3 
PC3 (control) 4.44 444 15 29.60 13.5–14.1 48 19.5–19.9 
 
Table 6.2  A Table listing the DNA volume and concentrations provided from each sample, and the Exome quality control data prior to sequencing. 
Despite what should be have  been sufficient quantities of DNA obtained  (as measured by the Qubit)  the M seq number was low and this meant 
there wasn’t sufficient  DNA, or that the fragments were possibly too short for analysis.
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6.6 Exploring the chemical properties of cultured CTCs 
6.6.1 Background 
One potential use of CTCs would be to explore their chemokine receptor expression. 
Chemokines are cytokines secreted by cells in order to enable motility towards cells with 
their corresponding ligands (Salazar et al., 2013, Ahmed et al., 2017b). Whilst chemokine 
mediated activity is not necessarily pathological (e.g. white cell infiltration as part of the 
inflammatory response (Wong et al., 2010)), there is increasing evidence that tumour cells 
may express chemokines that assist in the metastatic process (Engl et al., 2006, Singh and 
Lokeshwar, 2011, Singh et al., 2004, Kakinuma and Hwang, 2006, Ben-Baruch, 2008, Zlotnik 
et al., 2011).   
Knowing which chemokines are secreted by particular cell types means that if tumour cells 
have a chemokine receptor that would bind with this protein, a prediction could be made on 
where that cell might metastasise to. This could help target specific treatments; e.g. early 
use of radium-223 in prostate cancer for men who have CTCs that are likely to spread to 
bone, or the interactions could be utilised for future drug discovery. 
Evidence from an assay where chemokines are placed in agarose gel spots, in a dish 
containing cells in media, has shown that migration of these cells towards the gel spot 
occurs if the cells contain the corresponding ligand (Ahmed et al., 2017b). Collaboration with 
the authors of this study led to the design of an experiment where a similar agarose spot 
assay would be performed using the cells grown in culture from patients. 
6.6.2 Choice of chemokine receptors and their corresponding ligands 
Before setting up the Agarose Spot assay, a decision had to be made about which chemokine 
receptors on potential prostate cells would be most useful to look at, and therefore which 
ligands to put in the gel spots. The published study (Ahmed et al., 2017b) used two cell lines: 
PC3 cells which express CXCR4 and CCR7, and SW480 cells which express CXCR4. They had 
used the chemokines CXCL12, CCL19 and CCL21 in the gels; the former would attract cells 
expressing CXCR4 and the latter two would attract those expressing CCR7 (Ahmed et al., 
2017b). Rather than just repeat the experiment, the literature was studied to find which 
chemokine receptors are most likely to be expressed on prostate cancer cells. 
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CXCR6 interacts with the ligand CXCL16, and expression in prostate cancer tissue correlates 
with a more aggressive phenotype, with earlier progression to metastatic disease 
(Richardsen et al., 2015, Wang et al., 2008). Matrix-metalloproteinases (specifically MMP1, 
MMP9 and MMP13) are activated by CXCR6 expression (Singh et al., 2016) which increases 
cell invasiveness by promoting degradation of the basement membrane and extracellular 
matrix (Curran and Murray, 2000). Additionally, the interaction between CXCR6 and its 
ligand CXCL16 affects cell motility by affecting the actin binding potential of the cell 
cytoskeleton to the extracellular matrix (Singh et al., 2016).   
The ligands of CCR7 (CCL19 and CCL21) are predominantly secreted by lymphocytes 
(particularly B-cells, T-cells and natural killer cells)  and high levels have been found in the 
lymph node metastases of various cancers (Cassier et al., 2011, Du et al., 2017). 
Upregulation of CCR7 in both prostate and gallbladder cancer has been shown to be 
mediated by TNF- via the ERK pathway (Maolake et al., 2018, Hong et al., 2016b, Hong et 
al., 2016a).  
The ligand CXCL12 is secreted by numerous cell types including osteoblasts and skeletal 
muscle cells (Ratajczak et al., 2003, Ponomaryov et al., 2000) and interacts with the receptor 
CXCR4. Levels increase after damage to tissues, promoting haematopoietic invasion as a 
response to injury (Wang et al., 2006). In prostate cancer specifically, the CXCR4/CXCL12 
interaction encourages adherence of the tumour cells to bone marrow endothelium via v3 
integrin upregulation and activation of CD164 (Sun et al., 2007). 
Choosing chemokine receptors CXCR6, CCR7 and CXCR4 would potentially provide 
information about the aggressiveness of the tumour, and whether it is likely to metastasis to 
bone and/or lymph nodes. As a result, these three chemokine receptors were used for this 
experiment, with the aim of using the ligands CXCL16, CCL19, CCL21 and CXCL12.  
6.6.3 Demonstrating the presence of chemokine receptors in cell lines 
Before setting up the agarose spot assay, expression of the three receptors was explored 
using immuno-fluorescence on both cell lines and the cells from patients in culture. Table 6.3 
lists the purchased antibody and fluorescent conjugate. 
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Chemokine Receptor Fluorescent 
conjugate 
Isotype control Manufacturer 
CXCR6 PE REA (S) Miltenyi Biotec 
CCR7 FITC REA (S) Miltenyi Biotec 
CXCR4 APC REA (S) Miltenyi Biotec 
Table 6.3 A table to show the chosen Chemokine Receptors, the corresponding conjugated 
fluorochrome, the isotype control and the manufacturer from which they were supplied. 
 
PC3 cells were used and the antibody was diluted at increasing amounts and run in parallel 
with the isotype control (Figures 6.22-6.25). 
Figure 6.22 Three immuno-fluorescent images demonstrating the 1:10 dilution of the isotype 
control for a) CXCR6, b) CCR7 and c) CXCR4. (As these were negative the images showing 




Figure 6.23 Immuno-fluorescent images to show PC3 cells stained with increasing antibody dilutions of the chemokine receptor CXCR6 (PE). No 




Figure 6.24 Immuno-fluorescent images to show PC3 cells stained with increasing antibody dilutions of the chemokine receptor CCR7 (FITC). No 






Figure 6.25 Immuno-fluorescent images to show PC3 cells stained with increasing antibody dilutions of the chemokine receptor CXCR4 (APC). Some 
staining was seen at the highest concentration, but this is likely to be non-specific.
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Aside from what is likely to be non-specific fluorescence when using the CXCR4 antibody, 
none of the three chemokine receptors were detected on PC3 cells, despite using low 
passage cells. Although most studies in the literature describe expression of these three 
chemokine receptors on PC3 cells, a small number have not found any expression (Darash-
Yahana et al., 2004, Heresi et al., 2005). Despite this, attempts were made at looking for 
chemokine receptor expression in the cultured CTCs. 
6.6.4 Demonstrating the presence of chemokine receptors in CTCs 
Cells from five patients were plated out for the immuno-fluorescence protocol used for the 
cell lines. But despite culture over several weeks, the cells were so sparse that when the 
antibodies were added there were not enough cells on the coverslips to give meaningful 
results. 
Instead, the cells from each patient were stained in suspension and processed using the 
Imagestream. Figures 6.26 - 6.30 show some example cells from each patient and the 




Figure 6.26 Imagestream images of cells cultured from patient CTC-JACH-73 demonstrating 













Figure 6.27 Imagestream images of cells cultured from patient CTC-JARO-110 demonstrating 








Figure 6.28 Imagestream images of cells cultured from patient CTC-STCH-122 demonstrating 








Figure 6.29 Imagestream images of cells cultured from patient CTC-PEWA-123 





Figure 6.30 Imagestream images of cells cultured from patient CTC-JEWR-124 demonstrating 
CCR7 and CXCR4 expression on these cells. 
 
These images show that there is some heterogeneity between cells from the same patient, 
which is to be expected. Table 6.4 tabulates the chemokine receptors found on cells from 
each patient. 
 
 Chemokine Receptor  
Patient CXCR6 CCR7 CXCR4 Location of 
metastases 
CTC-JACH-73  + + Bone, Lymph Nodes 
CTC-JARO-110 + + + Bone, Lymph Nodes 
CTC-STCH-122  + + Bone 
CTC-PEWA-123  + + Lymph Nodes 
CTC-JEWR-124  + + Bone, Lymph Nodes 
Table 6.4 A table listing the chemokine receptors that cells from each patient expressed, and 
the clinical location of their metastases. 
 
These results are encouraging when considering the authenticity of the cells. If they are CTCs 
they only provide a glimpse of the heterogeneous population of tumour cells that were 
present at the time of sampling, but correlation to clinical presentation is significant. The 
only patient with cells expressing all three receptors (CTC-JARO-110) had a very aggressive 
form of the disease and died within a month of his blood being taken. Patient CTC-JACH-73 
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had a small number of lymph node metastases but predominantly bony disease and not all 
of his cells expressed CCR7. Patients CTC-STCH-122 and CTC-JEWR-124 expressed both CCR7 
and CXCR4 in all cells despite no obvious lymph node metastases in CTC-STCH-122, and 
patient CTC-PEWA-123 had cells with no expression at all, despite lymph node metastases. 
Whilst this data alone is insufficient to draw any meaningful conclusions, progression to the 
agarose spot assay was planned. Unfortunately, during the culturing process (which took 
several months) the cells became infected and had to be discarded. As this was the end of 
the project there was insufficient time to repeat the culture, so the agarose spot assay was 
not performed. Frozen cells from earlier passages are still available and future plans to 
proceed with the assay are in formation. 
 
6.7 Development of an in-vivo model using NSG mice 
6.7.1 Background 
The CDX mouse model created from CTCs in patients with small-cell lung cancer (Hodgkinson 
et al., 2014) resulted in tumour development in mice. These subsequently responded to 
chemotherapeutic agents in the same way as tumours in the corresponding patients, and 
therefore provided a relevant in vivo model for target discovery. To date, no such model 
exists in prostate cancer as all previous in vivo prostate cancer models have been created by 
using either prostate cancer cell lines, organoids or cells from solid tumours (Karthaus et al., 
2014, Chua et al., 2014, Clevers, 2016). Organoids have been created from CTCs in advanced 
prostate cancer by a group that have experience with creating in-vivo organoid models (Gao 
et al., 2014, Gao and Chen, 2015), currently these have not been implanted in mice, nor have 
any CDX models have been directly created from CTCs. Because prostate biopsies are rarely 
taken in advanced disease, and also because sampling bias can overlook tumour 
heterogeneity, using CTCs in prostate cancer to create a CDX model could offer a clinically 
relevant tissue model for target discovery. Therefore, an attempt was made to create a CDX 
mouse model in prostate cancer, using the cells cultured from patients.  
Due to timing and financial constraints only one patient’s cells were used (CTC-JARO-110) 
but implanted into five NOD/LtSz-scid IL2R_null (NSG) mice. These mice were chosen due to 
their immune-deficiency and because other members of the institution had successfully 
created PDX models using these mice. Because of the low numbers of cells, the decision was 
made to implant them intrafemorally, rather than subcutaneously or via the tail vein as it 
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was felt that this would be a more protective environment that could encourage tumour 
growth. Additionally, as the patient from which the cells were derived had multiple bony 
metastases, a bone environment was felt most likely to be successful for the cells to engraft.  
6.7.2 Pre-mortem findings 
The mice showed no significant changes for the first four months. During the fifth month, 
one (Left Notch) developed a palpable lump at the femoral injection site and a second (Right 
Notch) developed this three weeks later. These were not usual following intra-femoral 
injections, but due to both maintaining their weights and showing no obvious signs of 
distress, observation continued. During the sixth month, a third mouse (Both Notch) 
developed sudden onset hind leg paralysis, consistent with spinal cord compression, and was 
culled humanely. Shortly afterwards, the two mice with the femoral lumps started to look 
scruffy and started shallow breathing. The remaining four mice were culled at this stage.  
6.7.3 Post-mortem analysis 
Post-mortem X-ray images of the two mice with femoral lumps were obtained (Figure 6.31), 
and a CT scan (Figures 6.32 and 6.33) was performed on the spine and lower limbs of Both 
Notch, to ascertain if there was an obvious spinal cord compression. No obvious lesions were 
seen on the X-rays. The CT showed possible sclerosis in the pelvis and femura but 
unfortunately the scan did not show the entire lumbar spine or any of the thoracic spine and 
so a cord compression could not be confirmed. This was because of the sudden onset of 
symptoms from that mouse – the CT scanner had been installed only the previous day and it 
was unknown how long scanning would take. The first set of images was taken but the 





Figure 6.31 X-ray images of the femurs of both mice with palpable femoral lumps. No 




Figure 6.32 CT reconstructed images of the lower limbs of Both Notch. Image a) shows a left 
oblique-lateral view and image b) shows a right oblique-lateral view. No obvious lesions 




Figure 6.33 CT reconstructions of the pelvis and spine of Both Notch. No obvious bony 
lesions were identified 
 
Whilst the CT results were inconclusive, attempts to perform immuno-histochemical staining 
on the mouse with the presumed cord compression (Both Notch) were made. The spine and 
right femur (injection site) were sectioned and stained with Haematoxylin and Eosin (H&E), 
and for PSA and MT1-MMP expression. This was performed by the pathology department 
within the Royal Victoria Infirmary, Newcastle-upon-Tyne. A control mouse of the same age 
and species without cells implanted was also sectioned, and staining was performed 
simultaneously as a negative control. 
The H&E staining of the femur (Figure 6.34) and spine (Figures 6.35 and 6.36) of Both Notch 








Figure 6.35 H&E staining of two sections of spine from Both Notch. 
 
 
Figure 6.36 H&E staining of a section of spine from a control mouse. This shows a 
comparable histological picture to Both Notch. 
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Despite the clinical findings, the H&E staining did not detect any obvious spinal cord lesions 
or tumour cells that were recognisably prostatic in origin. Further staining with PSA was 
therefore attempted (Figures 6.37-6.39). Control tissue from prostate tumour can be seen in 
Figures 6.37 and 6.38 to demonstrate the validity of the antibody.   
Figure 6.37 PSA staining from the right femur of a) Both Notch and b) a control mouse. The 
circular sections in the top left are positive controls from human prostate tissue. No PSA 
staining is identified. 
 
Figure 6.38 PSA staining from two sections of spine taken from Both Notch. The circular 




Figure 6.39 PSA staining from the spine of the control mouse. No PSA staining is identified. 
 
None of the PSA staining was positive from the right femur or spine of Both Notch. Further 
staining with MT1-MMP was attempted (Figures 6.40-6.42) as the patient from which the 
cells were taken had MT1-MMP positive bone lesions when he presented with a pathological 
fracture.  
 
Figure 6.40 MT1-MMP staining from the right femur of a) Both Notch and b) the control 




Figure 6.41 MT1-MMP staining from the spine of Both Notch. There is non-specific 




Figure 6.42 MT1-MMP staining from the spine of the control mouse. There is non-specific 
background staining in both specimens. 
 
 
Although initially this appeared positive, there is no difference between the staining in Both 
Notch and the control mouse, and a Consultant Pathologist confirmed that they were 
negative. Therefore, the conclusion was made that there was no evidence of PSA+ or MT1-
MMP+ cells in the femur or spine of the mouse with the suspected spinal cord compression.  
Because the clinical findings led to suspicions of positive pathology, attempts were made to 
look for any human cells within this mouse, in case cell differentiation had occurred. An anti-
human-mitochondrial antibody was used for this purpose, which should detect any human 
cell, regardless of whether the cell was prostatic or had differentiated (Figures 6.43-6.46). I 




Figure 6.43 Anti-mitochondrial human antibody staining of the right femur of a) Both Notch 




Figure 6.44 Anti-mitochondrial human antibody staining of the spine of Both Notch. No 






Figure 6.45 Anti-mitochondrial human antibody staining of a second section of the spine of 
Both Notch. No antibody was detected. 
 
 
Figure 6.46 Anti-mitochondrial human antibody staining of a third section of the spine of 
Both Notch. Non-specific staining was detected. 
 
Despite sectioning the entire spine and right femur of Both Notch, no obvious spinal cord 
lesion or cells positive for the anti-mitochondrial antibody were found. Some non-specific 
femoral staining was seen in the femur of both the control and Both Notch, despite using the 
mouse-on-mouse (MOM) kit. This was used to reduce endogenous mouse immunoglobulin 
staining caused by using an antibody raised in a mouse. The clinical sign of hind-leg paralysis 
is very unusual in the NSG mice without underlying pathology, but although efforts were 
made to find a lesion, nothing was confirmed. The conclusion must therefore be drawn that 





6.8 Exploring the physical properties of cultured CTCs 
6.8.1 Background 
CTCs can also provide us with information about the mechanical properties of tumour cells 
that may be more relevant than the cells obtained from solid tissue. They are likely to be the 
most clinically relevant cells from a tumour, and if cultured, the cells will still be living and 
therefore their structure not affected by a fixation process. Thus, information about their 
physical structure could help with the design of new drug treatments, particularly those 
aimed at cell wall degradation or rupture. Experiments using an Atomic Force Microscope 
(AFM) have demonstrated that changes in cell stiffness can be an indication of underlying 
pathology such as cancer (Guck et al., 2005, Lekka and Laidler, 2009) and the stiffness of cells 
can indicate how likely a cell is to metastasise (Luo et al., 2016, Cross et al., 2007, Cross et 
al., 2008). Comparisons in the Young’s Modulus of malignant and non-malignant cells using 
breast cancer cell lines have shown a lower value in the former group (Li et al., 2008). 
In prostate cancer there have been several studies to measure the Young’s modulus of the 
cell of prostate cancer cell lines (Faria et al., 2008, Raudenska et al., 2019, Murphy et al., 
2013) and tissue (Chen et al., 2015b), and a study using PC3 cells looking at cytoskeletal 
changes in response to different drug treatments showed corresponding changes in the 
Young’s modulus of the cell membrane (Ren et al., 2015). There has been one study looking 
at prostate CTCs, which found that cells from patients with castrate-resistant disease were 
three times less stiff than those with castrate-sensitive disease (Osmulski et al., 2014). This 
study identified CTCs using EpCAM staining following a filtration process, which may have 
excluded cells undergoing EMT, or those not expressing EpCAM. Although other techniques 
for measuring the mechanical properties of cells exist, such as optical or acoustic tweezers, 
electrical field stimulation or parallel plate flow, the AFM is the most commonly used in 
cancer research (Rodriguez, 2013). With this in mind, some preliminary experiments were 
conducted on the patient cells in culture, some white cells and two different cell lines to look 
at cell stiffness using an AFM. I am very grateful to Dr Daniel Frankel for his help and 
guidance with this experiment. 
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6.8.2 Principles of an AFM 
An AFM uses a tip (either spherical or conical) on the end of a flexible cantilever to indent a 
cell. The attractive or repulsive force between the cell and the tip of the cantilever is 
measured, and using the value of the force, and the distance between the cell surface and 
the tip, a force-separation curve can be plotted (Kuznetsova et al., 2007). Analysis of this 
force-separation curve can be used to estimate the Young’s modulus of a cell, (Puricelli et al., 
2015) using either the Sneddon model for a conical tip, or the Hertz model for a spherical tip. 
The smaller the value of the Young’s modulus, the more deformable the cell (Deng et al., 
2018). The cantilever tip is repeatedly inserted and retracted into the cell numerous times, 
to allow an average force to be calculated. These models assume elastic deformation (the 
cell is viscoelastic) but are valid for small indentations into the surface. Thus the model is 
fitted to the first part of the indentation curve whereby viscoelastic effects are minimal. 
In addition, the movement of a laser aimed at the cantilever is detected by a photodiode and 
used to create a three-dimensional image of the cell surface (Mozafari et al., 2005). The 
resolution of the AFM is much higher than electron or light microscopes (Deng et al., 2018) 
therefore enabling the precise indentation of the cantilever tip into a cell.  
6.8.3 Results of the AFM indentation experiments 
Cells were cultured onto glass coverslips and transported in media to the School of 
Engineering at Newcastle University. Each coverslip was placed separately inside the AFM 
liquid cell, buffer exchanged to PBS (600 ul) and then loaded into the Agilent 5500 AFM. 
Indentation measurements for conical probes were taken using silicon cantilevers (PPP-
CONTR, Nanosensors, Switzerland) and borosilicate spherical probes 5 m in diameter 
(NovaScan Technologies). After laser alignment on the back of the cantilever and calibration 
of the photodetector, the optical microscope was used to identify the cells of interest. 
Repeated indentations and retractions were then undertaken (approximately 500 cycles) 
was recorded. The software, SPIP version 6.3.3 (Image Metrology, Lyngby, Denmark) was 
then used to process the force/separation curves and fit the indentation model to the 
approach curve allowing the Young’s modulus of the cell to be calculated. Below are the 
force/separation curves obtained from indenting into the glass coverslip with no cells (Figure 
6.47) and different cell types (Figures 6.48 – 6.51). 
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Figure 6.47 A force/distance curve showing the indentation (blue curve) and retraction (red 
curve) of a spherical tip into the glass coverslip. The indentation curve at close separations 
shows a typical elastic response (sharp vertical line increase in force) of a probe indenting 
into glass. This serves a control for comparison with the softer cell indentation profiles. 
 
 
Figure 6.48 A force/separation curve showing the indentation (blue curve) and retraction 
(red curve) of a spherical tip into a U2OS cell. The difference between the indentation curve 
and the indentation curve into the glass slide (Fig 6.47) is striking. The indentation profile is 
curved rather than straight, a characteristic of viscoelastic materials. This is consistent with 
literature data for the indentation of cells. 
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Figure 6.49 A force/separation curve showing the indentation (blue curve) and retraction 
(red curve) of a spherical tip into a healthy volunteer white cell. This was repeated for 500 
cycles. This has a characteristic indentation profile, showing a viscoelastic form. 
 
Figure 6.50 A force/distance curve showing the insertion (blue curve) and retraction (red 
curve) of a spherical tip into a patient putative CTC. This cell came from a patient with very 
advanced metastatic prostate cancer that had EpCAM+ and triple marker Oct4/SOX2/Nanog 
positive cells when processed on the Imagestream. It is also the patient from which the cells 
that were implanted into the mice were taken. The fit of the Hertz indentation model at the 
point of indentation is shown. The CTC profile appears to show a different form to that of 




Figure 6.51 A force/separation curve showing the indentation (blue curve) and retraction 
(red curve) of a conical tip into a PC3 cell demonstrating the viscoelastic characteristics 
typical of cell indentation experiments. 
 
Table 6.5 outlines the type of cell or material, the tip used to make the indentations and the 
calculated Young’s Modulus of the cell (or glass). 
 
Cell Type / Material Tip (Spherical / Conical) Young’s Modulus of cell (kPa) 
Glass slide Spherical 1300 
U2OS cell (cell line) Spherical 13.3 
White cell Spherical 30.4 
Patient cell Spherical 10.0 
PC3 cell (cell line) Conical 183 
Table 6.5 A table to show the cell type or material that was indented, the type of cantilever 
tip and the Young’s Modulus of the cell wall or material (glass) that was calculated. The 





The work conducted in this chapter was not planned at the outset of the project but 
developed during the course of the three years. Collaboration with colleagues led to some 
interesting opportunities but lack of time and financial resources meant that some 
experiments could not be completed or repeated. This work will hopefully form the basis for 
future projects, some of which are currently underway. 
The four separation techniques that were chosen were not the only techniques available but 
were used either due to what had been successful in other studies (e.g. the Rosette-Sep) or 
what was readily available in the lab (e.g. the Parsortix). All had the benefit of sorting the 
CTCs either by physical properties or negative selection, meaning that downstream analysis 
would not be affected should further antibodies need to be used in experiments. Some 
methods (e.g. the Rosette-Sep) were probably more affected by user error than others, and 
further attempts at spiked cell retrieval would be performed if this work was to be 
continued. Those based on separation by physical properties (the Rosette-Sep and the 
Parsortix) may have a higher loss of the more fragile CTCs due to cell disruption, and it is 
possible that the density-separation technique may not detect the smaller, denser CTCs at 
all. Although the cell retrieval was not statistically different for any of the methods for each 
of the three spiked cell amounts, spiking with 10 000 or 100 000 cells may not be that 
representative as any clinical samples are unlikely to contain this many CTCs. Part of the 
reason for doing this was to increase the chances of finding the spiked cells, and also due to 
the fact that cell lines were counted using a manual haemocytometer, which would 
introduce a higher proportional error when using lower numbers. Using an automated 
haemocytometer could improve this in future experiments. 
For future experiments looking at optimum media and culture conditions, comparing growth 
rates using different media would be attempted. Culturing under hypoxic conditions would 
also be useful, to see if this made any difference to the rate of growth. Using the 
Imagestream or conventional FACS could also be used to confirm that there were no white 
cells in the experiment described in section 6.3.  
The inability to prove the phenotype of the cells from patients in culture was a huge 
drawback to this work, but one that is probably inevitable at this early stage. With such low 
numbers of cells in culture, extracting DNA, even when using a kit that is specifically 
designed for low cell numbers, was always going to be challenging in inexperienced hands. 
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The cells growing in culture did appear to adhere strongly to the plates, and so even with 
gentle trypsin agents it was difficult to harvest all of the cells that were growing. Planning 
future work where culture conditions are investigated and a more optimal rate of growth 
established could help increase cell number, which would in turn increase the chances of 
getting DNA in sufficient quantities, and hopefully higher quality, to sequence. User 
inexperience was likely to have contributed to the failure of the RT-qPCR experiment as it 
was not a technique that was familiar. 
The chemokine receptor experiment shows promising early results, but without 
corresponding sequencing data it would be difficult to prove the cell phenotype using this 
method alone. Further experiments looking at the chemokine expression in white cells from 
the same patient would be useful, in addition to looking at the expression in cells from more 
patients, particularly those with early metastatic disease. Discussions are underway to 
develop this work in the near future. 
The attempted CDX model was ambitious given the resources but the clinical findings were 
encouraging. Unfortunately, the subsequent inability to confirm engraftment, either at the 
implantation site or the spine, was frustrating and means that the clinical symptoms were 
unlikely to be related to the implanted cells. Repeating this experiment would be possible 
but sequencing the cells prior to implantation would be preferable. 
The AFM work is only very preliminary, and in order to make statistical comparisons of the 
Young’s Modulus of the cell walls of different cells, much larger numbers of cells would need 
to be included in the experiment. What is interesting is the shape of the curves; the most 
rigid material (the glass coverslip) has a very different shape, consistent with an elastic 
material, compared to the gentle curve of the patient cell which is more viscoelastic. As the 
PC3 cell and the U2OS cell were indented with different shaped tips the curves can’t be 
directly compared, but the PC3 data was included to show proof of principle. Both the U2OS 
cell and the patient cell have much gentler curves compared to the white cell, and a lower 
Young’s modulus, which would indicate that the cancer cells are more deformable. This is 
consistent with findings in the literature (Cross et al., 2007, Cross et al., 2008, Luo et al., 
2016) but due to heterogeneity of individual cancer cells and the pure lack of numbers of 
cells, it is not possible to draw any conclusions from this experiment. However the concept 
has been tested and if further work confirms that the patient cells in culture are CTCs, 
ongoing experiments in this field could easily be replicated in sufficient quantities to allow 
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statistical analysis. This could potentially lead to work with a clinical impact, and as such, this 
data has been included in a grant application in order to further the work. 
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Chapter 7. Discussion and future work 
 
With respect to the original aims of the project, the first aim of optimising an assay to enable 
detection of embryonic stem cell markers in combination with epithelial and mesenchymal 
markers has partially been achieved. Whilst these cells are not CTCs as defined by the FDA, 
they are putative CTCs and for the purpose of this study will be referred to as CTCs. The 
Imagestream assay was robust and white cells could be confidently excluded, in addition to 
cells expressing either epithelial and stem cell markers being positively identified. The 
healthy volunteers had no CTCs detected, and the patients with metastatic disease had the 
most CTCs. This is consistent with what is found in the literature both in relative terms but 
also absolute numbers. It is not possible to directly compare CTCs numbers as the ones 
detected in this assay are putative due to the non-FDA approved antigen combination, and 
the fact that 4mls of blood was sampled compared to 7.5ml. But the order of magnitude is 
comparable and I am therefore confident that this demonstrates the reliability of the assay. 
The downsides of this assay were the fact that it was relatively laborious compared to 
conventional FACS assays, and gating strategies had to be adopted prior to saving data. As 
CD45 positive cells were chosen to be excluded, potential CTCs that were adherent to white 
cells may have been overlooked by using this method. There are lots of different ways to 
approach the gating, and whilst colleagues within the institute had gated on size, saving data 
from cells over a certain size threshold, because of the fact that many prostate CTCs are 
smaller than CTCs from other tumours (Park et al., 2014), the decision had been made not to 
use size as a criteria. The lack of ability to capture the cells at the end of the process for any 
downstream analysis was also a flaw, but one that was accepted prior to choosing the 
platform for this study. 
Not having a prostate specific marker to identify prostate cells was another downside to this 
assay. As explained already the lack of channels to use different fluorochromes meant that 
using a prostate marker in addition to epithelial and stem cell markers would not have been 
possible. One way to circumvent this in future would be to divide the blood samples from 
each patient and run different combinations of markers, e.g. have a prostate specific marker, 
two stem cell markers and an epithelial marker, and then a second panel with the remaining 
stem cell marker in conjunction with the prostate marker and epithelial marker. Perhaps if 
this was done, a third panel with the combination described in Chapter 3 should still be used 
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as the study from which this work was based on looked at expression of all three embryonic 
stem cell antigens and found that prognosis and disease specific survival was worst when all 
three were expressed (Hepburn et al., 2019). Whilst this would make the assay even more 
laborious, if fewer clinical samples were obtained then work could be focused, or if this was 
explored as part of a trial then utilising more than one member of staff would help with 
processing time. 
The FACS assay was carefully optimised but despite this, DAPI could not be used due to 
fluorescent overlap.  This was addressed by using forward and side scatter to identify whole 
cells, and if the cell sort issue could be overcome then DAPI or another nuclear identifier 
could be used when downstream analysis was undertaken. This issue with the cell sort was 
really unfortunate and could have easily been overcome by using a non-fixative lysing agent 
if the implications had been realised when designing the assay. For future work, changing 
this first step in the protocol would be very straight forward as the antibody panel could 
remain the same. All the samples from the cell sort are still in storage under HTA approved 
conditions, so if a product becomes available that would enable DNA or RNA extraction from 
low cell numbers then these samples could still be utilised. The main benefit of the FACS 
assay was the ability to explore multiple markers simultaneously, in addition to the fact that 
most centres will have access to a FACS platform, making it accessible for use in a clinical 
trial. 
In terms of the second aim of the project, Oct4, SOX2 and Nanog expression in CTCs has not 
been shown to correlate with prognosis. However, it is possible that it is too early to 
demonstrate a relationship. Correlating CTC results with PSA and ALP levels was probably 
not going to yield a positive relationship, as neither of these is a substantial predictor of 
disease progression, and there was such limited clinical data (with respect to length of 
follow-up).  The original work looked at time to castrate resistance and disease specific 
mortality in patients who had had radical prostatectomies (Hepburn et al., 2019). With 
respect to castrate resistance, it would only be possible to look at some of the patients 
included in this project, as many were on hormone treatment already. Disease progression 
could be used instead and looking at the incidence of radiologically defined metastatic 
disease would be one option but would need to be looked at over a much longer time 
period. Survival data would be very interesting and a correlation with the embryonic stem 
cell marker expression alone or in combination could easily be performed, again over a 
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longer time period. This work is already in progress as clinical data is being recorded at 
regular intervals. It is likely that the data from only the Imagestream assay could be used for 
this purpose as without the confirmation of the cells captured, falsely high numbers of Oct4, 
SOX2 and Nanog positive cells may be included. 
Because MT1-MMP can also be expressed by haematopoietic cells (Nishida et al., 2012), the 
high levels of MT1-MMP expression even in the healthy control samples meant that for the 
FACS assay, the results for this antigen couldn’t really be interpreted. If MT1-MMP was 
added to the Imagestream panel then this could be overcome by visual exclusion after CD45 
gating, or if the FACS sort was possible then downstream processing could include a step to 
determine which cells were haematopoietic and which were true mesenchymal tumour 
cells. 
As a result of the issues described above, the hypothesis for this project cannot be proven, 
although it is hoped that once longer-term clinical data becomes available that this may 
change. If doing the project again I would ensure that ethical permission was granted to 
allow serial samples to be obtained from patients. This would enable CTC detection at 
different time points so rather than comparing CTC count to clinical information, progression 
in terms of an increase or decrease in CTC number, or CTC expression could be explored. 
In terms of the final aim of the project, cells obtained from patients were successfully 
cultured in-vitro for up to a year, but the genetic signature of these cells is still unclear. 
Whilst there were undoubtedly some white cells, the morphology, stem cell expression and 
cell stiffness suggested that there were some other cells within the population. Whether 
these were tumour cells it is not possible to say due to the unsuccessful attempts to 
sequence them. But these findings are promising and form the basis for future planned 
work. The results of the experiments using the Atomic Force Microscope have already been 
included in a grant application for some further work looking at the stiffness of tumour cells, 
and cells from five patients at various different passages (up to passage five) are still in 
frozen storage. One grant application for further work by the author of this study has been 
unsuccessful but if further funds did become available, ongoing work to culture cells from 
patients would be undertaken, in order to progress the work in Chapter 6. 
To conclude, the assay developed for the Imagestream has allowed me to detect putative 
CTCs and I intend to publish this as a methods paper. By collecting survival data at the two-
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year point, I hope to see whether there is a correlation between putative CTC count and/or 
expression and publish these results from the Imagestream assay too. The cells obtained 
from patients that were maintained in culture are currently in frozen storage, and if funding 
becomes available to do further experimentation on them to determine their genotype then 
this will be pursued. And if the grant application for the Atomic Force Microscope work is 
approved then that experiment will be expanded to look at multiple different types of cells 
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